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Summary 
 
 The objective of this thesis is to investigate the chemopreventive potential of a 
small group of flavonoids called aurones.  A prime motivation for this investigation is 
the presence of structural features in the aurone template that are associated with the 
induction of the chemopreventive Phase II enzyme, NAD(P)H: quinone 
oxidoreductase 1 (NQO1).  These are the exocyclic double bond and the Michael 
acceptor moiety of which it is a part.  A review of the literature showed that only two 
naturally occurring aurones were reported to induce NQO1 and with only modest 
potencies.  It seems likely that the NQO1 induction potential of the aurones has not 
been fully exploited and that structural changes to the scaffold may be a viable means 
of uncovering more potent members.  To this end, a series of 87 aurones and related 
compounds were synthesized, purified and characterized.  Nearly two-thirds of these 
compounds have not been reported in the literature.  The compounds were classified 
according to (i) the substitution on ring A (dimethoxy, dihydroxy, monohydroxy or 
without substituents (Series 1-5), (ii) modification of ring C to give the isoaurones 
(Series 6, 7) and (iii) reduction of the exocyclic double bond (Series 8).  Investigation 
of the E/Z stereochemistry of the double bond resulted in the assignment of the Z 
configuration for aurones and a predominant E configuration for isoaurones.  
 The synthesized compounds were evaluated for induction of NQO1 activity in 
murine hepatoma Hepa1c1c7 cells by the Prochaska assay.  Screening at a fixed 
concentration was initially carried out to shortlist compounds that were able to 
increase NQO1 activity by at least two-fold at 5 μM or failing which, at 25 μM.  A 
group of 31 “actives” were identified and their CD values (concentration at which 
NQO1 activity is increased by two-fold) were determined.  Ten aurones were found to 
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induce NQO1 with submicromolar CD values. These are the most potent NQO1 
inducers to have been identified from this class to date.  Structural features for good 
activity were (i) presence of an intact exocyclic double bond, (ii) dimethoxy (in 
preference to dihydroxyl) substituents on ring A, (iii) halogens, methoxy or hydroxyl 
on ring B and at positions 2’ or 3’, and (iv) maintaining the carbonyl in ring C as a 
ketone carbonyl (= aurone) and not an ester carbonyl (= isoaurone).  
 The synthesized compounds were investigated for their mode of NQO1 
induction.  It was found that the compounds induced NQO1 activity by activating the 
AhR/XRE signaling pathway.  This was evident from the inability of the compounds 
to induce NQO1 activity in mutant Hepa1c1c7 cells (Bprc1) that did not have a 
functional AhR.  Furthermore, they increased CYP1A1 activity in Hepa1c1c7 cells 
when monitored by the EROD assay but to a lesser extent when compared with their 
effects on NQO1 activity at the same concentration.  On the other hand, several 
aurones that were potent NQO1 inducers were found to induce thioredoxin reductase 
(TrxR) expression leading to enhanced TrxR activity and increase glutathione levels 
in Hepa1c1c7 cells. Compounds with lesser or no NQO1 induction activity failed to 
bring about these changes.   Transcriptional activation of NQO1 is brought about by 
the activation of AhR/XRE and Nrf2/ARE pathways. On the other hand, the 
transcriptional activation of thioredoxin reductase and γ-glutamylcysteine ligase (the 
rate limiting enzyme in the de novo synthesis of glutathione) is controlled by the Nrf2 
gene/protein battery. The role of Nrf2 in the coordinated induction of these enzymes 
was further ascertained by immunoblotting experiments that showed an up-regulation 
of Nrf2 in the presence of active aurones. These findings implied that aurone-
mediated induction of NQO1 is the likely outcome of two pathways. Thus, they may 
be classified as mixed activators, a class of inducers that is distinct from the 
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conventional bi- and monofunctional inducers and widely thought to have greater 
chemopreventive potential. On the other hand, the findings may be interpreted to 
mean that the aurones are capable of exploiting the proposed cross-talk between the 
AhR and Nrf2 gene batteries by mechanisms that remain to be understood.  
A QSAR analysis of the induction activities of 33 test compounds (31 
“actives” and two inactive compounds) was carried out by Partial Least Squares 
Projection to Latent Structures (PLS) and the genetic algorithm (GA) approach. The 
compounds were characterized by 17 descriptors that encompassed the steric, 
lipophilic and electronic properties of the compounds.  In spite of the intrinsically 
different QSAR approaches adopted in this study, both PLS and GA identified size 
parameters to be important determinants of activity.  The importance of area, volume, 
non-polar surface areas and lipophilicity were strongly emphasized in PLS but 
accorded a lesser weightage in GA.  These descriptors reflect the state of substitution 
of rings A and B, with possibly a greater role for the former.  The energy of the lowest 
unoccupied molecular orbital (E LUMO) was identified by GA as the main contributor 
to activity.  In this analysis, potent inducers were those with low lying E LUMO.  It was 
found that this term described some feature related to the exocyclic double bond.  It 
may be that E LUMO reflected the reactivity of the double bond (and the Michael 
acceptor of which it is a part) as an electrophile or that E LUMO is linked to the 
conformational flexibility of the scaffold.  Thus the reduction of the exocyclic double 
bond abolishes the Michael acceptor moiety and introduces greater flexibility to the 
molecule, and these changes may contribute to the dramatic loss of induction activity.  
 In conclusion, aurones are potentially useful chemopreventive agents.  
Appropriate functionalization of the scaffold has resulted in potent NQO1 inducers 
that may act by activating both AhR/XRE and Nrf2/ARE signaling pathways.  
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Moreover, aurones have desirable drug-like profiles, are readily synthesized by 
accessible routes, and have low cytotoxic properties.  These are advantageous features 
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NQO1  NAD(P)H: Quinone Oxidoreductase 1 (EC 1.6.99.2) 
Nrf2  Nuclear factor-erythroid related factor 2 
PAH  Polyaromatic hydrocarbons 
PI3K  Phosphoinositide 3-kinase 
PKC  Protein kinase C 
PLS  Partial Least Squares Projection to Latent Structures 
PPA  Polyphosphoric acid 
PPAR-γ Peroxisome proliferators-activated receptor-γ 
ROS  Reactive oxygen species 
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Chapter 1  Introduction 
 
1.1 Cancer Chemoprevention 
Cancer is a disease characterized by the uncontrolled growth and spread of 
aberrant cells. It is one of the three major killers in the world today, alongside 
cardiovascular ailments and infectious diseases.  A sizeable 12.6 percent of annual 
global deaths have been attributed to cancer and estimates suggest that this figure is 
likely to increase by 50 percent in the next two decades [1, 2].  In spite of these dismal 
statistics, important advances have been made in our knowledge of cancer. The 
landmark work of Bishop and Varmus [3] gave us the genetic basis of cancer, and the 
watershed discoveries in the 1970s and 1980s heralded the era of target-oriented 
chemotherapy with imatinib (Gleevec™) and Herceptin as prominent successes.  
However, optimism has to be tempered with the realization that the signaling network 
of the cancer cell is complex [4] and molecular defects are too widespread and varied 
to be addressed by a single intervention. Hence, cancer drug discovery remains a 
challenging task. 
 The development of cancer is a long-term process involving distinct molecular 
and cellular interactions that occur at different stages of the disease process [5].  
Carcinogenesis starts with the recruitment of normal cells as pre-cancerous cells 
(initiation) which subsequently progress to full malignancy. The protracted nature of 
carcinogenesis offers many opportunities for intervention to prevent or slow down the 
process.  Common prevention strategies include avoiding exposure to known cancer-
causing agents, enhancement of host defense mechanisms, life style modifications and 
supplementation with chemopreventive agents [2, 6]. 
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Chemoprevention is a term introduced by Sporn and co-workers [7] to 
describe the use of natural or synthetic agents to slow, reverse or inhibit 
carcinogenesis in healthy persons or in those who have known cancer risks.  A large 
number of chemopreventive agents are dietary phytochemicals [8-10]. These include 
isothiocyanates such as sulforaphane and glucosinolate-derived indoles from 
cruciferous vegetables, curcumin from turmeric, resveratrol from grapes, and 
epigallocatechin-3-gallate from green tea. The structures of some examples are given 
in Figure 1-1.  Since these are common dietary components, they have received 
enthusiastic public endorsement supported in part by positive media coverage.  Less 
recognized is the fact that many of these phytochemicals have poor stability profiles, 
unsatisfactory pharmacokinetics or unpredictable toxicities. For example, several 
green tea polyphenols have low and variable bioavailability that could hamper their 
chemopreventive activity [11].  A pharmacokinetic study on the bioavailability of 
curcumin in humans revealed the failure to achieve systemic concentrations required 
for clinical efficacy in spite of the high oral doses (10 g/day) administered [12]. 
 














Chemopreventive agents of synthetic origin are mainly established drugs with 
existing clinical indications and whose chemopreventive properties were discovered 
fortuitously.  They include the non-steroidal anti-inflammatory drugs (NSAIDs) such 
as celecoxib [13] and aspirin, the antiestrogens tamoxifen and raloxifene [14], the 
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antiparasitic agent oltipraz [15] and the lipid-lowering agent atorvastatin [16]. The 
structures of some examples are given in Figure 1-2.  Unlike their phytochemical 
counterparts, these synthetic agents are the output of rigorous drug discovery efforts 
and thus have more favorable pharmacokinetic profiles.  However, due to their pre-
existing pharmacological properties, there is always a risk of adverse effects if these 
agents are taken by healthy individuals on a long term basis for cancer 
chemoprevention.  For example, the adverse cardiovascular events associated with the 
cyclooxygenase -2 (COX-2) inhibitor rofecoxib became apparent when it was used 
for an extended period in chemoprevention trials for colorectal adenoma [17]. 
 













Several laboratories have approached the discovery of novel cancer 
chemopreventive agents by turning to naturally occurring compounds for starting lead 
structures.  Sulforaphane, an isothiocyanate isolated from broccoli is a case in point 
(Figure 1-3).  A novel analog sulforamate,  synthesized to address the toxicity of 
sulforaphane, proved to be as potent as sulforaphane as an inducer of a Phase II 
enzyme but with three times less toxicity (IC50 34.9 μM versus 9.9 μM) [18]. 
Unfortunately it was difficult to synthesize and attempts to improve on the synthetic 
route led to oxomate, a keto analog of sulforamate.  Oxomate had weaker Phase II 
induction potencies but it was also less toxic and synthetically more accessible.  Other 
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sulforamate derivatives have been synthesized and found to be comparable to 
sulforamate in terms of potency but with lower cytotoxicities [19]. 
 


























R = n-C3H7, n-C4H9
Sulforamate analogs
  
Another example of a successful lead search is that of oleanolic acid, a 
naturally occurring triterpenoid that is widely distributed in plants.  Modification of 
oleanolic acid resulted in multifunctional triterpenoids that suppressed inflammation, 
inhibited proliferation, induced apoptosis of cancer cells and that were effective for 
the prevention and treatment of cancer in experimental animals [20, 21].  Two of 
these compounds, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) and 
its methyl ester (CDDO-Me) have been evaluated in phase I clinical trials for the 
treatment of leukemia and solid tumors (Figure 1-4).  Encouraged by the success of 
the oleanane triterpenoids, lead modification was carried out on betulinic acid, one of 
the active components present in the American paper birch bark [21].  Betulinic acid 
selectively inhibits the growth of human cancer cell lines but was hampered by poor 
potency.  Introduction of a cyano-enone functionality in ring A coupled with 
esterification to give a methyl ester (CBA-Me) or an imidazolide (CBA-Im) resulted 
in markedly improved anti-inflammatory activity and the induction of Phase II 
cytoprotective enzymes (Figure 1-4). 
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1.2 Chemopreventive agents: Blocking Agents and Suppressing Agents 
 Carcinogenesis consists of four sequential stages: initiation, promotion, 
progression and malignant transformation [5]. Initiation occurs when reactive oxygen 
or nitrogen species (RNOS) and electrophiles interact with DNA to produce strand 
breaks, or more often, an altered nucleotide (“adduct”). If the genome is replicated 
before the damage is corrected by enzymatic repair, a heritable error ensues and will 
affect subsequent cell populations. This is particularly relevant to cells involved in 
tissue renewal (stem cells) which are the actual targets of carcinogenesis. If the 
damage is found at DNA sequences that encode growth advantages, they will be 
singled out for expansion by endogenous promoters, namely growth regulators and 
hormones (androgens, estrogens).   At this stage, these colonies of promoted cells will 
be manifested as benign adenomas and hyperplasia such as polyps. When the 
dysplastic cells enter the progression phase which is the most extended period in 
carcinogenesis, they accumulate additional genetic “gains of function” due to further 
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exposure to electrophilic insults or inherent genomic instabilities, culminating in the 
malignant phenotype. Inflammation plays an important role in carcinogenesis because 
it produces sustained oxidative stress long after the original insult has been removed 
and is closely linked to growth promotion [22]. 
 Chemopreventive agents are conventionally classified as blocking and 
suppressing agents [8, 23, 24]. Blocking agents act to protect normal cells from 
interactions with electrophilic insults by inducing the activities of an ensemble of 
cytoprotective and antioxidant enzymes (Phase II response) which include enzymes 
involved in the biosynthesis of glutathione (GSH) and its subsequent role in 
biotransformation,  as well as other enzymes like NAD(P)H: quinone oxidoreductase 
1 (NQO1), heme-oxygenase 1 (HO-1), thioredoxin, thioredoxin reductase 1 (TrxR), 
UDP-glucuronosyl transferase (UDPGT) isoenzymes, and superoxide dismutase. At 
the heart of this chemical induction is the activation of the master regulator nuclear 
factor erythroid-2 (Nrf2) [25] and the promoter gene (antioxidant response element, 
ARE) that drives the production of the Phase II proteins. Examples of Phase II 
inducers are sulforaphane [26], the brassinins [27], the curcuminoids [28], oltipraz 
[29] and the oleanane triterpenoid analogues [30]. Blocking agents may also act by 
culling initiated cells by oxidative stress-mediated apoptosis as many Phase II 
inducers are electrophiles [31].  In this way, the genomic integrity of normal cells is 
maintained and the initiation process of carcinogenesis is kept at bay. Suppressing 
agents act on the promotion and progression stages of carcinogenesis.  A variety of 
mechanisms are involved such as modulation of inflammation (COX-2 and inducible 
nitric oxide synthase inhibition, inflammatory signaling pathways involving NF-кB 
and JAK-STAT), epigenetic modulation, nuclear receptor modulation (anti-estrogens, 
retinoids, rexinoids and PPAR-γ ligands) and inhibition of growth signaling cascades 
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such as PI3K, the epithelial responsive kinases (ERK) and the mitogen-activated 
protein kinases (MAPK) [24]. Classic suppressing agents include all-trans retinoic 
acid and its analogues [32], selective estrogen receptor modulators (SERMs) like 
tamoxifen, and COX-2 inhibitors. More recently, a chemopreventive role has been 
proposed for the multitargeting kinase inhibitors erlotinib and gefitinib in view of 
their ability to inhibit growth signaling kinases. [33].   
 
1.3 NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as a chemopreventive  target 
NAD(P)H: Quinone Oxidoreductase 1 (NQO1) is a homodimeric flavoprotein 
that is upregulated in mammalian tissues in response to oxidative stress caused by 
electrophilic xenobiotics [34-36]. The enzyme provides the cell with multiple layers 
of protection against environmental insults [35]. It is able to detoxify highly reactive 
quinones to quinols without generating reactive semiquinones, maintain endogenous 
lipid soluble antioxidants (ubiquinone /co-enzyme Q10, α-tocopherol-quinone) in 
their reduced and active forms, and stabilize the tumor suppressor p53 in response to 
DNA-damaging stimuli [37]. In addition, recent findings showed that induction of 
NQO1 was linked to estrogen receptor-β mediated chemoprotection by estrogen 
ligands such as tamoxifen and genistein [38]. 
 The widely accepted function of NQO1 is its single-step, obligatory two-
electron reduction of quinones to inert and easily excretable quinols thereby avoiding 
the generation of toxic and reactive semiquinone intermediates which may participate 
in harmful redox cycling [39] (Figure 1-5). Quinones are a significant source of 
oxidative stress as they are present in the environment and diet. They are also 
produced endogenously as catechol quinone metabolites of estrogen.   
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Figure 1-5: Role of NQO1 in quinone metabolism. One electron reduction leads to 
harmful redox cycling. NQO1 catalyses two-electron reductions which result in 





2 e reduction by NQO1
OH
OH













 Under basal conditions, NQO1 and other Phase II enzymes are not expressed 
at their maximal levels. When NQO1 activity is induced by a chemopreventive agent, 
the activities of other Phase II enzymes are concurrently up-regulated because of their 
shared mechanism of action as described in the subsequent paragraphs.  The induction 
of Phase II enzymes provide cells with a protective advantage, particularly those that 
are vulnerable to electrophilic insults like epithelial tissues of the skin, the eye and the 
gastrointestinal tract [40, 41].  Even a transient exposure to inducing agents can result 
in the up-regulation of enzyme activity for an extended period [41]. 
 NQO1 induction is widely used as a biomarker for the screening of 
compounds for chemopreventive activity [42].  Screening is carried out in murine 
hepatoma (Hepa1c1c7) cells using the Prochaska assay [43].  Hepa1c1c7 cells are 
chosen for their robust responsiveness to inducing agents, thus permitting quantitative 
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comparisons of induction potencies to be made [44].  There is also a good correlation 
between the NQO1 induction elicited in Hepa1c1c7 cells and their in vivo 
chemoprotective effects in murine tissues. The Prochaska assay has been used 
successfully to identify promising chemopreventive agents like the withanolides [45], 
4'-bromoflavone [46], and the oleanane triterpenoids [30].  
 Induction of NQO1 is brought about by two different signaling pathways, 
namely Keap1/Nrf2/ARE and AhR/XRE.  The Keap1/Nrf2/ARE signaling cascade 
initiates the upregulation of NQO1 and other Phase II enzymes in response to 
oxidative stress (ROS and xenobiotic electrophiles) [35]. Under normal 
circumstances, Nrf2 (a basic leucine zipper transcription factor) is bound to a 
cytosolic inhibitor known as Keap1 (Kelch-like ECH-associated protein-1). Keap1 
sequesters Nrf2 in the cytoplasm and hastens its degradation by ubiquination. In the 
presence of electrophiles (including Phase II inducers), the Keap1-Nrf2 is disrupted 
by the oxidative modification of several reactive cysteine residues in Keap1 [47a]. 
Nrf2 is liberated in the process and it migrates to the nucleus to bind to the promoter 
sequences (antioxidant response element, ARE) that are found in genes of Phase II 
proteins. The result is the upregulation of Phase II proteins such as NQO1, UDP-
glucuronosyltransferases (UGTs), glutathione-S-transferases (GSTs), glutamyl-
cysteine ligase (the rate-limiting enzyme in glutathione synthesis), heme oxygenase, 
ferritins, and epoxide hydrolase [48].  Alternatively, Nrf2 may be activated by the 
phosphorylation of upstream protein kinases such as the protein kinase C, MAPKs, 





Figure 1-6:  Activation of Phase II enzymes by the Keap1-Nrf2-ARE pathway  
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 NQO1 induction may also occur by the Aryl hydrocarbon receptor (AhR)-
xenobiotic response element (XRE) pathway [50, 51]. AhR is a cytosolic protein that 
belongs to the basic helix-loop-helix family.  Ligands of AhR include synthetic 
chemicals like polyaromatic hydrocarbons (PAHs) and 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), as well as natural ligands like indolo[3,2-b]carbazole found in some 
vegetables, bilirubin and tryptophan metabolites. Once formed,  the AhR ligand 
complex translocates to the nucleus where it heterodimerizes with a protein partner 
(AhR nuclear translocator) to form a transcription factor that binds to XREs present in 
the 5’-promoter region of  genes related to xenobiotic metabolizing enzymes (XMEs) 
to bring about transcription. XMEs include cytochrome P450 enzymes (CYPs) and 
some (but not all) Phase II enzymes like NQO1, GSTA2 and UGT1A6 [48, 51]. The 
CYPs are major enzymes that participate in Phase I xenobiotic metabolism. They 
catalyze functionalization reactions such as oxidation and reduction of xenobiotics 
prior to Phase II conjugation reactions.  
 16
Figure 1-7: Activation of CYP450 and some Phase II enzymes by the AhR-XRE 
pathway. 


















1.4  Monofunctional inducers, bifunctional inducers and mixed activators of Phase 
II cytoprotective enzymes 
 Agents that induce Phase II enzymes are traditionally classified as 
monofunctional and bifunctional inducers [52]. A monofunctional inducer is one that 
induces Phase II enzymes without inducing Phase I enzymes.  Mechanistically, this is 
achieved through the activation of the Keap1/Nrf2/ARE pathway by the inducing 
agent. The latter may interact with cysteine residues in Keap1, a binding partner of 
Nrf2 that is involved in regulating Nrf2 transcriptional activity through cytoplasmic 
sequestration of Nrf2 as well as regulation of Nrf2 steady state by targeting it for 
ubiquitin-dependent proteosomal degradation [47b]. On the other hand, a bifunctional 
inducer acts through an Ah dependent mechanism (AhR/XRE pathway) to induce the 
activity of Phase I and Phase II enzymes.  The elevation of Phase I enzyme activity 
(such as CYP1A1) is generally considered undesirable because it leads to the 
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metabolic conversion of procarcinogens to active carcinogens [53].  Hence, an agent 
that selectively induces Phase II enzymes (a monofunctional inducer) would 
theoretically be more desirable than an agent that brings about induction of both 
Phase I and II enzymes.  
Recent findings have made it necessary to re-visit the classification of mono- 
and bifunctional inducers based on functional (induction of Phase II enzymes versus 
Phase I and II enzymes) and mechanistic (Nrf2 activators versus AhR agonists) 
criteria. First, there is compelling evidence to support links between the AhR and 
Nrf2 gene batteries [51, 54, 55].   For example, DNA sequence analysis of the mouse 
Nrf2 promoter region has shown the presence of 3 functional XREs and 2 AREs.  The 
human Nrf2 promoter contains 5 copies of XRE-like elements.  Thus, Nrf2 may be a 
downstream target of AhR. Moreover, ROS and electrophiles are required to disrupt 
the Keap1-Nrf2 complex and the translocation of Nrf2 into the nucleus.  Some of 
these ROS / electrophiles are generated from CYP1A1 [51, 133].  Thus Nrf2 is 
activated indirectly by CYP1A1-generated ROS/electrophiles. XRE and ARE were 
also found in close proximity in the regulatory region of murine NQO1 [55] and this 
may lead to a direct interaction between AhR/XRE and Nrf2/ARE signaling.   The 
presence of coordinated regulation of AhR and Nrf2 would make it difficult to 
distinguish between mono- and bi-functional inducers based on their target signaling 
pathways alone.   
Second, some inducers of Phase II enzymes activate both the AhR and Nrf2 
and have been termed “mixed AhR/Nrf2 activators” [48].  Most of these compounds 
are phytochemicals, notably flavonoids.  In fact, some flavonoids like quercetin and 
β-naphthoflavone were originally classified as mono- and bi-functional inducers 
respectively [56] and only found to be mixed activators recently [48, 57]. It was 
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further shown that some flavonoids (quercetin, fisetin, flavonol, 3,3’-dihydroxy and 
3,3’,4’-trihydroxyflavones) induced ARE- and XRE-mediated gene expression at 
different concentration ranges, with greater induction of the former at physiologically 
relevant concentrations [58].  Thus, the classification of Phase II enzyme inducers 
should be expanded to include three classes, namely mono-functional inducers /Nrf2 
activators, bifunctional inducers /AhR agonists and mixed AhR/Nrf2 activators [48].  
In spite of its recent emergence, there is great interest in the chemopreventive activity 
of mixed activators.  Bonnessen et al. [59] noted that pretreatment of human colon 
LS-174 cells with both indolo[3,2-b]carbazole (a bifunctional inducer) and 
sulforaphane (a monofunctional inducer) provided substantial protection against the 
genotoxic effects of benzo[a]pyrene, and that this protection was greater than was 
achieved by either agent alone.  Mixed activators chrysin or BNF were stronger 
inducers of the Phase 2 enzyme UGT1A6 (which is activated via AhR and Nrf2 
pathways) than TCDD, a selective AhR activator [60, 61]. These findings suggest that 
mixed activators may have a chemopreventive advantage over monofunctional 
inducers.  
 
1.5       Overview of aurones and their chemopreventive potential 
Aurones (2-benzylidenebenzofuran-3(2H)-ones) are a class of flavonoids 
found extensively in fruits and flowers where they function as phytoalexins against 
infections and also contribute to the yellow pigmentation of the plant parts [62, 63].  
They are structurally related to flavones (Figure 1-8) but unlike other members in the 
flavonoid family (flavones, isoflavones, chalcones) which are widely investigated for 
their biological properties, aurones have received less attention.  
 
 19


















Chalcones Aurones  
 
In the first comprehensive review of aurones to appear in the last 10 years, the 
following activities were cited for this class of compounds: anti-cancer activity via the 
inhibition of cyclin-dependent kinases, adenosine receptors or telomerase; 
antiparasitic activity against Leishmania and Plasmodium; anti-microbial activity;  
inhibition of thyroxine metabolism (deiodination) and inhibition of the Mallaird 
reaction which contributes to complications in diabetes [62].  More recent updates 
include the following:   A naturally occurring hydroxylated aurone (4,6,4’-
trihydroxyaurone) was found to be a potent inhibitor of the tyrosinase enzyme which 
is involved in melanogenesis and skin hyperpigmentation [64].  5-Iodo-4’-
aminoaurones were reported to intensely stain β-amyloid plaques in mice brain 
sections, raising the possibility of their use as amyloid imaging agents in Alzheimer’s 
disease [65].  Liu and co-workers [66] evaluated 25 flavonoids for inhibition of the 
influenza viral neuraminidase and found potent activity in two hydroxylated aurones.  
However, these aurones failed to show significant in vitro anti-viral activity [66].  A 
series of functionalized 4,6-dimethoxyaurones were found to be potent and selective 
inhibitors of the ATP binding cassette transporter protein ABCG2 compared to 
ABCB1 (p-glycoprotein) [67]. These varied activities reported for the aurone scaffold 
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suggest that it may be a “privileged structure” capable of binding to multiple and 
possibly unrelated classes of receptors or enzymes.   
 Unlike other flavonoids which have been widely investigated for their 
chemopreventive properties, less is known for aurones. Jang and co-workers [68] 
were the first to report the NQO1 induction properties of two aurones isolated from 
the seeds of the Tonka Bean (Dipteryx odorata) (Figure 1-9).  Both compounds were 
modest inducers of NQO1 with CD values (concentration required to increase by two 
fold the basal activity of NQO1 in Hepa1c1c7 cells) in the low micromolar range. 
 






R = OH Sulfuretin     CD = 20.7 µM
R = OMe                     CD = 6.4  µM  
Aurones are structural isomers of flavones and the closed ring derivatives of 
chalcones.  Flavones have a six membered ring C with the double bond located within 
ring C and aligned in an s-trans conformation to the carbonyl bond. (Figure 1-10)  In 




Figure 1-10:  Comparison between the flavone and aurone templates. Dotted circles 
denote the Michael acceptor moiety.    
O
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These differences notwithstanding, a Michael acceptor moiety is embedded in 
the structures of these flavonoids.  The reactivity of the Michael reaction acceptor as 
electrophiles is closely correlated to their potencies as NQO1 inducers [52, 69]. In this 
context, the observation that 2-methylene-4-butyrolactone and 3-methylene-2-
norbornanone which have exocyclic double bonds were more potent NQO1 inducers 
than furan-2(5H)-one where the double bond is endocyclic, is of particular interest 
(Figure 1-11) [52]. 
 
Figure 1-11: Comparison in NQO1 induction potency between exocyclic- and 
endocyclic-type Michael acceptor compounds [52]. 







CD = 210 µMCD = 22 µMCD = 7µM
Exocyclic olefins Endocyclic olefin
 
The greater reactivity was attributed to the absence of acidic hydrogens on the 
carbon atom adjacent to the electrophilic centre of the olefin [52]. Such acidic protons 
would interfere with Michael addition by neutralizing the attacking nucleophile, thus 
diminishing the electrophilic character of the acceptor (Figure 1-12).  If this motif is 
indeed associated with greater Michael reactivity, it may be argued that aurones 
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which are unique among flavonoids in having an exocyclic double bond should be 
outstanding NQO1 inducers.  
 
Figure 1-12: Reaction sequence to illustrate the reduced reactivity of a Michael 


















1.6     Statement of Purpose 
The purpose of this thesis is to investigate the potential of aurones as inducers 
of chemopreventive Phase II enzymes.  It is hypothesized that aurones are potent 
inducers for the following reasons: (i) Aurones are a subclass of flavonoids and 
flavonoids are  widely associated with chemopreventive properties; (ii) A Michael 
acceptor moiety is embedded in the aurone framework and the presence of this 
electrophilic moiety has been linked to induction activity, in particular induction via 
the Keap1/Nrf2/ARE pathway; (iii) Aurones are unique among flavonoids in having 
an exocyclic double bond as part of the Michael acceptor moiety.   A structure-
activity study has shown that this feature is associated with greater NQO1 induction 
activity compared to the corresponding analogues with endocyclic double bonds.  On 
the other hand, only two aurones have been reported to be NQO1 inducers and their 
induction activities are surprisingly modest.  It seems likely that the NQO1 induction 
potential of aurones has not been fully exploited and that structural changes to the 
scaffold would give more potent members.  Hence, the hypothesis will be investigated 
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by modifying the substitution pattern of the aurone template.  The purpose is to 
determine if these changes would result in more potent inducers perhaps by 
moderating the reactivity of the Michael acceptor moiety which is the assumed centre 
of reaction, or by influencing physicochemical properties that may impact induction 
activity.     
Several flavonoids (quercetin, chrysin, luteolin, fisetin) have been shown to be 
mixed activators of Phase II enzyme activity.  It is not known if the naturally 
occurring aurones, sulferetin and 6,4’-dihydroxy-3’-methoxyaurone, induce NQO1 
activity by activating Keap1/Nrf2/ARE, AhR/XRE or both pathways.  The 
chemopreventive potential of aurones would undoubtedly be enhanced if they are 
found to be mixed activators and this aspect would be investigated.  A related issue is 
the limited information on the structure- activity /property relationships of mixed 
activators, due in part to the small number of mixed activators (diverse flavonoid, 1,2-
dithiol-3-thiones, oltipraz) identified so far and for most of them, serendipitously.  
Certainly, no mixed activator has emerged from a rational design approach.  The 
insights gained in this work may contribute to a better understanding of the structural 
requirements of mixed activators. 
In summary, the hypothesis will be investigated on two fronts: (i) the synthesis 
of a series of functionalized aurones and related analogs with the purpose of 
establishing structure activity relationships with respect to NQO1 induction activity; 
(ii) mechanistic studies on the mode of action of NQO1 induction with the purpose of 






Chapter 2  Design and Synthesis of Target Compounds 
 
2.1 Introduction 
This chapter describes the design and synthesis of target compounds 
investigated for chemopreventive activity.  The compounds were divided into two 
classes – aurones and isoaurones, and within each class, there were further divisions 
to give different series. The rationale underpinning the design of these compounds, 
chemical considerations for their syntheses and general experimental methods are 
described in this chapter. Spectroscopic data, melting points, yields and purities of 
individual compounds are listed in Appendix 1.  
 
2.2 Rationale of design 
Eighty seven target compounds were synthesized in this investigation, most of 
which were functionalized aurones (n = 71) with regioisomeric isoaurones (n = 16) 
making up the rest.  They were organized into eight series which were distinguished 
by the type of substituent on ring A.  The focus on ring A arose from anecdotal 
evidence highlighting significant changes in the biological activities of aurones when 
the substitution pattern of ring A was altered. Lawrence and co-workers noted that 
5,6,7-trimethoxyaurones had greater cell growth inhibitory properties than their 
corresponding 4,5,6-trimethoxy regioisomers [70].. Another investigation on the 
inhibitory effects of aurones on the tyrosinase enzyme in human melanocytes showed 
that the most active compounds had hydroxyl groups on ring A whereas less active 
compounds had rings A that were either unsubstituted or with only one hydroxyl 
group [64].   Among flavones,  variations in ring A significantly affected NQO1 
induction activity, as seen from the greater potency of β-naphthoflavone compared 
with α- and γ-naphthoflavones [71].  As for the type of substituents on ring A, 
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hydroxyl (OH) and methoxy (OCH3) groups were selected because these are the most 
common groups in naturally occurring aurones and usually at positions 4 and 6 of ring 
A [72].   With this background in mind, the following series were proposed:  
(i) Series 1 and 2 comprised of 4, 6-dimethoxyaurones (n = 26) and 4, 6-
dihydroxyaurones (n = 15) respectively.  These two series provide a ready comparison 
of the OCH3 and OH groups on ring A.  Hydroxylated aurones are less lipophilic and 
have hydrogen (H) bond donor and acceptor properties.  Methoxylated aurones are 
bulkier, more lipophilic and without H bond donor properties.  
(ii) Series 3 and 4 comprised of 5-hydroxyaurones (n = 12) and 6-hydroxyaurones (n 
= 12) respectively.  Ideally, 4-hydroxyaurones and 6-hydroxyaurones would give the 
best comparisons to 4,6-dihydroxyaurones on the benefits of mono- versus di-
hydroxylation of ring A.  Unfortunately, the synthesis of 4-hydroxyaurones was 
challenging and thus the choice fell on 5-hydroxyaurones which were synthetically 
more accessible. It is of interest to note that the two naturally occurring aurones 
(sulfuretin, 6,4'-dihydroxy-3'-methoxyaurone) with NQO1 induction activity were 6-
hydroxyaurones.  
(iii) Series 5 consists of two aurones without ring A substituents.  It was included to 
confirm the necessity of maintaining ring A in a substituted state. 
(iv) Series 6 and 7 are isoaurones which have a different ring C from aurones.  The 
rationale for including isoaurones is discussed in another section.  Two types of 
substitution on ring A were employed: 4,6-dimethoxy (Series 6) and 5-hydroxy 
(Series 7). They are equivalent to the aurones of Series 1 and 3 respectively and 
comparisons would give insight on the relative merits of the two isomeric templates.  
(v) Series 8 consists of two compounds, structurally related to members in Series 1, 
but with reduced exocyclic double bonds.  These compounds (dehydro-aurones) are 
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particularly relevant because they highlight the importance of the double bond and the 
Michael acceptor moiety to which it belongs, for induction activity. 
 Besides ring A, modifications were also made to ring B. Ring B was either 
replaced by a basic heteroaromatic ring (pyridine, quinoline) or substituted with 
different groups, selected primarily to give a broad coverage of lipophilicity (Hansch 
π) and electron-withdrawing/-donating (Hammett σ) characteristics.  The Craig Plot 
was used for this purpose [73].  The type of groups on ring B is reputed to affect its 
torsion and the overall planarity of the scaffold [46].  Thus ring B substituents are 
expected to influence the physicochemical profile as well as the conformational 
orientation of the target compound.   
Analogues with di- and trisubstituted ring B were also synthesized, with 
groups restricted to OH and OCH3 which are prevalent in naturally occurring aurones.  
Wherever possible, the effect of locating the same group (halogen, OH, OCH3, CH3) 
at 2’, 3’ or 4’ on ring B was investigated.  The systematic variations on ring B 
described here closely parallel other investigations directed towards the discovery of 
novel chemopreventive agents [46, 69].    
Series 1 had the largest number of ring B variations because it was identified 
as the most promising series in preliminary investigations.  Although the other series 
(2-4, 6, 7) had fewer members, the groups included on ring B still had varied 
lipophilicity and electronic characteristics.  The structures of Series 1-8 compounds 

















Compound R1 Compound R1 
1-1 H 1-15 4'-F 
1-2 2'-Cl 1-16 4'-CN 
1-3 3'-Cl 1-17 4'-CF3 
1-4 4'-Cl 1-18 4'-NO2 
1-5 2'-OH 1-19 2'-CH3 
1-6 3'-OH 1-20 4'-CH3 
1-7 4'-OH 1-21 4'-N(CH3)2 
1-8 2',3'-(OH)2 1-22 4'-N-methylpiperazinyl 
1-9 2',4'-(OH)2 1-23 2'-pyridinyl a 
1-10 2'-OCH3 1-24 3'-pyridinyl a 
1-11 3'- OCH3 1-25 4'-pyridinyl a 
1-12 4'- OCH3 1-26 3'-quinolinyl a 
1-13 2'-F   
1-14 3'-F  1-27 b 4,6-Dimethoxybenzofuran-
3(2H)-one  
a Ring B is replaced by heterocyclic ring. 













Compound R1 Compound R1 
2-1 H 2-10 4'- OCH3 
2-2 2'-Cl 2-11 4'-CN 
2-3 3'-Cl 2-12 4'-CH3 
2-4 4'-Cl 2-13 2'-F 
2-5 2'-OH 2-14 3'-OCH3, 4'-OH 
2-6 3'-OH 2-15 3',4',5'-( OCH3)3 
2-7 4'-OH   
2-8 2'-OCH3   2-16 a  4,6-Dihydroxybenzofuran-
3(2H)-one  
2-9 3'- OCH3   
 



















Compound R1 Compound R1 
3-1 H 3-7 4'-OH 
3-2 2'-Cl 3-8 2'-OCH3 
3-3 3'-Cl 3-9 3'- OCH3 
3-4 4'-Cl 3-10 4'- OCH3 
3-5 2'-OH 3-11 4'-CN 

















Compound R1 Compound R1 
4-1 H 4-7 4'-OH 
4-2 2'-Cl 4-8 2'-OCH3 
4-3 3'-Cl 4-9 3'- OCH3 
4-4 4'-Cl 4-10 4'- OCH3 
4-5 2'-OH 4-11 4'-CN 
4-6 3'-OH 4-12 4'-CH3 




























































        
Compound 
R1 Compound R1 
7-1 H 7-6 4'-OCH3 
7-2 2'-OHl 7-7 2'-Cl 
7-3 3'-OH 7-8 4'-Cl 
7-4 4'-OH 7-9 2'-F 
7-5 2'-OCH3 7-10 3'-F 





















Modifications were also made to ring C of the aurone template. The 1st  
modification was to omit the exocyclic double bond, thus removing the benzylidene 
side chain (1-27, 2-16).  These compounds together with those in Series 8 would 
provide evidence on the importance of the Michael acceptor moiety for induction 
activity.  The 2nd modification on ring C was to switch the positions of the carbonyl 
functionality and exocyclic double bond to give isoaurones.  As a result of this 
relocation, the carbonyl function in isoaurones is embedded as a lactone unlike 
aurones where it is present as a ketone carbonyl.  Talalay and co-workers have noted 
that lactones were poorer NQO1 inducers (Figure 2-1) and proposed that this could 
arise from the hydrolysis of the lactone or the weaker electron withdrawing effect of 
the carbonyl group when it is part of an ester/lactone as compared to a ketone [52]. 
The latter finds support from the Swain and Lupton F (inductive) and R (resonance) 
values for an ester (-COOC2H5: F = 0.47; R = 0.67) and ketone (-COCH3: F = 0.50; R 
= 0.90), with values of greater magnitude indicating a stronger electron withdrawing 
effect [75].  Thus, switching the positions of the carbonyl group and double bond is 
likely to affect the electron density on the double bond and its reactivity as a Michael 
acceptor moiety. The hydrolytic instability of isoaurones has not been noted in the 
literature.   
 
Figure 2-1: Concentration (CD) of some lactones and related compounds required to 








2.3. Chemical considerations 
2.3.1. Aurones 
Two synthetic routes have been reported for aurones (Figure 2-2).  The first 
method involves the formation of a common benzofuran-3(2H)-one core and 
subsequent aldol condensation with a benzaldehyde. [64, 76, 77]  The second method 
involves the oxidative cyclization of 2'-hydroxychalcones [78, 79]. The first approach 
was adopted in this thesis because it provided greater flexibility in the choice of 
starting materials, many of which are commercially available. 
 











Benzofuran-3(2H)-one as common core




The dimethoxylated aurones of Series 1 were synthesized as shown in Scheme 
2.1. It involved the sodium hydride-catalyzed condensation of 3,5 -dimethoxyphenol 
with chloroacetic acid to give phenoxyacetic acid 1-28.  Intramolecular Friedel-Craft 
acylation of the carboxyl side chain in the presence of polyphosphoric acid (PPA) 
gave benzofuranone core 1-27. This common intermediate was reacted with various 



















Scheme 2.1 Reagents and conditions: (a) Chloroacetic acid, NaH, DMF, rt, 12 h. (b) 
Polyphosphoric acid, 90 °C, 8 h.  (c) Substituted benzaldehyde, KOH 50 % in water, 
MeOH, rt, 1-3 h. 
 
 Figure 2.3 depicts the mechanism involved in the synthesis of 1-27. In the 
cyclization step, the carbonyl oxygen of the acid side chain is protonated by PPA, 
followed by loss of water (PPA also serves as a dehydrating agent) and the formation 
of the electrophilic acylium ion. The ensuing Friedel-Craft acylation reaction is 
facilitated by the two methoxyl groups at positions 3 and 5 of the aromatic ring. Their 
activating and  ortho-para directing effects facilitate the intramolecular attack by the 
electrophilic acylium, resulting in ring closure to give 1-27.   
 























The reaction of the benzofuran-3-one 1-27 with various benzaldehydes or 
heteroaromatic aldehydes proceeded by an aldol condensation.  Under the basic 
conditions of the reaction, 1-27 forms an enolate which reacts with the electron 
deficient carbonyl carbon of the benzaldehyde with loss of water to give the desired 
aurone.  (Figure 2-4). 
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The synthesis of the dihydroxylated aurones of Series 2 involved the Hoesch acylation 

























Scheme 2.2 Reagents and conditions: (a) Chloroacetonitrile, HCl, ZnCl2, Et2O, 0 
°CÆ rt, 24 h.  (b) 1N HCl, 100 °C, 1h.  (c) NaOAc, MeOH, reflux, 2 h.  (d) 
Substituted benzaldehyde, KOH 50% in water, MeOH, microwave heating, 110 °C, 
10-15 min. 
 
In the presence of HCl and zinc chloride (as Lewis acid catalyst), 
chloroacetonitrile formed an electrophilic species that is probably analogous to the 
acylium electrophile depicted in Figure 2-5. The electron rich phloroglucinol was 
readily attacked by this electrophilic specie to give an iminium hydrochloride salt 
which precipitated out of the ethereal reaction medium and was removed by filtration.  
It was then hydrolyzed under acidic conditions to form the chloroacetophenone 2-17 
in moderate yields (40-60%).  Ring closure to give the benzofuranone 2-16 was 
carried out under basic conditions, probably by a nucleophilic attack by the phenoxide 
on the α-carbon with the loss of chloride as leaving group.   
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Figure 2-5 Mechanism of the Hoesch acylation of phloroglucinol to form intermediate 





































The synthesis of several 4,6-dihydroxyaurones (including some reported here) 
were previously reported by Okombi et al. [64].  In their procedure, the phenolic OH 
groups on the benzofuranone 2-16 were protected with 2-methoxyethoxymethyl 
chloride (MEM-Cl) before condensation with the aldehyde, mainly to avoid side 
reactions that would lead to poor yields.  These groups were then removed by 
hydrolysis of the final product to regenerate the phenolic OH. The additional steps of 
protection and deprotection would normally reduce the overall yield. In order to avoid 
these additional steps, the condensation reaction was carried out with microwave 
heating (110oC, 10-15 minutes) in a commercial microwave reactor. This method 
significantly reduced the time for condensation from 1-2 hours to a few minutes and 
gave the products with satisfactory yields (15-68 %).  The shortened reaction times 
may be the reason why the phenolic groups could be left unprotected for the aldol 
condensation.  There were however two compounds 2-13 and 2-14 which could not be 
obtained by microwave assisted synthesis and for these compounds, the conventional 
 35
method of protecting the phenolic OH with MEM chloride, aldol condensation and 
removal of the protective ether groups to give the desired aurone was followed [64].  
It is not known why microwave assisted synthesis did not proceed for these 
compounds. 
The monohydroxylated aurones of Series 3 (5-hydroxyaurones) and Series 4 
(6-hydroxyaurones) were synthesized by the bromination of the α-carbon of 2',5'-
dihydroxyacetophenone and 2',6'-dihydroxyacetophenone which were commercially 
purchased.  Bromination was carried out with cupric bromide to give intermediates 3-
13 and 4-13. Ring closure to give the benzofuranones 3-14 and 4-14 was achieved by 
the loss of bromide (a good leaving group) and nucleophilic attack by the ortho-OH 
on the electron deficient α-carbon. The benzofuranones were then condensed with 
benzaldehydes to give the Series 3 and 4 aurones.  Condensation was carried out 
without protection of the phenolic OH group and by conventional heating, as reported 
by others [64].  It seemed that protection of the phenolic OH was necessary only for 












R R R R
R = 5-OH
R = 4-OH
R = 5-OH  3-13
R = 4-OH  4-13
R = 5-OH 3-14
R = 6-OH 4-14
R = 5-OH  Series 3
R = 6-OH  Series 4
 
Scheme 2.3 Reagents and conditions: (a) CuBr2, CHCl3-ethyl acetate, reflux, 8 h.  (b) KOH 
50 % in H20, methanol, reflux, 2 h.  (c) Substituted benzaldehyde, KOH 50 % in H20, 
methanol, 60 °C, 1 h. 
 
Aurones 5-1 and 5-2 of series 5 were synthesized by aldol condensation of the 
commercially available benzofuran-3(2H)-one with 2’-hydroxybenzaldehyde and 2’-
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chlorobenzaldehyde respectively.  The dehydro-aurones 8-1 and 8-2 were synthesized 






R' = H (1-1)






R' = H (8-1)
R' = 2'OH (8-5)  
Scheme 2.4 Reagents and conditions: (a) H2, 40 psi, 10% Pd/C, MeOH, 24 h 
 
In cases where phenolic hydroxyl groups were present on the reacting 
benzaldehydes, these were protected by conversion to tetrahydropyranyl ethers with 
2H-3,4-dihydropyran in the presence of pyridinium p-toluenesulphonate. 
Deprotection was effected by acid hydrolysis of the final condensation product. The 
protection-deprotection step was carried out for all phenolic OH groups except those 
attached to the ortho position of the benzaldehyde.  
 
2.3.2. Isoaurones 
The isoaurone template is rarely found in nature, with no more than two 
members reported to date [81, 82].  Accordingly, only a few methods are available for 
the synthesis of this template.  Two methods were attempted for the synthesis of the 
Series 6 isoaurones.   
The 1st method was based on an intramolecular Heck reaction reported by 
Rizzi et al. [83] (Figure 2-6).  In this method, a substituted cinnamic acid was 
esterified with a functionalized ortho-iodo phenol.  The resulting ester is subjected to 
Heck reaction in the presence of Pd(OAc)2 with tri-(o-tolyl)phosphine and 
triethylamine to give the isoaurones as mixtures of E and Z isomers.  This method was 
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reported to give reasonable yields [83] but it did not work well when attempted for the 
Series 6 isoaurones. 
























E:Z 1:1  
 The 2nd method was based on an early report described by Gripenberg and 
Juselius [84].  In this route, the benzofuran-2-one was synthesized and then reacted 
with benzaldehyde by an aldol condensation.  It is very similar to that described for 
the synthesis of the aurones and uses several common reagents as well. As shown in 
Scheme 2.5, the first step involved the condensation of the starting 3,5-dimethoxy-2-
hydroxyacetophenone with sulphur and morpholine in a Willgerodt-Kindler reaction 
to yield a thiomorpholide intermediate.  Base-catalyzed hydrolysis of the 
thiomorpholide gave a phenylacetic acid intermediate 6-6 which underwent 
cyclization in the presence of phosphorus oxychloride to give the benzofuran-2(3H)-
one core 6-7. The latter was then reacted with substituted benzaldehydes in an aldol 

























Scheme 2.5  Reagents and conditions: (a) Sulphur, morpholine, 150 °C, 24 h.  (b) 2 
M NaOH, reflux, 6 h. (c) POCl3, dichloroethane, rt, 16 h.  (d) Substituted 
benzaldehyde, Et3N, Ac2O, 60 °C, 6-12 hours. 
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  Many aspects of the mechanism underlying the Willgerodt-Kindler reaction 
are not well understood [85].  It may entail the formation of an enamine which then 
undergoes thiation. After a cascade of thio-substituted iminium-azidirinium 
rearrangements as shown in Figure 2-7, a thioamide adduct is formed which is then 
hydrolyzed to give the carboxylic acid [86]. The Willgerodt-Kindler reaction is an 
important route for the preparation of aryl carboxylic acids from aryl ketones [85].  
 
Figure 2-7: Mechanism for the Willgerodt-Kindler reaction.  




















































                
 
The 5-hydroxyisoaurones of Series 7 were readily synthesized because 5-
hydroxybenzofuran-2(3H)-one was commercially available.  A straight forward base 
catalyzed aldol condensation of the benzofuranone with suitably substituted 
benzaldehydes gave the desired functionalized 5-hydroxyisoaurones in good yields 










Scheme 2.6.  Reagents and conditions: (a) Subsituted benzaldehydes, KOH 4%, 
ethanol, rt, 12h. 
 
2.4. Assignment of configurations 
2.4.1. Aurones  










E -aurone Z-aurone  
Aurones exist as E or Z isomers, with the Z isomer regarded as the 
thermodynamically more stable form [87]. Many authors have made the E/Z 
assignment based on the 1H chemical shift of the olefinic proton (Cβ-H) [76, 78, 88].  
In the literature, a chemical shift of δ 6.70 ppm was cited for Cβ-H in the Z isomer 
and δ 7.01 ppm for Cβ-H in the E isomer [76].  This assignment may be explained by 
the anisotropic diamagnetic shielding by the circulating π electrons of the carbonyl 
bond on the olefin proton [89].  In the Z isomer, Cβ-H is shielded because it is found 
in a region where the induced magnetic field due to the circulating π electrons of the 
carbonyl bond opposes the applied magnetic field.  Therefore it comes to resonance at 
a lower δ value.   In the E isomer, Cβ-H lies in the plane of the double bond and is 
thus deshielded.  Z/E isomers were also distinguished by the 13C chemical shift of the 
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exocyclic carbon (Cβ) [90]. In the Z isomer, the chemical shift was reported at δ 111 
ppm while in the E isomer, it was observed at a higher frequency of δ 120–130 ppm.  
Both 13C and 1H chemical shifts were used to assign the Z/E configuration of the 
synthesized aurones.  
The 13C chemical shifts of Cβ appeared at δ 105–111 ppm, in keeping with a Z 
configuration of the exocyclic double bond. However, there was some ambiguity 
when the 1H chemical shifts of the Cβ-H were considered. Most of the aurones had 
values in the range of δ 6.68–6.77 ppm which was consistent with reported values for 
known Z aurones. On the other hand, aurones with 2' substituents had values of δ 
6.90–7.18 ppm which falls within the range of E isomers.  To complicate matters, an 
ortho-substituted aurone (4,6-dihydroxy-2-(2'-hydroxybenzylidene)-benzofuran-
3(2H)-one, 2-5 in Series 2) was assigned the Z configuration [64], in spite of a 1H 
chemical shift of 7.12 ppm for its olefinic (Cβ-H) proton.  Clearly, assigning the 
configuration of 2’-substituted aurones based solely on chemical shifts may not be 
reliable.   Hence, x-ray structures were obtained for two aurones (1-10, 3-10).  Aurone 
1-10 has 2’-methoxy on ring B and a 1H chemical shift of 7.33 ppm for its olefinic 
(Cβ-H) proton.  Its X-ray structure showed that the double bond in the Z configuration 
(Figure 2-9a).  Hence, other 2’-substituted aurones were similarly assigned the same 
configuration.  Aurone 3-10 has 4’-methoxy on ring B and 1H chemical shift of 6.87 
ppm for its olefinic (Cβ-H) proton. It was found to have the Z configuration as well 
(Figure 2-9b)  Thus, aurones with 2’-substituents have anomalous 1H chemical shifts 





































Like aurones, isoaurones are present as E and Z isomers. Assignment of E/Z 
configuration by 1H and 13C NMR chemical shifts is not as clear cut as for aurones.  
There is some uncertainty in the literature [83, 91, 92] and most authors make their 
assignments by analogy to earlier reports.   The chemical shifts of the olefinic proton 
(Cβ-H) and the ortho (2', 6') protons of ring B are most widely used to make the 
assignment, with a general preference for the latter because of the larger chemical 
shift differences of the E and Z isomers [92].  Assignments based on a representative 
reference are given in Figure 2-11. 
Figure 2-11: Chemical shifts (δ) of olefinic proton (Cβ-H) and ortho (2’, 6’) protons 


























The differences in chemical shifts in the two isomers are attributed to the deshielding 
effect of the carbonyl group.  The ortho protons on ring B are deshielded by the ring 
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current associated with the carbonyl bond in the Z isomer but not in the E isomer.  
The downfield shift of the olefinic proton in the E isomer is less readily explained, 
and seems to be at odds with the observations made with aurones.  The differences in 
13 C shifts of the olefinic (Cβ) carbon between E (169 ppm) and Z (166 ppm) isomers 
were reportedly too small to be useful [92].  
 Analyses of the 1H and 13C NMR spectra of the Series 6 and 7 isoaurones, 
pointed to the presence of mixtures of E and Z isomers.  Other investigators have also 
found that synthesis of isoaurones gave E/Z mixtures, with E to Z ratios ranging from 
10: 1 to 1: 1 [83, 92].  By integrating peak areas for the olefinic Cβ-H and ortho-H on 
ring B, it was concluded that the predominant product was the E isomer (80-90%).  
Table 2-7 gives a summary of the 1H chemical shifts of the CβH and ortho H for the 
synthesized compounds   
 
Table 2.2 Comparison of 1H NMR chemical shifts of E and Z isomers for the 
isoaurones.   








E isomer Z isomer
H H
 
E isomer Z isomer Compound 


































































































a   In series 6, E isomers had 2', 6' or 6' protons with smaller shifts (δ 7.36-7.65)  than 
the corresponding protons of  Z isomers (δ 7.73-8.26).  In series 7, the same trend was 
observed with δ 7.47-8.21 in E isomers versus δ 7.98-8.60 in Z-isomers. 
b   In series 6,  E isoaurones had olefinic protons with larger shifts (δ 7.76-7.98) than 
those of the Z-isomers (δ 7.31-7.67). In series 7, this trend was seen with δ 7.75-7.97 
in E isomers versus δ 7.10-7.79 in Z-isoaurones. 
 
2.5. Experimental methods 
2.5.1. General details 
Reagents (synthetic grade or better) were obtained from Sigma-Aldrich Chemical 
Company Inc (Singapore) and used without further purification.  Melting points were 
determined on a Gallenkamp melting point apparatus and reported as uncorrected 
values.  Mass spectra were captured on an LCQ Finnigan MAT equipped with a 
chemical ionization (APCI) probe and m/z values for the molecular ion were reported. 
HRMS were taken using a Q-TOF Premier (Waters Corp., Milford, USA).   1H and 
13C NMR spectra were determined on a Bruker Spectrospin 300 Ultrashield 
spectrometer and referenced to TMS for 1H NMR spectra and residual CHCl3 ( δ 
77.0) and DMSO (δ 39.5) for 13 C NMR.  Merck silica 60 F254 sheets and Merck 
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silica gel (0.040-0.063 mm) were used for thin layer chromatography (TLC) and flash 
chromatography respectively.  Purity of final compounds were verified by combustion 
analysis (C,H) on a Perkin Elmer PRE-2400 Elemental Analyzer or by HPLC on two 
different solvent systems (for 6-2, Section 2.5.12). Spectroscopic data, melting points, 
yields and purities of individual compounds are listed in Appendix 1.  
 
2.5.2. General Procedure for the synthesis of Series 1 (4, 6-dimethoxyaurones) 
2.5.2.1.  3, 5-dimethoxyphenoxyacetic acid (1-28) 
The method of Lawrence et al. [70] was followed. To a solution of 3,5-
dimethoxyphenol (0.83 g, 5.44 mmol) in anhydrous DMF (10 ml) was added sodium 
hydride (0.33 g, 13.6 mmol). Chloroacetic acid (0.51 g, 5.44 mmol) in DMF (10 ml) 
was added dropwise and the mixture stirred under cover of nitrogen gas at room 
temperature for 12 h. After this time, the mixture was quenched with 4M HCl (100 
ml) and extracted with dichloromethane (3× 50 ml). The organic phase was washed 
with brine, dried with anhydrous Na2SO4 and evaporated in vacuo to give brownish 
oil which solidified to a white solid on cooling in an ice-bath. Recrystallisation in 
chloroform–hexane gave 1-28 in 60-70 % yield. White needle-like crystalline solid; 
mp 148–149 °C (Lit [93] mp: 118-122 °C); 1H NMR (CDCl3, 300 MHz): δ 6.14 (t, 
1H, J = 2.0 Hz), 6.11 (d, 2H, J = 2.1 Hz), 4.65 (s, 2H), 3.74 (s, 6H); MS (APCI) m/z 
[M+1]+  212.5.   
 
2.5.2.2.  4, 6-Dimethoxybenzofuran-3(2H)-one (1-27) 
20 g of polyphosphoric acid was heated to 80 °C after which was added 0.5 g of 
compound 1-28. The mixture was stirred at 90 °C for 8 h and then poured into ice-
water (100 ml) and subsequently extracted with dichloromethane (4×50 ml). The 
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combined organic phase was washed with brine, dried with anhydrous Na2SO4 and 
evaporated in vacuo. The residue was purified by column chromatography, with 
hexane: ethyl acetate 2:1 as eluting solvent. 1-27 was obtained as a pale yellow solid, 
yield: 56%. Mp 137–139 °C (Lit [76] mp: 132-133 °C); 1H NMR (CDCl3, 300 MHz): 
δ 6.16 (d, 1H, J = 1.5 Hz), 6.02 (d, 1H, J = 1.1 Hz), 4.60 (s, 2H), 3.91 (s, 3H), 3.87 (s, 
3H); 13 C NMR (CDCl3, 75 MHz): δ 55.8, 56.2, 75.2, 89.4, 92.8, 158.2, 169.2, 176.2, 
194.0; MS (APCI) m/z [M+1]+ 195.1. 
 
2.5.2.3    Condensation of 1-27 with substituted benzaldehydes 
To a solution of 1-27 (100 mg, 0.52 mmol) in methanol (10 ml) was added the 
substituted benzaldehyde (0.76 mmol), followed by a solution of KOH (500 mg, 8.92 
mmol) in distilled water (1 ml). The solution was stirred at room temperature for 1–3 
h. The desired compound was obtained as a precipitate, removed by filtration, washed 
with cold methanol and crystallized in ethanol or methanol to give the purified 
aurone. In cases where the compounds did not precipitate, the reaction mixture was 
quenched with dilute HCl and extracted with ethyl acetate (3 × 20 ml). The organic 
phase was washed with brine, dried over MgSO4, evaporated in vacuo to yield crude 
products and purified by column chromatography with hexane: ethyl acetate as 
eluting solvents.   
 
2.5.3. General Procedure for the synthesis of Series 2 (4, 6-dihydroxyaurones) 
2.5.3.1     2', 4', 6'-trihydroxy-2-chloroacetophenone (2-17) 
The method of Beney et al. [76] was followed. To a solution of phloroglucinol (2 g, 
15.8 mmol) in anhydrous diethyl ether were added chloroacetonitrile (1.2 ml, 15.8 
mmol) and freshly heated ZnCl2 (60 mg, 0.52 mmol). The reaction mixture was 
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cooled to 0° C. Dry HCl gas (generated by slow addition of concentrated HCl to 
concentrated sulfuric acid [94]) was bubbled through the reaction for 15 minutes. The 
reaction mixture was stirred at 0° C for 3 hours, followed by 24 hours at room 
temperature. The precipitated iminium salt was removed by filtration, washed with 
diethyl ether (3 × 50 ml) and dried in a desiccator. The imine was dissolved in 100 ml 
of 1N HCl and refluxed at 100 °C for 1 hour. The red solution was kept overnight at 
0° C. Compound 2-17 was obtained as a yellow precipitate in 39% yield, collected by 
filtration under suction, washed with ice-cold water and dried. Mp 208-210 ° C; 1H 
NMR (DMSO-d6, 300 MHz):  δ 4.96 (s, CH2), 5.81 (s, 2H), 10.5 (s, 1H), 12.0 (s, 2H, 
-OH). 
 
2.5.3.2   4, 6-Dihydroxybenzofuran-3(2H)-one (2-16) 
2-17 (5 mmol) was dissolved in methanol (30 ml), treated with NaOAc (14 mmol) 
and refluxed (2 h). The solvent was removed in vacuo to give a residue that was 
diluted in water, extracted with diethyl ether, washed with brine and dried with 
Na2SO4. On removal of the solvent under reduced pressure, 2-16 was obtained as a 
brown solid in 88% yield, Mp 211-212 °C (lit. [84] mp 210-212 °C).  1H NMR 
(Methanol-d4, 300 MHz): δ 4.59 (s, 2H), 5.91 (d, J = 1.5 Hz, H5), 5.97 (d, J = 1.9 Hz, 
H7); 13 C NMR (Methanol-d4, 75 MHz): δ 74.8, 90.1, 96.2, 99.6, 102.6, 157.5, 167.6, 
175.6, 193.9; MS (APCI) m/z [M+1]+ 167.2. 
 
2.5.3.3.   Condensation of 2-16 with substituted benzaldehydes 
To a solution of 2-16 in methanol (10 ml/mmol) was added the substituted 
benzaldehyde (0.76 mmol), followed by a solution of KOH 50% in water (1.5 
ml/mmol). The reaction was carried out in a sealed tube and heated in a microwave 
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reactor (Biotage Initiator) at 110 °C for 10-15 min. The reaction mixture was 
quenched with dilute HCl and extracted with ethyl acetate (3 × 20 ml). The organic 
phase was washed with brine, dried over Na2SO4, and evaporated in vacuo to yield the 
crude product which was purified by column chromatography using hexane: ethyl 
acetate (9:1) as eluting solvent.  
 
2.5.3.4     Protection and deprotection of phenolic hydroxyl groups of 2-16  
A solution of 2-16 (3 mmol) and N, N-diisopropylethylamine (2 equiv) in anhydrous 
DMF was cooled to 0°C. 2-Methoxyethoxymethyl chloride (MEM-Cl, 2 equiv) was 
added dropwise and the reaction mixture was stirred at room temperature for 30 min. 
The mixture was then diluted with water and extracted with ethyl acetate (3 × 60 ml). 
The organic fraction was washed with brine, dried with Na2SO4 and evaporated in 
vacuo to yield the product as an oil.  It was used without further purification for 
condensation with the benzaldehyde (2-fluorobenzaldehyde or 3-methoxy-4-
hydroxybenzaldehyde). At the end of the reaction, the protecting groups were 
removed by adding ethereal HCl to acidify the methanolic solution and heating at 60 
°C for 2 h. The reaction mixture was diluted with water and extracted with ethyl 
acetate (3 × 20 ml), after which the organic phase was washed with brine, dried over 
Na2SO4, and evaporated in vacuo to yield the crude product which was purified by 
column chromatography as described earlier. 
 
2.5.4. General Procedure for the synthesis of Series 3 (5- hydroxyaurones) 
2.5.4.1   5-Hydroxybenzofuran-3(2H)-one (3-14) 
The method of King and Ostrum was followed [95]. Briefly, a solution of 2', 5'-
dihydroxyacetophenone (16.4 mmol) in ethyl acetate-chloroform (20 ml) was added 
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to cupric bromide (33 mmol) contained in a round-bottom flask under a blanket of 
nitrogen gas. The reaction mixture was refluxed (8 h) with vigorous stirring after 
which reduced copper (I) bromide was filtered off and the filtrate evaporated in vacuo 
to give 2-bromo-1-(2,5-dihydroxyphenyl)ethanone (3-13) as an amber-colored oil 
which was used without further purification. Crude 3-13 was dissolved in methanol 
(10 ml), treated with 0.5 ml of KOH (50% in distilled water) and refluxed (2 h). The 
solvent was removed in vacuo and the residue purified by column chromatography 
(hexane: ethyl acetate = 8:1) to give 3-14 as a light yellow solid, 55% yield. Mp 133-
135 ° C (lit [96a] 152-153 ° C) 1H NMR (DMSO-d6, 300 MHz):  δ 4.74 (s, 2H), 6.86 
(d, J = 2.3 Hz, H4), 7.12 (d, J = 9 Hz, H7), 7.18 (dd, J1 = 2.3 Hz, J2 = 11 Hz, H6); 13C 
NMR (DMSO-d6, 75 MHz):  δ 75.1, 106.3, 114.1, 121.1, 126.7, 152.3, 167.2, 199.9; 
MS (APCI) m/z [M+1]+ 151.2.   
 
2.5.4.2   Condensation of 3-14 with substituted benzaldehydes 
To a solution of 3-14 in methanol (10 ml/mmol) was added the substituted 
benzaldehyde (0.76 mmol), followed by a solution of KOH 50% in water (1.5 
ml/mmol) and heated at 60 °C for 1 hour. The reaction mixture was quenched with 
dilute HCl and extracted with ethyl acetate (3 × 20 ml). The organic phase was 
washed with brine, dried over Na2SO4, and evaporated in vacuo to yield the crude 
product which was purified by column chromatography with hexane: ethyl acetate 






2.5.5. General Procedure for the synthesis of Series 4 (6- hydroxyaurones) 
2.5.5.1   6-Hydroxybenzofuran-3(2H)-one (4-14) 
The same procedure described in 2.5.4.1 was followed. The intermediate 2-bromo-1-
(2,4-dihydroxyphenyl)ethanone (4-13) was obtained and used without further 
purification to give 4-14 as a light yellow solid in 21% yield. Mp 242-244 °C. (lit. 
[96b] mp 245° C) 1H NMR (DMSO-d6, 300 MHz):  δ 4.70 (s, 2H), 6.50 (d, J = 1.5 
Hz, H7), 6.61 (dd, J1 =1.9 Hz, J2 = 10 Hz, H5) 7.48 (d, J = 8.3 Hz, H4), 10.9 (br s, -
OH); 13C NMR (DMSO-d6, 75 MHz):  δ 80.8, 101.0, 108.1, 115.6, 131.1, 163.2, 
166.3, 198.4; MS (APCI) m/z [M+1]+ 151.1  
 
2.5.5.2   Condensation of 4-14 with substituted benzaldehydes 
The procedure described in Section 2.5.4.2 was followed. 
 
2.5.6.  General Procedure for the synthesis of Series 5 (ring A unsubstituted 
aurones). 
Commercially purchased benzofuran-3(2H)-one (purity 97%) was reacted with 2-
hydroxybenzaldehyde or 2-chlorobenzaldehyde as described in Section 2.5.4.2. 
 
2.5.7. Protection and deprotection of phenolic hydroxyl groups on 3-
hydroxybenzaldehyde, 4-hydroxybenzaldehyde, 2, 3-dihydroxybenzaldehyde and 2,4-
dihydroxybenzaldehyde.  
The benzaldehyde (3 mmol), pyridinium p-toluenesulphonate (50 mg, 0.2 mmol) and 
3,4-dihydro-2H-pyran (673 mg, 8 mmol) were dissolved in dichloromethane (10 ml) 
and stirred for 4 h at room temperature. The reaction mixture was then washed with 1 
M Na2CO3 (3 x 20 ml), dried over anhydrous Na2SO4 and the solvent removed in 
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vacuo to give the crude tetrahydropyranyl ether as an oil.  It was used without 
purification for the condensation with the benzofuranone as described in earlier 
paragraphs.  At the end of the reaction, deprotection was carried out by acidifying the 
reaction mixture with 4M HCl and stirring for 4 h at room temperature.  The reaction 
mixture was extracted with ethyl acetate and worked up as described earlier. 
 
2.5.8. General Procedure for the synthesis of Series 6 (4,6-dimethoxyisoaurones) 
2.5.8.1    4, 6-Dimethoxy-2-hydroxyphenylacetic acid (6-6) [84] 
Briefly, 4,6-dimethoxy-2-hydroxyacetophenone (1 g, 5 mmol) was heated with 
sulphur (0.24 g, 7.5 mmol) and morpholine (1.2 ml, 7.5 mmol) at 150 °C for 24 hours. 
The reaction mixture was taken into dichloromethane, washed successively with brine 
and dilute HCl. On removal of solvent, the residue was crystallized in ethanol to give 
the thiomorpholide which was then hydrolysed by refluxing (6 hours) in 2 M NaOH. 
The solution was then neutralized with 1 M HCl, extracted with diethyl ether, the 
organic layer washed with brine and dried with Na2SO4. On removal of solvent in 
vacuo, 6-6 was obtained in 16% yield. White crystals, mp 140-142 °C (lit. [84] mp 
140-140.5 °C); 1H NMR (CDCl3, 300 MHz): δ 3.69 (s, CH2), 3.76 (s, OCH3), 3.79 (s, 
OCH3), 6.10 (s, 1H), 6.11 (s, 1H). 
 
2.5.8.2   4, 6-Dimethoxybenzofuran-2(3H)-one (6-7)  
A mixture of 6-6 (0.5 g, 2.35 mmol) and phosphorus oxychloride (2 ml) in 
dichloroethane (20 ml) was stirred at room temperature for 18 hours,  after which the 
reaction mixture was diluted with distilled water and extracted with dichloromethane. 
The organic layer was washed successively with dilute NaHCO3, water and brine, and 
dried with MgSO4. The solvent was removed in vacuo and the residue was purified by 
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column chromatography with hexane: ethyl acetate (5:1) to give 6-7 as a white solid 
in 80% yield, mp 155-156 °C (lit. [84] mp 154 °C)  1H NMR (CDCl3, 300 MHz): δ 
3.60 (s, 2H), 3.81 (s, OCH3), 3.82 (s, OCH3), 6.22 (d, J =1.8 Hz, 1H), 6.32 (d, J =1.8 
Hz, 1H); 13C NMR (CDCl3, 75 MHz): δ 30.8, 55.5, 55.7, 89.4, 94.2, 102.3, 155.8, 
156.1, 161.6, 174.8; MS (APCI) m/z [M+1]+ 194.7 
 
2.5.8.3    Condensation of 6-7 with substituted benzaldehydes 
A solution of 6-7 (50 mg, 0.25 mmol) in acetic anhydride (5 ml) was added with 1.5 
ml of triethylamine and the substituted benzaldehyde (0.5 mmol). The mixture was 
heated at 60 ° C for 6-12h.  TLC was used to monitor if reaction was completed. 
Thereafter, the mixture was diluted with water, refluxed (20 min), cooled and 
extracted with dichloromethane (3 × 20 ml). The organic layer was then washed, dried 
with MgSO4 and removed under reduced pressure to give the crude product which 
was purified by column chromatography with hexane: ethyl acetate (8:1) as eluting 
solvent.  
 
2.5.9. General Procedure for the synthesis of Series 7 (5-hydroxyisoaurones) 
Commercially purchased 5-hydroxy-2-benzofuran-2-(3H)-one (purity >98%) (100 
mg, 0.67 mmol) was dissolved in ethanol (10 ml), treated with 1.5 ml of ethanolic 
KOH (4 g in 100 ml) and the substituted benzaldehyde (1.3 mmol). The reaction 
mixture was stirred at room temperature for 12 hours after which the mixture was 
diluted with dilute HCl and extracted with ethyl acetate (3 × 30 ml). The organic 
fractions were washed with brine and dried with Na2SO4. The solvent was evaporated 
to yield the crude product which was purified by column chromatography with 
hexane: ethyl acetate (5:1) as eluting solvent.  
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2.5.10.   General Procedure for the synthesis of Series 8 (8-1, 8-2) 
1-1 or 1-5 (80 mg, 0.3 mmol) was dissolved in methanol (50 ml) and 10 mg of 10 
%Pd/C was added under a blanket of nitrogen.  Reaction with H2 (40 psi) was carried 
out in a Parr hydrogenator with agitation for 24 hours.  At the end of the reaction, the 
catalyst was removed by filtration afterwhich the filtrate was removed under reduced 
pressure to give the crude product as an oily residue. The desired product was 
obtained after purification by column chromatography with hexane: ethyl acetate (5:1) 
as eluting solvent.  
 
2.5.11.    X-ray crytallography of compound 1-10 and 3-10  
Aurones 1-10 and 3-10 were grown in methanol and mounted on glass fibres. X-ray 
data were collected with a Bruker AXS SMART APEX diffractometer, using Mo K_ 
radiation at 223 K, with the SMART suite of Programs (SMART version 5.628 (200), 
Bruker AXS Inc., Madison, WI). Data was processed and corrected for Lorentz and 
polarization effects with SAINT (SAINT+ version 6.22a (2001) Bruker AXS Inc., 
Madison, WI), and for absorption effect with SADABS (SADABS, version 2.10 
(2001), University of Göttingen). Structural solution and refinement were carried out 
with the SHELXTL, suite of  programs (SHELXTL, Version 6.14 (2000), Bruker AXS 
Inc., Madison, WI). The structure of each compound was solved by direct methods to 
locate the heavy atoms, followed by difference maps for the light non-hydrogen 
atoms. All non-hydrogen atoms were generally given anisotropic displacement 





2.5.12.   High pressure Liquid Chromatography (HPLC) analysis on compound 6-2  
The purity of isoaurone 6-2 was verified by high pressure liquid chromatography 
(HPLC) on a Waters Delta 600-2487 system. Briefly, 6-2 was dissolved in methanol 
and injected through a 50 μl loop at a flow rate of 1ml/min, with UV detection at 280 
nm. A Nova Pak® C18 column (2.0 x 150 mm, 10 μm particle size, (Waters Corp., 
Milford, USA) was used for analysis.    Elution was done with two mobile phases - 
methanol: water (25:75) and acetonitrile: water (20:80) and monitored at λmax 285 nm. 
The retention times and peak areas were recorded for each compound from at least 
two independent determinations. Peaks were found to have > 95% AUC. 
 
2.6. Summary 
The synthesis of 87 compounds comprising of aurones and isoaurones was 
successfully achieved by several reported procedures. A search on the SciFinder 
ScholarTM (Chemical Abstract Service) revealed that 56 of the 87 compounds have 
not been previously reported.  The remaining compounds have been cited in previous 
reports either as naturally occurring compounds [63, 81, 97-99] or products of 
synthesis [64, 76-77, 79, 84, 92, 100-104]. The synthesis of the aurones gave the 
thermodynamically more stable Z isomer as the only product whereas the isoaurones 
were obtained as E/Z mixtures with the E isomer being predominant. All final 







Chapter 3 NQO1 Induction by Aurones and Isoaurones 
 
3.1 Introduction 
This chapter describes the NQO1 induction activity of the synthesized 
compounds in Series 1-8 with the objective of providing insight into their mode of 
NQO1 induction.  NQO1 induction is a useful and predictive biomarker for the 
discovery of chemopreventive agents. Induction activity was measured in murine 
hepatoma cells (Hepa1c1c7) by the well known Prochaska assay.  An outline of the 
sequence of investigations in this chapter is as follows:  (i) Compounds were screened 
at a fixed concentration (5 μM for most compounds) for cytotoxicity on the 
Hepa1c1c7 cells.  (ii) If cell viability was maintained at > 90%, NQO1 induction 
activity was investigated at the same concentration. (iii) If the test compound failed to 
increase NQO1 activity by 2-fold at 5μM, steps (i) and (ii) were repeated at 25 μM of 
test compound. (iv) Compounds that increased NQO1 induction activity by 2-fold at 5 
μM or 25 μM were short listed as promising inducers or “actives.” (iv) The induction 
activities of the short-listed compounds were determined over a range of 
concentrations to give the CD, which is the concentration required to increase NQO1 
activity of Hepa1c1c7 cells by 2-fold as compared to untreated control cells. (v) The 
process was repeated on a mutant Hepa1c1c7 cell (Bprc1) that possessed 
dysfunctional AhR.  
 
3.2. Experimental methods 
3.2.1. Materials 
Chemicals and reagents for cell-based assays and cell culture were purchased from 
Sigma-Aldrich Pte Ltd, Singapore.  They were penicillin G sodium, streptomycin 
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sulfate, phosphate-buffered saline, Tris base, Tween 20, bovine albumin serum, 
digitonin, glucose-6-phosphate, FAD, NADP, yeast glucose-6-phosphate 
dehydrogenase, 3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
menadione, dicoumarol, activated charcoal, sulforaphane, and beta-naphthoflavone. 
Hepa1c1c7 and Bprc1 cell lines were obtained from the American Type Culture 
Collection (Rockville, MD, USA). Test compounds were dissolved in DMSO and 
diluted with media before use to achieve a final concentration of DMSO of ≤ 0.5% 
v/v in the 96 well plate or its equivalent. The stock solutions of test compounds in 
DMSO were kept at -4° C and used within three months after preparation.  Freeze-
thaw cycles were kept at a minimum and when carried out, solutions were always 
checked for precipitation upon thawing. 
 
3.2.2 Cell culture 
Mouse hepatoma Hepa1c1c7 and Bprc1 cell lines were grown in 75 cm3 flasks 
in a humidified, 5% CO2 incubator at 37° C. Growth medium consisted of α-minimal 
essential medium (Invitrogen Corp., CA, USA) supplemented with 0.1 g/L penicillin 
G sodium, 0.1 g/L streptomycin sulfate, and 10% fetal bovine serum (Hyclone, UT, 
USA). Fetal bovine serum was treated with 1 g/L of activated charcoal and heated at 
55° C for 1.5 hours before addition to medium. Cells were sub-cultured when they 
reached 80-90% confluency and passage numbers between 4 to 20 were used for 
experiments. 
 
3.2.3 Procedure for NQO1 induction assay 
The method of Prochaska and Fahey [44, 105] was used to measure NQO1 
activity in Hepa 1c1c7 cells and its variant Bprc1. Cells (10 4/well) were grown in 96 
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well plates for 24 h and subsequently incubated with test compounds for another 48 h, 
after which the media was decanted and the cells lysed by incubation (10 min) with a 
solution (50 μl per well) of 0.8% w/v digitonin and 2 mM EDTA.  The  lysed cells 
were gently agitated (10 min) prior to the addition of a freshly prepared reaction 
cocktail of the following composition :  0.5 M Tris-Cl (pH 7.4) (2.5 ml), bovine 
serum albumin (33 mg), 150 mM glucose-6-phosphate (330 µl), 7.5 mM FAD (33 µl), 
50 mM NADP (90 µl), yeast glucose-6-phosphate dehydrogenase (100 units), MTT 
(15 mg) and deionized water to give a  final volume of 50 ml. Menadione (1 µl of 50 
mM stock in acetonitrile per ml reaction mixture) was added just before the reaction 
mixture (200 µl per well) was dispensed into the wells.  Five minutes after the 
addition of the reaction mixture, the reaction was quenched by the addition of 0.3 mM 
dicoumarol in 0.5% DMSO and 5 mM K3PO4 pH 7.4 (50 µl per well). A blue color 
due to the formation of formazan was observed in each well and its absorbance was 
measured at 590 nm on a plate reader.  Blank wells were similar to treated wells 
except for the exclusion of cells and control wells were similar to treated wells except 
for the absence of test compound. NQO1 induction activity of test compound at a 
given concentration was determined from the expression:   
Degree of induction = A test compound – A blank / A control – A blank   where A is absorbance 
of formazan measured at 590 nm. 
Sulforaphane and BNF were determined under similar conditions as positive 
controls.  The results were plotted (degree of induction versus concentration) with 
OriginPro 7.5 (OriginLab Corporation, MA, USA) and the concentration of test 
compound required to increase the basal NQO1 activity by two fold (CD) was 
determined from the plot.  CD was reported as mean ± SD from 3 separate 
determinations.  
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 3.2.4 Procedure for MTT assay 
The MTT assay was carried out to determine the cytotoxicity profiles of the 
test compounds. Hepa1c1c7 cells were grown in 96-well microtiter plates at 10 4 cells 
per well for 24 h. The cells were then incubated with 5 or 25 µM test compounds for 
48 h after which the media was decanted, 100 µl of MTT solution (0.5 mg/ml) was 
added into each well and the plate incubated at 37 ºC for 3 hours. The contents of the 
wells were decanted and 150 µl of DMSO was added into each well to dissolve the 
purple formazan crystals.  Cell viability was measured by the expression :  
Cell survival (%) = [(A cells + test compound – A blank) / (A untreated cells – A blank)]   x 
100  
where A is the absorbance of formazan measured at 590 nm in the test (A cells + test 
compound), control (A untreated cells) or blank (A blank) wells. Each concentration of test 
compound was evaluated on 3 separate occasions.  
 
3.3 Results  
3.3.1. Measurement of NQO1 induction assay by the Prochaska assay 
The Prochaska assay is a rapid, efficient and inexpensive assay for measuring NQO1 
in cells cultured in microtitre plates [43].  It is widely used for the screening for new 
and potential chemopreventive agents. Several novel inducers like withanolides [45], 
4'-bromoflavone [46], and oleanane triterpenoids [30] were detected by this assay. A 
comprehensive review on the Prochaska assay is given by Fahey and co-workers [44]. 
The principle of the assay is based on the generation of NADPH when 
glucose-6-phosphate (G6P) is reduced by G6P dehydrogenase in the presence of its 
cofactor NADP+.  NADPH serves as an electron donor for the NQO1 mediated 
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reduction of menadione (a quinone) to menadiol (a diphenol).  The latter reduces 
MTT to the blue formazan which can be measured over a range of wavelengths (550-
640 nm).  A compound that induces NQO1 increases the rate at which menadiol (or 
another suitable substrate) is formed, and hence the generation of formazan. Other 
oxidizable substrates besides menadione may be used for the assay [106].  Figure 3.1 
depicts the sequence of reactions involved in the Prochaska assay with menadione as 
substrate.  
 




















 The cell line commonly employed in the Prochaska assay is the mouse 
hepatoma Hepa1c1c7 although other cell lines like the human breast cancer MCF7, 
human skin keratinocytes HaCat, human colon cancer HCT116, human gastric 
epithelial AGS, human adult retinal pigmented epithelial APRE-19, human prostate 
LNCaP, and murine leukemia L1210  have been used [41, 106]. The choice of the cell 
line is determined primarily by the responsiveness of the cellular NQO1 to induction.  
In this respect, the Hepa1c1c7 cells are outstanding [44] and the use of this cell line 
has provided reliable quantitative measures of induction potencies. In addition, the 
responses elicited in Hepa1c1c7 cells were correlated to in vivo responses of murine 
tissues and chemoprotective effects in chemical carcinogenesis models [44].  
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Although the Hepa1c1c7 is a mouse cell line, there are close inter-species 
similarities between human and rodent NQO1 protein sequences as well as the ARE 
sequences regulating the transcriptional activation of NQO1 [34, 35]. This supports 
the use of this cell model in the development of clinically relevant chemopreventive 
agents. 
 
3.3.2. Preliminary Evaluation of NQO1 induction activity of Series 1-8 compounds 
  The test compounds were initially screened at 5 μM for cytotoxicity against 
Hepa1c1c7 cells.  At this concentration, only 3 compounds (1-9, 1-10, 1-13) reduced 
cell viability by more than 90%, Hence, these compounds were tested at 1 μM for 
NQO1 induction while the other compounds were screened at 5 μM.  The choice for 
this concentration was based on physiologically achievable levels of related 
flavonoids such as quercetin in human [58]. In this way, 23 compounds (including 1-
10 and 1-13) were found to increase NQO1 activity by two fold (indicated by * in 
Table 3.1).  
Noting that sulfuretin, one of the naturally occurring aurones with NQO1 
induction activity, had a CD value of 20.7 μM, it was thought that many “active” 
compounds may have been missed because of the low concentration (5 μM) used 
here. Hence, the compounds that failed to increase NQO1 activity by 2 fold at 5 μM 
were re- evaluated at a higher concentration of 25 μM.  As before, they were initially 
tested for their cytotoxic effects on the Hepa1c1c7 cells. The compounds were found 
to be remarkably non-cytotoxic even at 25 μM and all were tested for NQO1 
induction.  An additional 9 compounds were identified, bringing the total number of 
compounds that caused a 2 –fold (or greater) induction of NQO1 activity at 5 μM or 
 61
25 μM to thirty two.  These compounds were designated as “actives” and shortlisted 
for CD determinations (Section 3.3.3.) 
 Table 3-1 provides a tabulation of the induction activities expressed as fold 
induction (relative to control cells) and % viability of Hepa1c1c7 cells in the presence 
of the test compounds at 5 μM and 25 μM (where applicable).  Sulforaphane and 
beta-naphthoflavone (BNF) were used as positive controls.  They were tested at 0.5 
μM and 0.05 μM respectively and at these concentrations, caused more than a 3 fold 
increase in NQO1 activity (Table 3-1) 
                                  
Table 3.1:  Screening of Series 1-8 compounds for NQO1 induction activity at fixed 
concentrations of 5 μM and /or  25 µM. 
      Fold Induction a     Percent Survival b Compound 
5 µM  25 µM 5 µM 25 µM 




























7.70 ± 0.79*  
5.60 ± 0.91* 
3.98 ± 0.94* 
2.13 ± 0.56* 
5.28 ± 0.14* 
1.20 ± 0.40 
1.18 ± 0.30 
2.53 ± 0.51* 
1.03 ± 0.14  (1 µM) 
3.66 ± 0.47*(1 uM) 
0.91 ± 0.24 
1.06 ± 0.22 
2.60 ± 0.17*(1 uM) 
4.47 ± 0.33* 
2.16 ± 0.48* 
1.36 ± 0.35 
1.08 ± 0.08 
1.61 ± 0.24 
1.79 ± 0.36 
1.34 ± 0.08 
1.16 ± 0.20 
1.25 ± 0.07 
2.26 ± 0.49* 








2.07 ± 0.13* 
1.29 ± 0.10 
 
1.40 ± 0.10 
 
1.59 ± 0.02 




1.37 ± 0.20 
0.83 ± 0.07 
1.60 ± 0.50 
1.42 ± 0.10 
1.34 ± 0.10 
0.96 ± 0.05 
1.40 ± 0.03 
 
1.90 ± 0.34 
 
 
93 ± 3 
105 ± 16 
103 ± 4 
93 ± 9  
102 ± 11 
104 ± 10 
94 ± 9 
88 ± 10 
51 ± 3  
82 ± 9 
100 ± 12 
93 ± 13 
66 ± 11 
89 ± 6 
93 ± 11 
91 ± 9 
90 ± 5 
88 ± 4 
91 ± 1 
89 ± 7 
101 ± 19 
93 ± 6 
92 ± 10 








100 ± 11 




103 ± 8 




95 ± 4 
93 ± 8 
88 ± 5 
87 ± 10  
93 ± 6 
98 ± 4 
89 ± 5 
 




















































1.82 ± 0.35 
1.79 ± 0.27 





1.39 ± 0.27 
 2.64 ± 0.16* 
 1.45 ± 0.25 
 1.59 ± 0.45 
 2.92 ± 0.52* 
 1.60 ± 0.24 
 1.23 ± 0.04 
 1.48 ± 0.40 
 2.15 ± 0.11* 
 1.15 ± 0.03 
 1.14 ± 0.04 
 1.38 ± 0.09 
 2.20 ± 0.21* 
 1.53 ± 0.15 
 1.47 ± 0.12 





2.28 ± 0.24* 
 1.33 ± 0.34 
 4.68 ± 0.51* 
 1.32 ± 0.13 
 2.65 ± 0.07* 
 1.29 ± 0.29 
 1.22 ± 0.24 
 3.10 ± 0.19* 
 1.19 ± 0.07  
 1.00 ± 0.19 
 1.30 ± 0.28 





1.14 ± 0.21 
1.02 ± 0.14 
2.85 ± 0.48* 
1.51 ± 0.30 
1.45 ± 0.05 
1.64 ± 0.40 
1.01 ± 0.02 
4.50 ± 0.75* 
1.50 ± 0.26 





1.30 ± 0.02 
 
1.71 ± 0.20 
1.70 ± 0.40 
 
1.58 ± 0.02 
1.95 ± 0.23* 
1.52 ± 0.11 
 
0.82 ± 0.01 
1.35 ± 0.40 
1.49 ± 0.20 
 
2.54 ± 0.30* 
1.60 ± 0.34 






1.71 ± 0.30 
 
1.18 ± 0.02 
 
1.66 ± 0.14 
0.94 ± 0.01 
 
1.18 ± 0.60 
1.17 ± 0.01 
1.25 ± 0.02 





1.85 ± 0.20 
1.30 ± 0.10 
 
2.55 ± 0.07* 
2.11 ± 0.07* 
2.92 ± 0.12* 
1.80 ± 0.01 
101 ± 17 
93 ± 17 





110 ± 9 
101 ± 16  
96 ± 10 
93 ± 12 
102 ± 8 
111 ± 19 
105 ± 11 
103 ± 9 
112 ± 8 
109 ± 16 
115 ± 8 
103 ± 11 
110 ± 2 
97 ± 5 
99 ± 7 





102 ± 14 
98 ± 19 
101 ± 14 
92 ± 9 
99 ± 7 
98 ± 11 
96 ± 16 
97 ± 15 
104 ± 21 
101 ± 4 
109 ± 1 





115 ± 21 
120 ± 18 
111 ± 9 
120 ± 10 
113 ± 15 
112 ± 11 
100 ± 3 
110 ± 12 
97 ± 7 





100 ± 8 
 
86 ± 5 
96 ± 4 
 
106 ± 7 
98 ± 4 
100 ± 5 
 
114 ± 8 
102 ± 5 
95 ± 5 
96 ± 4 
98 ± 5 
94 ± 6 






94 ± 5 
 
86 ± 5 
104 ± 10  
89 ± 9 
87 ± 6 
95 ± 5 
110 ± 10 
99 ± 7 
101 ± 9 





110 ± 10 
117 ± 15 
 
98 ± 10 
102 ± 9 
106 ± 7 







































0.46 ± 0.14 
1.22 ± 0.45 
1.19 ± 0.11 
1.15 ± 0.06 
1.59 ± 0.15 
 
 
1.41 ± 0.13 




1.43 ± 0.15 
1.49 ± 0.08 
1.79 ± 0.01 
2.12 ± 0.15* 




1.15 ± 0.03 
2.43 ± 0.24* 
1.64 ± 0.57 
1.30 ± 0.10  
1.01 ± 0.17 
1.35 ± 0.15 
1.02 ± 0.33 
2.49 ± 0.27* 
1.05 ± 0.16 
1.14 ± 0.10 




1.46 ± 0.21 
1.55 ± 0.11 
0.61 ± 0.01 
1.01 ± 0.10 
1.50 ± 0.22 
1.31 ± 0.05 
0.90 ± 0.01 
 
 
1.61 ± 0.10 




2.10 ± 0.20* 
1.10 ± 0.25 
3.57 ± 0.40* 
 




1.37 ± 0.40 
 
1.83 ± 0.20 
1.60 ± 0.45 
1.44 ± 0.07 
1.71 ± 0.21 
1.30 ± 0.30 
 
1.34 ± 0.17 
1.32 ± 0.30 
1.23 ± 0.03 
 
95 ± 13 
85 ± 10 
91 ± 20 
94 ± 27 
98 ± 9 
 
 
110 ± 8 




100 ± 11 
121 ± 15 
118 ± 12 
90 ± 10 




89 ± 8 
115 ± 15 
95 ± 9 
111 ± 10 
92 ± 9 
110 ± 10 
93 ± 12 
90 ± 3 
102 ± 7 
127 ± 13 




95 ± 12 
102 ± 14 
96 ± 3 
84 ± 9 
95 ± 3 
90 ± 8 
100 ± 10 
 
 
102 ± 10 




96 ± 8 
89 ± 4 
107 ± 10 
 




94 ± 4 
 
87 ± 3 
101 ± 9 
110 ± 5 
118 ± 4 
87 ± 8 
 
114 ± 10 
120 ± 11 
121 ± 7 
 
Sulforaphane (0.5 µM)d 
BNF (0.05 µM)d 
 
 
3.70 ± 0.25 
3.46 ± 0.21 
 
a  Fold induction : Ratio of NQO1 activity in treated versus control untreated cells.   
Mean ± SD for n = 3.  (*) indicates compounds with fold induction ≥ 2.0.  
b Percent survival of cells determined by MTT assay. Mean ± SD for n = 3.   










The distribution of the active compounds among the different series was 
analyzed.  Within each series, the percentage of actives identified at 5 μM and 25 μM 
were determined.  The results are shown in Figure 3-2.  The more promising series 
would be those that have a larger percentage of actives at the lower concentration of 5 
μM.  This was observed for Series 1, 2, 3 and 7 and an arbitrary ranking based on this 
criteria would be Series 1 (4,6-dimethoxyaurones) > Series 2 (4,6-dihydroxyaurones), 
Series 3 (5-hydroxyaurones) > Series 7 (5-hydroxyisoaurones).   Series 2 have more 
actives (6 out of 16 compounds) than Series 3 (4 out of 11 compounds) but both have 
the same number of actives identified at 5 μM.  In the case of Series 4 and 6, most of 
the actives were identified at 25 μM.  The weakest series would be 5 and 8 with no 
active members represented.  It should however be noted that the number of 
compounds in each series are not the same, with Series 1 having more members (27) 
and Series 5 and 8 with only 2 members each.  These differences may influence the 
outcome of the screening process. 
 





















3.3.3. Determination of CD values of active compounds in Hepa1c1c7 cells 
CD is the concentration of the test compound required to bring about a two 
fold increase in NQO1 activity of Hepa1c1c7 cells.  Unlike “fold induction” which is 
determined at a fixed concentration, CD is derived from determinations made over a 
range of concentrations (usually 100 fold).  Thus it provides a more reliable and 
reproducible measure of induction potency. The CD values of the actives are given in 
Table 3-2.  Mention should be made of 1-4 which turned out to be a “false” active 
because its induction activity did not show the expected concentration dependency. 
As seen from Figure 3-3, the induction activity of 1-4 remained at 2.0 (± 0.1) from 5 
μM to 30 μM.  Hence, it was removed from the list of actives.   
Figure 3-3.  Induction of NQO1 at various concentrations of 1-4.  


















Table 3-2: CD values of test compounds on murine Hepa1c1c7 cells 




































0.31 ± 0.02 
0.40 ± 0.07 
0.61 ± 0.05 
0.18 ± 0.05 
9.8 ± 1.3 
3.37 ± 0.15 
0.31 ± 0.02  
0.16 ± 0.1  
0.15 ± 0.03 

















































































































3.8 ± 0.5 
8.5 ± 0.4 
 
 
1.7 ± 0.1 
3.0 ± 0.26 
24.3 ± 1.7 
4.4 ± 0.2 
5.5 ± 1.1 
16.5 ± 1.2 
 
3.9 ± 0.4 
0.96 ± 0.17 
2.4 ± 0.4 




2.8 ± 0.1 
7.8 ± 1.2 
9.4 ± 1.1 
11.2 ± 1.5 
 
 
25.2 ± 1.8 
11.6 ± 1.2 





2.8 ± 0.5 
3.4 ± 0.2 
 
Sulforaphane 
   
0.21 ± 0.02 
      
BNF 
   
0.012 ± 0.05 
a   Mean ± SD for n = 3 
b  Ring B is replaced by a pyridine ring 
 
As seen from Table 3-2, several aurones have submicromolar CD values.  
These were members of Series 1 (1-1, 1-2, 1-3, 1-5, 1-10, 1-13, 1-14, 1-15) and Series 
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3 (3-3, 3-8).  Both Series 1 and 3 were considered to be the more promising templates 
for NQO1 induction (Figure 3-2).  These compounds were also more active than 
sulfuretin (20.7 µM) and 6,4’-dihydroxy-3’-methoxyaurone (6.4 µM) which are 
presently the only aurones found to induce NQO1 in Hepa1c1c7 cells.  These findings 
lend support to the effectiveness of functionalization as a means of uncovering more 
potent inducers within the aurones. 
 
3.3.4. Determination of CD values of active compounds in BPrc1 cells, a mutant  
Hepa1c1c7 cell line 
Besides measuring NQO1 induction in Hepa1c1c7 cell line, CD 
determinations were also carried out on a mutant Hepa1c1c7 cell line (BPrc1).  The 
BPrc1 cells contain mutations in the Ah-receptor-mediated pathway resulting in the 
failure to translocate the Ah receptor-ligand complex to the nucleus.  As a result, these 
cells fail to respond to compounds that mediate the induction of NQO1 activity via the 
Ah receptor.   
When investigated on the Bprc1 cells, none of the actives induced NQO1 
activity.   Some representative figures are given in Figure 3-4, with the rest are found 
in Appendix 2.     In contrast, sulforaphane induced NQO1 activity in the Bprc1 cells 
(CD = 0.34 μM ± 0.01) to almost the same degree as the Hepa1c1c7 cells (CD = 0.21 
μM ± 0.02).  On the other hand, BNF, like the aurones, did not demonstrate induction 






Figure 3-4.  NQO1 induction of representative compounds in Hepa1c1c7 and BPrc1 
cell lines. CD values are given in parentheses. 
 























    




















1-1 (0.31 µM)     1-2 (0.4 µM) 
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The ability of sulforaphane to induce NQO1 activity in both Hepa1c1c7 and 
Bprc1 cells have been reported by others [30, 42]. It reflects the ability of 
sulforaphane to induce NQO1 by an AhR independent pathway, namely the  Keap1-
Nrf2-ARE signaling pathway [35].  In the conventional classification, sulforaphane is 
a monofunctional inducer.  The activity profile of BNF is more difficult to explain, 
mainly because BNF has been re-classified from its original status as a bifunctional 
inducer that acts by the AhR/XRE pathway to a mixed activator that acts by both the 
AhR/XRE and Nrf2/ARE pathways [48, 107]. As a mixed activator, BNF should 
induce NQO1 activity in BPrc1 cells but this was not observed here.  This may be 
because BNF acts more on the AhR pathway with the Nrf2-ARE pathway being 
secondary. Yanni and coworkers [56] also reported the failure of BNF to induce 
NQO1 activity in BPrc1 cells and this led them to conclude that BNF acted via the 
AhR pathway to induce NQO1. It may be that the BPrc1 cells are useful for 
distinguishing between inducers that worked exclusively by the AhR/XRE 
(bifunctional) or Keap1/Nrf2/ARE (monofunctional) signaling pathways.  For mixed 
activators that act on both pathways, it may not be a suitable screen and in fact could 




A review of the induction activities of the test compounds revealed some interesting 
structure-activity trends.  An important observation was the inactivity of the Series 8 
compounds (dehydro-aurones 8-1, 8-2) and compounds without the benzylidene side 
chain (1-27, 2-16).  These findings underscore the importance of the exocyclic double 
bond and the Michael acceptor moiety of which it is a part, for induction activity.  
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Figure 3-5 compares the induction activities of the dehydroaurones 8-1 and 8-2 with 
that of the corresponding aurones 1-1 and 1-5.  These compounds have similar rings 
A and B and the significant difference in their activities highlight the importance of 
maintaining an intact exocyclic double bond.    
 
Figure  3-5.  NQO1 induction activities of aurones (1-1, 1-5) and their dehydro 
analogues (8-1, 8-2). 
























        




























Another significant observation is the predominance of 4,6-dimethoxyaurones (Series 
1) among the “actives” (Figure 3-2) and the significantly large number of these 
compounds with submicromolar CD values (Table 3-2).  A comparison of the 
induction activities of representative aurones from Series 1, 2, 3, 4 and 5 provides 








Figure 3-6:  CD values of aurones with the same group on ring B (2’-OH) but 


















1-5: 0.18 μM 2-5: 3.0 μM







Replacement of the dimethoxy groups on ring A with dihydroxy groups 
resulted in a marked drop in induction activity.  An unsubstituted ring A was also 
unfavourable as seen from 5-1 which caused an insignificant 1.3 fold induction at 5 
μM. These observations suggest that the contribution of the methoxy groups may be 
related to its lipophilicity or bulk (compared to the hydroxyl OH).  If this is true, then 
a bulkier tri- or di-substituted ring A would be preferred to a mono-substituted ring A. 
Unfortunately a mono- or tri-methoxylated ring A aurone was not available for 
comparison.  The monohydroxylated aurones (3-5, 4-5) have smaller van der Waals 
areas and volumes but are more lipophilic (Log P) than the dihydroxylated aurone (2-
5) (Appendix 3, table a)  Both 3-5 and 4-5 were not significantly more potent than 2-
5, which may imply that bulkiness of ring A is a more important factor than 
lipophilicity.   
Talalay and co-workers found lactones to be poor NQO1 inducers and 
proposed that this was either due to the hydrolysis of the lactones or the weaker 
electron withdrawing effect of the carbonyl group when it is part of a lactone (ester) 
[52].  Since ring C is a lactone in isoaurones, they are anticipated to be poor inducers 
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and this was duly observed here.  Hydrolytic instability among the isoaurones was not 
apparent during their syntheses or biological evaluation.  Thus the weaker 
electrophilic character of the exocyclic bond in the isoaurone may be a contributing 
factor.  
There is some indication that a 5-OH on ring A is associated with better 
induction activity.  As seen from Figure 3-2, there are more “active” 5-
hydroxyaurones (Series 3) at 5 μM than 6-hydroxyaurones (Series 4), and this is also 
observed when 5-hydroxyisoaurones (Series 7) are compared with 4,6-
dimethoxyisoaurones (Series 6).  Substitution at the 5 position is not typical of 
naturally occurring aurones and more examples would be required to confirm this 
proposal. 
 The structure-activity relationship of ring B is best seen in Series 1 because of 
the large number of variations made to ring B.  It is observed that (i) ring B need not 
be substituted for good activity. 1-1 has a submicromolar CD (0.31 μM) which is 
comparable to 1-10 which has a substituted ring B.   (ii) There were four positional 
isomers in Series 1, namely chloro, fluoro, methoxy and hydroxyl at 2’, 3’ or 4’ 
position.  These groups have varying lipophilicity and electron donating/withdrawing 
properties but the most active analogue was always the one at the 2’ position and the 
least favoured was the 4’ position.  Only the 4’ F analogue 1-15 was shortlisted for 
CD determination and it was less active than the 2’-F and 3’-F analogues.  
Nevertheless, it was still the most active among ten other Series 1 compounds with 4’-
substituent on ring B.  It is possible that there are steric restrictions at this position and 
only a small group like fluoro is allowed.   (iii) Replacing the phenyl ring B with 
pyridine or quinoline is not desirable although the pyridine-2-yl 1-23 and pyridine-4-
yl 1-25 were moderately active inducers. (iv) The most active compounds in Series 1 
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(ranked by CD) had the following substituents : 2’-F ( equivalent to 3’-F  and 2’OH) 
> 2’ OCH3, H > 2’ Cl.   
Only a few of the preceding observations applied to ring B of the other series.  
An unsubstituted ring B did not fare well for most of them, except 5-hydroxyaurones 
(Series 3:  3-1).  Moreover, for each series, the optimal substituents on ring B were 
different which would suggest a dependency on the type of ring A (Figure 3-7).  
Notwithstanding these differences, a common feature was the recurrence of halogens 
(chloro, fluoro), hydroxyl and methoxy groups among the actives, and a preference 
for the 2’ and 3’ positions on ring B (with the exceptions of  4-4 and 7-8). 
 


















2'Cl > 2'OH> 3'OCH3
3'Cl > 4'Cl > 2'OH
2'OCH3>3'Cl > 2'OH





2'OH  > 4'Cl
Only two actives were
identified in this series
2'F, 3'F, 2'OH > H, 2'OCH3 > 2'Cl
Series 1 Series 2 Series 3
Series 4 Series 6
Series 7
Only three actives









The association of the 2’ OH with good induction activity has been observed 
by Dinkova-Kostova et al. for the phenylpropenoids [69]. They proposed that the 
presence of a hydrogen-donating OH group adjacent to the Michael acceptor would 
 74
facilitate the nucleophilic addition by reactive cysteine residues of the Keap1 target 
protein to the Michael acceptor moiety (Figure 3-8) [69]. This explanation may not be 
applicable to aurones since groups that are not hydrogen bond donors (Cl, F, OCH3) 
were also favoured at the 2’ position.    
 
Figure 3-8. The effect of ortho-OH on the reactivity of benzylidenealkanones with 
sulfhydryl groups as suggested in reference 69. 











 Comparisons between the active members (4-5, 4-6) of Series 4 and the two 
natural aurones with induction activity (sulfuretin and 6,4’-dihydroxy-3’-
methoxyaurone) revealed certain SAR regarding Ring B substitution. 4-5 and 4-6 with 
a single OH at 2’ and 3’ of ring B respectively were more potent than sulfuretin which 
had two OH groups at 3’ and 4’ positions. On the other hand, locating the OH at the 
4’ position (4-7) was deleterious for activity. Interestingly, replacing the 3’OH of 
sulfuretin with a methoxy to give 6,4’-dihydroxy-3’-methoxyaurone (CD 6.4 μM) 
resulted in improved activity compared with 4-5 and 4-6. The 3’-methoxy-4’-hydroxy 
motif is a common feature among natural products and some were found among the 






Figure 3-9 summarizes the structure activity relationship established for 
NQO1 induction activity from the present investigation. 
 






Ring A requires 
substitution:
R1 = OCH3 > OH
R3 = OH
A



















R2 = F, Cl, OH, OMe
at positions 2' and 3' of ring B.




Switching the positions of carbonyl 





When tested for their abilities to induce NQO1 activity in the Ah receptor-
defective Bprc1 cells, none of the compounds demonstrated induction activity which 
clearly showed that these compounds depended on AhR binding to bring about NQO1 
induction.  However these compounds need not necessarily be bifunctional inducers 
(acting only through the AhR/XRE pathway).  They could be mixed activators like 
BNF which also failed to induce NQO1 in Bprc1 cells. Hence, additional 
investigations will be required to determine if the present series of compounds are 
bifunctional inducers, with no effect on Keap/Nrf2/ARE pathway or mixed activators 







The main findings in this chapter are as follows: 
(i) Several aurones were identified as potent NQO1 inducers with submicromolar CD 
values. To date, these are the most potent inducers to have emerged from this class of 
flavonoids.  Appropriate chemical modification is a viable means of enhancing the  
induction activity of the aurone scaffold. 
(ii) Some qualitative structure activity relationships are derived from an analysis of 
the induction activity of the test compounds.  Dimethoxy groups on ring A are 
preferred to  dihydroxy groups, suggesting the value of bulky and lipophilic groups on 
this ring. Position 5 on ring A is a potentially promising position that should be 
investigated in greater detail.  The preferred groups on ring B were halogens (Cl, F), 
OCH3 and OH, and at positions 2’ or 3’.  There are indications that the substitution on 
ring A influenced the type of ring B groups that were optimal for activity. A switch in 
the positions of the exocyclic double bond and the carbonyl functionality in ring C to 
give isoaurones diminished induction activity.  An intact exocyclic double bond was 
found to be essential for NQO1 induction.  Modifications that removed this double 
bond and abolished the Michael acceptor moiety of which it is a part caused a sharp 
drop in activity.  
(iii)  The active aurones and isoaurones failed to induce NQO1 activity in mutant 
Hepa1c1c7 cells that lacked a functional Ah receptor (Bprc1 cells).  These compounds 
may be bifunctional inducers or mixed activators and more investigations (described 





Chapter 4 Investigations into the mode of NQO1 induction in Hepa1c1c7 cells 
by selected aurones  
 
4.1 Introduction 
This chapter discusses investigations into the mode of NQO1 induction by the 
target compounds.  Based on the findings of Chapter 3, it is hypothesized that the 
compounds act as mixed activators and induce NQO1 activity by activating the 
Keap1/Nrf2/ARE and AhR/XRE pathways.  To investigate this possibility, the 
compounds were tested for their ability to induce CYP1A1 activity in Hepa1c1c7 
cells The transcriptional activation of CYP1A1 is regulated by AhR and an increase in 
the catalytic activity of CYP1A1 would confirm the involvement of the AhR/XRE 
pathway.  The compounds were also tested to determine if they induced other Phase II 
enzymes that are under transcriptional regulation by the Nrf2-ARE pathway. 
Thioredoxin reductase (TrxR) is an antioxidant enzyme whose transcription is 
activated by the Nrf2 pathway [109].   Glutathione (GSH) levels in Hepa1c1c7 cells 
were also monitored because the enzyme (γ-glutamylcysteine ligase, GCL) which is 
involved in the de novo synthesis of GSH is regulated by Nrf2 acting on the ARE 
sequence of the GCL gene [110].   
 
4.2. Overview of the glutathione and the thioredoxin systems 
4.2.1. The glutathione system 
The glutathione network comprises of the endogenous thiol glutathione (GSH) 
and several enzymes involved in its synthesis and catalytic activity.  These include a 
family of glutathione transfer enzymes called glutathione S-transferases (GSTs), 
glutamyl-cysteine ligase (GCL) which is involved in the de novo synthesis of 
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glutathione, glutathione reductase (GR) which maintains glutathione in its reduced 
and catalytically useful form, a large family of glutathione-dependent peroxidases 
(termed GSH-Prxs) which participate in the elimination of peroxides, and the 
glutaredoxins (Grxs) which are GSH-dependent reductases.  
Glutathione represents the most abundant cellular non-protein thiol with 
concentrations ranging from 0.1 mM to 1 mM.  A primary determinant of intracellular 
GSH content is the rate of its de novo synthesis [111]. The rate-limiting step is 
catalyzed by two subunits (catalytic/heavy and regulatory/light) of the GCL enzyme, 
both of which are equally important for the production of GSH. The induction of the 
GCL heterodimer is regulated in part by the Nrf2-ARE pathway as several ARE 
motifs are found as promoter sequences [110]. Electrophiles, pro-oxidants and some 
chemopreventive agents are known to up-regulate GCL leading to an increase in GSH 
levels. These include sulforaphane and other isothiocyanates, BNF, dithiolthiones, 
and Michael acceptors such as the curcuminoids and benzylidenealkanones.  Oltipraz, 
a chemopreventive agent currently undergoing Phase II trial in smokers with lung 
dysplasia [112] was first discovered due to its remarkable ability to elevate GSH 
levels in murine tissues [113].  
 The cytoprotective properties of GSH and its related members may be brought 
about by various processes:  (i) GSH is an important buffer of redox homeostasis. It 
directly scavenges and reduces reactive oxygen species, being oxidized to the 
disulfide form (GSSG) in the process. The regeneration of GSH is accomplished by 
glutathione reductase which maintains the ratio of reduced to oxidized glutathione at 
99:1 [111].  Thus, the intracellular milieu is maintained in a reducing state.  The 
antioxidant function of GSH is also mediated by the GSH peroxidases (GSH-Prxs) 
which are selenoenzymes that catalyse the reduction of peroxides by GSH. For 
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example, GSH-Prx4 uniquely reduces phospholipid peroxides while GSH-Prx3 
reduces plasma peroxides [111].    
(ii) GSH participates in the phase II detoxification of xenobiotics via conjugation 
reactions catalyzed by the GSTs [114]. Xenobiotics are rendered polar and readily 
excreted by S-conjugation to form GSH adducts.  (iii) Glutathione is the “currency” of 
reversible glutathionylation of proteins which is an important redox signaling 
mechanism [115].  This is an emerging area of research which involves a group of 
GSH-dependent reductases known as glutaredoxins (Grxs). Grxs use GSH as reducing 
equivalents to perform antioxidant activity as well as to alter the redox status of 
proteins that are crucial for the survival of cells in conditions of oxidative stress. 
Examples of proteins that are regulated by Grxs are caspase-3, ASK-3, and protein 
kinase B [115].  The cytoprotective effects of GSH are summarized in Figure 4-1. 
 




























- gluthathionylation of proteins  
 
4.2.2. The thioredoxin system 
The thioredoxin antioxidant network consists of thioredoxin (Trx), thioredoxin 
reductase (TrxR) and thioredoxin peroxidases. TrxR is an enzyme that belongs to the 
flavoprotein family of pyridine nucleotide-disulfide oxidoreductase [116, 117]. It is a 
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homodimeric protein and each monomer consists of an FAD prosthetic group, an 
NADPH binding site and a redox-active disulfide site. Electrons are passed from 
NADPH via FAD to the disulfide active site of TrxR, which then reduces thioredoxins 
(Trxs), a group of redox-active peptides which provide reducing equivalents for 
various biological functions including protection against oxidative stress. 
 Unlike other flavoenzymes, mammalian TrxR is unique in having a second 
catalytic site which consists of an essential SeCys residue site located at its C-terminal 
[116].   Because of the flexibility of the C-terminal selenocysteine catalytic tail, TrxR 
exhibits antioxidant (reducing) activity on a variety of substrates like lipoic acid, 
hydrogen peroxide and lipid peroxides, dehydroascorbate and ascorbyl radicals, 
plasma GSH-Prx3 (together with GSH and Trx) and NK-lysin, a cytotoxic protein 
secreted by natural killer T-cells during bacterial infections [116, 117]. Figure 4-2 
shows the mechanism for the reducing activity of TrxR.  
 
Figure 4-2 The mechanism of mammalian/human thioredoxin reductase activity 
[116]. 





























Trx plays a crucial role in regulating DNA-binding activity and the expression 
of several redox-sensitive transcription factors such as p53, AP-1, NF-κB, and HIF-1 
[116]. It also plays an important part in cell proliferation and anti-apoptosis [118]. 
Figure 4-3 summarizes the biological functions of the thioredoxin system with 
emphasis on its antioxidant properties.   
Figure 4-3 Antioxidant properties of the thioredoxin system. 
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 One of the best known examples of Trx/TrxR modulation is the induction of 
TrxR activity by selenium supplementation in cell culture and rats. The presence of 
selenium at 1 µM in the media of cultured cells increased TrxR activity by as much as 
40-fold [119]. Tissues from rats fed with supranutritional levels of selenium showed 
transient increases in TrxR activity [120].  In these studies, TrxR enzymatic activity 
was increased, but there was no change in TrxR protein levels. Selenium-induced 
enhancement of TrxR activity is now known to be a post-transcriptional event [116]. 
 Electrophilic inducers of Phase II enzymes like sulforaphane are known to 
induce the activity of TrxR.  TrxR activity is induced via the Nrf2/ARE pathway [109, 
121, 122]. Two putative ARE consensus sequences have been identified in the TrxR 
promoter. Experiments with luciferase constructs of the TrxR promoter and mutated 
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versions of the putative ARE showed that intact ARE sequences were crucial for 
TrxR induction by electrophilic compounds such as sulforaphane, BNF and various 
Michael acceptor compounds [121]. These findings place TrxR as a member of the 
inducible phase II cytoprotective proteins. Interestingly, TrxR is reported to be highly 
expressed in epithelial cells vulnerable to ROS insult like human keratinocytes and 
melanocytes, a feature that is shared by NQO1 [123]. 
 The assay for Trx and TrxR activity in treated Hepa1c1c7 cells is based on an 
insulin-coupled chain of reactions described by Arner and Holmgren [124]. Lysates 
from cells treated with test compound were prepared and an aliquot was placed in a 
reaction mixture containing NADPH, insulin, and DTNB. As shown in Figure 4-4, 
insulin (a disulfide) reacts with thioredoxin (a thiol) to give the reduced form of 
insulin and the disulphide of thioredoxin.  Insulin is regenerated by the reaction of 
reduced insulin with DTNB.  The formation of thionitrobenzoic acid (TNB) is 
monitored as an endpoint of the assay.  At the same time, the disulphide of 
thioredoxin is converted to thioredoxin by the catalytic activity of TrxR.  Thus an 
increase in TrxR activity results in more TNB being formed.  To ensure that 
thioredoxin and TrxR are responsible for the observed reactions, each sample of 
lysate is divided into two portions.  To one portion is added exogenous thioredoxin (if 
the assay is meant to measure TrxR activity) and to the other portion is added 
exogenous thioredoxin reductase (if the levels of thioredoxin are being measured).  
The absorbances of TNB under these different conditions (for example, A TNB + 
exogenous thioredoxin  - A TNB without exogenous thioredoxin = thioredoxin reductase activity)  gives 




























4.3. Experimental Methods 
4.3.1.  Materials 
7-Ethoxyresorufin, salicylamide, glutathione (reduced), 5-sulfosalicylic acid, 5,5'-
dithiobis-(2-nitrobenzoic acid) (DTNB), yeast glutathione reductase, NADPH, 
digitonin, guanidine hydrochloride and bovine insulin were purchased from Sigma-
Aldrich, Singapore. Human thioredoxin and recombinant Escherichia coli rat 
thioredoxin reductase were obtained from Imco Corporation (Stockholm, Sweden, 
www.imcocorp.se).  Antibodies against Nrf2 and β-actin were purchased from Santa 
Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The antibody against thioredoxin 
reductase (TrxR) was obtained from Imco Corp. Ltd. (Stockholm, Sweden).  Bradford 
dye concentrate was from Bio-Rad Laboratories (Hercules, CA, USA). Hepa1c1c7 
cells (ATCC) were grown in α-minimal essential medium under similar conditions as 
those described in 3.2.2.  
 
4.3.2 Evaluation of test compounds for induction of CYP1A1 activity by the  
ethoxyresorufin O-deethylase (EROD) assay 
The method of Marchand et al. [125] was followed. Hepa1c1c7 cells were grown at a 
density of 104 cells per well in a 96-well plate for 24 h. A stock solution of test 
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compound was prepared in DMSO and serially diluted with medium to give the 
desired concentration in the well. The final concentration of DMSO was 0.5 % v/v. 
The cells were incubated with test compound for 48 h, after which the medium was 
removed, the cells washed with 200µl of phosphate-buffered saline and incubated 
(37° C, 40 min) with 5 µM 7-ethoxyresorufin and 2 mM salicylamide in 200µl of 
medium. The fluorescence of resorufin was measured at  λexcitation of 530 nm and 
λemission of 590 nm on a fluorometer.  The readings of empty wells (no cells, “blank”) 
and wells with Hepa1c1c7 cells in medium containing 0.5% DMSO but without test 
compound (“control”) were also determined. BNF and sulforaphane were used as 
controls.    
CYP1A1 induction activity was given by the expression: 
  Degree of induction = F Cells + test compound – F Blank / F Control – F Blank  
 
4.3.3. Evaluation of test compounds on total GSH content of Hepa1c1c7 cells  
The method of Tietze [126] was followed.  Briefly, Hepa 1c1c7 cells were grown in 
10-cm diameter tissue culture plates at a density of 106 cells / plate for 24 h. The cells 
were then incubated with test compounds (final concentration of 10 μM) for 24 h.  
Each compound was tested in duplicate on separate plates, with one plate used for 
GSH determination and the other for protein determination. After 24 h, the cells were 
trypsinized and the media containing detached and trypsinized cells were pooled and 
centrifuged (2000 rpm, 5 min). The pellets were washed with ice-cold PBS and 
treated with 3% w/v 5-sulfosalicylic acid (1 ml). The contents were vortexed and 
centrifuged (6000 rpm, 5 min) to remove precipitated proteins. Total GSH content 
was assayed by following the change in absorbance at 412 nm over 5 minutes in a 
cuvette (1 ml) containing a final concentration of 0.6 mM DTNB, 0.2 mM NADPH, 
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10 µg/ml GSH reductase and 20 µl of sample in 0.1 M sodium phosphate-5 mM 
EDTA buffer. The content of GSH in the supernatant was determined from a 
calibration plot constructed using five GSH concentrations (0.125 -1.5 nmol / 200 μl 
0.01 M HCl). For the determination of protein content, the cells were lysed with 
digitonin and 2 mM EDTA as described in Section 3.2.3 and analyzed with an assay 
kit based on the Bradford method [127].  
 
4.3.4. Preparation of cell lysates for the thioredoxin reductase assay and western blots 
Hepa1c1c7 cells were grown in 10-cm diameter tissue culture plates at a 
density of 1 - 2 × 106 cells / plate for 24 h. The cells were incubated with test 
compounds (10 μM) for 24 h (5% CO2, 37 oC) after which they were trypsinized, 
pelleted by centrifugation (2000 rpm, 5 min) and washed with ice-cold PBS.  The cell 
pellets were lysed in a freshly prepared lysis solution made up of  0.8% w/v digitonin, 
2 mM EDTA, and protease inhibitor cocktail (Roche Diagnostics, Mannheim, 
Germany). The lysate was incubated at 37° C for 10 minutes and then gently agitated 
for another 10 minutes prior to collection of supernatant from cell debris by 
centrifugation (10 4 rpm, 5 min). Total protein concentration of the lysate was 
determined by the Bradford method. 
 
4.3.5. Evaluation of test compounds on thioredoxin reductase (TrxR) and 
thioredoxin (Trx) activity 
TrxR activity was measured in 96-well plates using an end point insulin 
reduction assay as described by Arner and Holmgren [124]. Briefly, cell lysates (25 
µg total protein) were incubated in a final reaction volume of 50 µl containing 85 mM 
HEPES (pH 7.6), 0.3 mM insulin, 660 µM NADPH, 2.5 mM EDTA, and 5 µM 
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human thioredoxin for 20 minutes at 37° C. Background controls involved incubating 
cell lysates under similar conditions except for the absence of thioredoxin.  The 
reaction was then quenched by adding 250 µl of 1 mM DTNB in 6 M guanidine 
hydrochloride - 200 mM Tris-HCl, pH 8.0 solution.  The free thiols generated from 
the insulin reaction were reacted with DTNB to give the reduced product TNB, the 
absorbance of which was measured at 412 nm. TrxR activity was determined by 
subtracting absorbance due to the background control from that obtained with the 
treated lysates.  Trx activity was measured as described above except that exogenous 
recombinant Escherichia coli rat thioredoxin reductase was used in place of 
thioredoxin. 
 
4.3.6  Western blot of Nrf2 and TrxR 
Cell lysates (50 µg total protein) were fractionated on 15% SDS-PAGE gel, 
transferred to nitrocellulose membranes (Bio-Rad Laboratories Pte Ltd, Singapore), 
and blocked with 10% non-fat milk in Tris-buffered saline containing 0.05% Tween 
20. The membranes were blotted with primary antibodies at room temperature for 3 to 
5 hours and then incubated with horseradish peroxidase-conjugated secondary 
antibodies for 1 hour. Protein bands were visualized by enhanced chemiluminescence 
detection reagents (Amersham Pharmacia Biotechnology, UK) and quantified by 
densitometric measurements with the ImageJ Program (National Institute of Health, 






4.4 Results  
4.4.1.  Effect of Series 1-8 compounds on CYP1A1 activity of Hepa1c1c7 cells  
CYP1A1 activity was determined by the 7-ethoxyresorufin deethylase 
(EROD) assay which monitors the formation of fluorescent resorufin when 7-
ethoxyresorufin is de-ethylated by CYP1A1 (Figure 4-5).  Both 7-ethoxyresorufin and 
resorufin are fluorescent compounds but have different excitation and emission 
wavelengths.  The formation of resorufin is monitored as an endpoint in the assay.  
An increase in resorufin fluorescence would be observed if CYP1A1 activity is 
induced.  
 













Table 4-1 summarizes the ratio of resorufin fluorescence in treated and control 
cells obtained from Hepa1c1c7 cells that were preincubated (48 h) with test 
compounds (Table 4-1). The latter were compounds listed in Table 3-2 (except 1-13, 
1-15) and one additional compound 5-2.  They were tested at a concentration (1 μM, 5 
μM, 10 μM or 25 μM) at which the compound induced NQO1 activity by at least 2 
fold.  In order to evaluate the relative degrees to which CYP1A1 and NQO1 were 
induced, the quotient of the two induction ratios (NQO1 induction ratio / CYP1A1 
induction ratio) was determined at the same concentration for each compound.  A 




Table 4-1. Effect of test compounds on CYP1A1 activity and the quotient of their 
NQO1/  CYP1A1 induction ratios in Hepa1c1c7 cells.  


































9.65 ± 1.71 (10 µM) 
5.58 ± 0.87 (5 µM) 
3.98 ± 0.54 (5 µM) 
8.76 ± 1.25 (10 µM) 
3.41 ± 0.43 (25 µM) 
2.32 ± 0.30 (10 µM) 
3.56 ± 0.42 (1 µM) 
4.47 ± 0.27 (5 µM) 
3.34 ± 0.14 (10 µM) 
4.50 ± 0.21 (25 µM) 
 
 
3.75 ± 1.50 (10 µM) 
3.08 ± 0.21 (10 µM) 
1.96 ± 0.11 (25 µM) 
3.12 ± 0.15 (10 µM) 
2.81 ± 0.12 (10 µM) 
2.54 ± 0.08 (25 µM) 
 
 
2.75 ± 0.80 (10 µM) 
6.40 ± 0.77 (10 µM) 
4.05 ± 1.35 (10 µM) 
4.31 ± 0.09 (25 µM) 
 
 
3.20 ± 0.28 (10 µM) 
3.97 ± 0.35 (25 µM) 
 
2.04 ± 0.15 (10 µM) 
1.55 ± 0.09 (5 µM) 
1.18 ± 0.26 (5 µM) 
1.87 ± 0.22 (10 µM) 
1.16 ± 0.05 (25 µM) 
0.97 ± 0.04 (10 µM) 
1.56 ±  0.13 (1 µM) 
1.48 ± 0.02 (5 µM) 
0.98 ± 0.04 (10 µM) 
1.73 ± 0.23 (25 µM) 
 
 
1.18 ± 0.11 (10 µM) 
1.10 ± 0.17 (10 µM) 
1.05 ± 0.06 (25 µM) 
1.13 ± 0.07 (10 µM) 
1.00 ± 0.04 (10 µM) 
1.06 ± 0.02 (25 µM) 
 
 
2.36 ± 0.09 (10 µM) 
2.95 ± 0.24 (10 µM) 
2.01 ± 0.22 (10 µM) 
1.68 ± 0.20 (25 µM) 
 
 
1.05 ± 0.03 (10 µM) 

















































4.27 ± 0.11 (25 µM) 
2.92 ± 0.13 (25 µM) 
 
 




2.10 ± 0.04 (25 µM) 
3.57 ± 0.12 (25 µM) 
2.32 ± 0.28 (10 µM) 
 
 
2.35 ± 0.02 (10 µM) 
2.41 ± 0.06 (10 µM) 
 
9.75 ± 1.2 (1 µM) 
3.89 ± 0.21 (1 µM) 
1.07 ± 0.03 (25 µM) 
1.08 ± 0.03 (25 µM) 
 
 




1.04 ± 0.08 (25 µM)  
1.03 ± 0.05 (25 µM) 
0.97 ± 0.09 (10 µM) 
 
 
1.12 ± 0.08 (10 µM) 
1.04 ± 0.10 (10 µM) 
 
4.25 ± 0.15 (1 µM) 




















a Fold induction is reported as average ± SD (n =3 ). Concentration at which 
compound was tested is given in parenthesis. 
 b NQO1 fold induction/CYP1A1 fold induction 
  
As seen from Table 4-1, CYP1A1 induction ratios ranged from 0.97-2.95, 
indicating that most of the compounds were inducers of CYP1A1.  Comparison of 
induction potencies was not possible because the compounds were evaluated at 
different concentrations.  Table 4-1 also lists the quotients which were determined 
from the ratio of two values, namely NQO1 fold induction / CYP1A1 fold induction. 
The quotient showed the extent to which CYP1A1 and NQO1 were induced at the 
same concentration of test compound and serves as a crude measure of induction 
preference.  As seen from Table 4-1, most compounds had quotients in the range of 2-
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3, indicating that NQO1 was induced to a greater degree than CYP1A1. A notable 
exception was 5-2 (quotient = 1.52) which induced CYP1A1 more than NQO1.  
Compounds with the highest quotients were from Series 1 (1-1, 1-2 and 1-5) and 4-5.  
Sulforaphane and BNF were concurrently tested as controls. As expected, 
sulforaphane (1 μM) induced NQO1 by more than 4 fold compared to CYP1A1.  BNF 
(0.01 μM) induced NQO1 to a slightly lower degree (quotient of 1.6) but this value 
increased to 2.3 when tested at 1 μM BNF.  Previous investigations on the induction 
of CYP1A1 and NQO1 by BNF gave different results depending on the method of 
analysis.  BNF was reported to induce CYP1A1 to a greater extent than NQO1 based 
on the analysis of microsomal liver extracts and mRNA levels of these proteins in 
treated rats.  [128, 129].  When tested on stably transfected cell lines, BNF induced 
ARE-mediated reporter gene expression to a slightly greater degree (2.9 fold) 
compared to XRE-mediated reporter gene expression (2.4 fold) [58], which reflect the 
present findings.   
 
4.4.2.   Effect of selected aurones on total GSH content in Hepa1c1c7 cells          
 Only three compounds were tested for their effects on total GSH content.  
They were 1-1 and 1-5 which were among the most potent NQO1 inducers and 5-1 
which had negligible effects on NQO1 activity (Figure 4-6).   
 




















 Hepa1c1c7 cells were incubated with the test compounds (10 μM) for 24 
hours prior to the determination of total GSH content using the Ellmann’s reagent.  
Compounds 1-1 and 1-5 were found to significantly elevate total GSH levels to 44.2 
nmol (2.5 fold) and 51.3 nmol (2.9 fold) respectively compared to untreated cells 
(Figure 4-7a). In contrast, 5-1 did not bring about a significant elevation of GSH 
content.  1-5 was also tested at 0.1 μM and 1μM (Figure 4-7b) and found to increase 
GSH levels in a concentration dependent manner.   
 
Figure 4.7. (a) Total GSH content in Hepa1c1c7 cells treated with test aurones at 10 
µM for 24 hours. Values are averages ± SEM for n = 3 independent determinations. 
(*) indicate significant difference from untreated control (p<0.01, one-way ANOVA 
with  Dunnett as posthoc test). (b) Effect of different concentrations of 1-5 on total 
GSH content in Hepa1c1c7 cells. 


































































     
The extent to which 1-1, 1-5 and 5-1 increased GSH levels in the Hepa1c1c7 
cells correlated with their potencies as inducers of NQO1, further indicating the 
ability of active aurones to induce cytoprotective mechanisms. The rate limiting 
enzyme involved in the de novo synthesis of GSH is γ-glutamylcysteine ligase (GCL).  
GCL is regulated by the transcriptional activation of ARE consensus sequences in its 
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gene by Nrf2 [110]. Thus the elevation of GSH observed here suggests an aurone-
mediated induction of the Nrf2-dependent upregulation of the GCL pathway.  
 
4.4.3. Effect of  selected aurones test compounds on thioredoxin reductase  and  
thioredoxin (Trx) activity in Hepa1c1c7 cells 
To investigate if aurones induced other Phase II enzymes that are under 
transcriptional regulation by the Nrf2/ARE pathway, selected aurones were evaluated 
for their effects on thioredoxin reductase (TrxR) and thioredoxin.  The aurones 
selected for these experiments were 1-1, 1-5, 5-1 (previously evaluated for effects on 
GSH content), 2-5 and 8-2 (Figure 4-8). 5-1 and 8-2 represented inactive NQO1 
inducers whereas the rest were active NQO1 inducers.  Sulforaphane was used as a 
positive control. All compounds were tested at 10 µM. 
 
Figure 4-8: Aurones tested for effects on Trx and TrxR activity in in Hepa1c1c7 cells. 



















CD = 0.18 µM
2-5











Aurones  1-1, 1-5 and 2-5 showed significant induction of TrxR activity at 10 
μM after 24 h incubation, with 1-5 showing the highest level of induction (2 fold) 
(Figure 4-9).  As expected, 5-1 and 8-2 failed to induce TrxR activity.  TrxR activity 
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was induced by a modest 1.3 fold in the presence of sulforaphane.  Others have 
reported a similar level of TrxR induction by sulforaphane (12 μM) in HepG2 cells 
[122].   It was also reported in the same study that induction increased to 2.2 fold 
when the incubation period was increased to 72 h.  Thus, the induction of TrxR by 
sulforaphane may be time-dependent but this was not investigated here for 
sulforaphane or the aurones.       
 
Figure 4-9: Induction of TrxR activity by target compounds and sulforaphane (SUL) 
at 10 μM, 24 h incubation in Hepa1c1c7 cells.  Fold induction is measured by the 
ratio of absorbances of treated cells versus control cells.  Mean ± SEM (n =3).  * 
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The test compounds and sulforaphane did not increase Trx activity in 
Hepa1c1c7 cells (Figure 4-10). This finding concurred with other studies where 
inducers of TrxR failed to induce Trx activity [122, 130].  However increases in the 
mRNA of Trx were reported but this did not result in elevated Trx enzymatic activity 
or protein levels. A possible reason may be the instability of Trx mRNA. 
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Figure 4-10: Induction of Trx activity by target compounds and sulforaphane (SUL) at 
10 μM, 24 h incubation in Hepa1c1c7 cells.  Fold induction is measured by the ratio 
of absorbances of treated cells versus control cells.  Mean ± SEM (n =3).   
 
 
Figure 4-11 shows the effects on TrxR and Trx at varying concentrations of 1-
5.  An increase in TrxR activity was observed as 1-5 was increased from 0.1 μM to 10 
μM but declined at 25 μM. This decline may be due to the cytoxicity of 1-5 at 25 µM. 
The optimal concentration for TrxR induction by 1-5 may fall within the range of 10 
µM. Only small fluctuations in Trx activity was observed over the same concentration 
range.  
 
Figure 4-11:  Effect of different concentrations of 1-5 on TrxR and Trx activities of 









        






































To investigate if the induction of TrxR activity was accompanied by an up-
regulation in TrxR protein expression, the lysates used for the assay of TrxR activity 
were concurrently analyzed by western blotting for TrxR immunoreactivity.  As 
shown in Figure 4-12, compared to untreated cells, 1-1, 1-5, 2-5 and sulforaphane 
caused an increase in TrxR levels (Lanes 2-4 and 7).  Cell lysates treated with 5-1 and 
8-2 (Lanes 5 and 6) did not show elevated levels of TrxR protein.   
 
Figure 4-12: Effect of test compounds (10 μM) and sulforaphane (SUL, 10 μM) on 
TrxR protein in Hepa1c1c7 cell lysates determined by western blot analysis after an 
incubation period of 24 h. Immunoblot is representative of 3 independent 
experiments. Densitometry of TrxR bands are expressed as optical densities (O.D.). 
Control 1-1 2-5 5-1 SUL
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4.4.4 Effect of  selected test compounds on the levels of Nrf2 in Hepa1c1c7 cells      
The transcriptional activation of genes encoding TrxR and GCL are mediated 
by ARE regulatory sequences regulated by Nrf2.  As the aurones (1-1, 1-5, 2-5) 
induced TrxR activities and elevated GSH levels in Hepa1c1c7 cells, they were 
investigated for their effects on Nrf2 levels.  Hepa1c1c7 cells were treated with 10 
μM test compound or sulforaphane and lysates collected after 6 hours and 11 hours 
were subjected to western blotting and probed for Nrf2 immunoreactivity.  The results 
are depicted in a representative immunoblot (Figure 4-13).  In the lanes where cells 
were treated with 1-1, 1-5, 2-5 and sulforaphane, the Nrf2 bands were more intense 
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compared to those in the control lane at both time points.  Cells treated with 5-1 and 
8-2 did not increase Nrf2 levels which concurred with their lack of effect on TrxR.   
Marked reductions in Nrf2 induction were observed after 11 hours reflecting 
the time-dependent effect of the inducers on Nrf2 protein levels. This decrease in Nrf2 
may be caused by gradual degradation of the protein or its translocation to the 
nucleus. This transient induction of Nrf2 would be followed by later Nrf2-mediated 
downstream effects such as the upregulation of TrxR and NQO1. 
 
Figure 4-13: Effect of test compounds (10 μM) and sulforaphane (SUL, 10 μM) on 
Nrf2 protein levels in Hepa1c1c7 cell lysates determined by western blot analysis 
after 6 h and 11 h of incubation. Cells treated with MG132 (25 μM, 6h) caused 
accumulation of Nrf2 protein.  Immunoblot is representative of 3 independent 











MG132 Control 1-1 1-5  2-5 5-1 8-2 SUL 
 
  O.D.     0.423    0.138   0.275   0.262   0.249   0.115   0.145   0.209      




The ability of the aurones and isoaurones to induce CYP1A1 activity shows that they 
act via the AhR/XRE pathway.  This finding is in keeping with the earlier observation 
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that these compounds did not induce NQO1 activity in mutant Bprc1 cells that lack a 
functional AhR. There is also evidence to support a role for selected aurones (1-1, 1-
5, 2-5) as activators of the Keap1/Nrf2/ARE pathway, as seen from their ability to 
induce TrxR expression resulting in an increase in TrxR activity, as well as the 
elevation of GSH content.  The role of Nrf2 in the induction of TrxR activity and the 
increase in GSH was further ascertained by immunoblotting experiments that showed 
an increase in Nrf2 level in the presence of aurones that were potent inducers of 
NQO1 (1-1, 1-5, 2-5).  Poor NQO1 inducers (5-1, 8-2) gave appropriately weaker 
responses.  In the light of these findings, it seems likely that the aurones are mixed 
activators, rather than bifunctional inducers.  Thus, these compounds acted as 
activators of both pathways to induce NQO1 activity.  In this respect, aurones are 
similar to several flavonoids like quercetin and fisetin which are also reported to be 
mixed activators [57, 58]. 
The status of aurones as mixed activators raises the question as to whether 
they affect one pathway more than the other. The NQO1 to CYP1A1 induction ratios 
(“quotient”) suggests that aurones may preferentially act via the Keap1/Nrf2/ARE 
pathway. On the other hand, the quotient (1.52) derived for 5-2 suggests that for less 
active members, induction of CYP1A1 (and by implication AhR/XRE pathway) may 
dominate.  In any case, a more reliable method than the one used here is required. One 
approach would be to use reporter cell lines that are stably transfected with a firefly 
luciferase reporter gene under the regulation of an ARE or XRE-containing sequence 
from relevant genes.  Using these stably transfected cell lines, Lee Hiltz and co-
workers demonstrated that at physiologically relevant concentrations, some 
flavonoids (quercetin, fisetin and some hydroxylated flavones) induced ARE-
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mediated gene expression to a greater degree than XRE-mediated gene expression 
[58]. 
The present findings notwithstanding, there is a possibility that the present 
observations reflect the coordinated regulation of the AhR and Nrf2 gene batteries 
mentioned in Section 1.4.  Proposed links between the two pathways may involve 
Nrf2 as a target gene of AhR, Nrf2 is indirectly activated by CYP1A1-generated ROS 
/electrophiles or a direct interaction between AhR/XRE and Nrf2/ARE signaling due 
to their close proximities in the regulatory regions of NQO1 [51, 54, 55].  It may be 
that aurones interact with AhR to bring about activation of Nrf2 by one or more of the 
above mentioned routes.  Further investigations would be required to give a better 
understanding of the underlying mechanisms. 
 
4.6 Summary 
The findings in this chapter showed that the aurones activated both the AhR/XRE and 
Keap1/Nrf2/ARE pathways to bring about induction of NQO1.  The role of the 
AhR/XRE pathway was ascertained from the induction of CYP1A1 activity in 
Hepa1c1c7 cells. Evidence of Keap-1/Nrf2/ARE involvement was corroborated by 
the up-regulation of TrxR protein and increase in GSH levels in Hepa1c1c7 cells.  A 
concurrent increase in Nrf2 levels in the cells provided further confirmation.  A 
correlation between NQO1 induction and responses regulated by Nrf2/ARE pathway 
(TrxR activity, GSH levels) was also evident from the results.  In conclusion, aurones 
may be mixed activators of NQO1 induction. They may also be agents capable of 
exploiting the proposed cross-talk between the AhR and Nrf2 gene batteries by 
mechanisms that remain to be understood.  
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Chapter 5 Quantitative structure-activity relationship (QSAR) of the NQO1 
induction activity of aurones and isoaurones 
 
5.1 Introduction 
This chapter describes attempts to rationalize the NQO1 induction activity of 
the test compounds in quantitative terms. QSAR analysis would provide a more 
holistic overview of the factors that contribute to activity, in particular those that may 
be missed out by qualitative comparisons. The analysis was carried out by first 
collecting descriptors related to the size, electronic and hydrophobic properties of the 
target compounds.  QSAR was carried out by two different approaches - Partial Least 
Squares Projection to Latent Structures (PLS) and genetic algorithm (GA) – and the 
best models from each approach were discussed.    
 
5.2 Experimental methods 
Structures of compounds in Series 1-8 were drawn and geometry minimized 
using the Hamiltonian forcefield MMFF94x in Molecular Operating Environment 
(MOE 2007.09, Chemical Computing Group, Montreal, Canada).  The aurones 
(Series 1-5) and isoaurones (Series 6, 7) were represented in the Z and E 
configurations respectively based on earlier discussions on their stereochemistry 
(Section 2.4.) The R isomer was arbitrarily chosen to represent the Series 8 
compounds.  It was noted that descriptors generated with either isomer (R or S) did 
not differ significantly.  
The following molecular descriptors were collected for all compounds using 
the QuaSAR module in MOE :  molecular weight (MW), lipophilicity (Log P in 
octanol/water), number of rotatable bonds (Rot B), dipole moment (DM), molar 
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refractivity (MR), atom polarization (APOL), number of hydrogen bond acceptors 
(HA), and hydrogen bond donors (HD), topological polar surface area (TPSA), water 
accessible surface area (ASA), van der Waals surface area of hydrogen bond 
acceptors (VSA-HA) and hydrogen bond donors (VSA-HD), van der Waals area 
(VDW-Area) and volume (VDW-Vol), hydrophobic van der Waals surface area 
(HAS-HYD), polar van der Waals surface area (VDW-Pol). HOMO and LUMO 
energies (HOMO4 and LUMO4) were calculated separately using SPARTAN’06 for 
Linux server (Wavefunctions Inc., Irvine, CA) by the following procedure: structures 
initially minimized by MMFF94x of MOE were further minimized using semi-
empirical PM3, restricted Hartree-Fock, and a density functional theory (DFT) 
B3LYP functional using a 6-31G* basis set.  These values were determined for the 31 
actives (Table 3-2), as well as two inactive compounds (5-1 and 8-2).  It was noted 
that QuaSAR gave similar values for van der Waals surface areas of H bond donors 
(VDW-HD) for all compounds.  Thus, this parameter was removed from the list of 
descriptors.  
Induction activity was expressed either as CD values or induction ratios at 5 
μM as described in Chapter 3.  As CD values were determined for only 31 
compounds, a CD of 50 µM was assigned to the remaining compounds.   The values 
of the 18 descriptors, pCD (-log CD) and induction ratios of the compounds are given 
in Appendix 3. 
PLS was carried out on SIMCA-P+ version 11.0 (Umetrics AB, Umea, 
Sweden) with default settings. Water accessible surface area, van der Waals area, 
polar van der Waals surface area and topological polar surface area were transformed 
to their logarithmic values for this analysis. Other parameters were not transformed by 
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SIMCA.  The quality of the model generated was monitored by the regression 
coefficient (R2Y) and the cross-validated correlation coefficient (Q2)  
QSAR by genetic algorithm was carried out with the QuaSAR-Evolution 
module on MOE with default settings (population 100, generation 50 000, mutation 
probability 0.5, eugenic factor 100, initial length 4, operant density 4).  Both fixed and 
variable length runs were tried. The best model was evaluated using a suite of 
statistical parameters including the Akaike information criteria (AIC) which measures 
goodness-of-fit of several competing models and Lack-Of-Fit (LOF) which scores the 
fitness of the model.  Unless otherwise stated, the 1st equation generated is taken as 
the most appropriate.  
 Spearman’s rho values (SPSS 15.0 for Windows, Chicago, IL) were used to 
determine significant correlations (p ≤ 0.05) among descriptors.  
 
5.3. Results  
5.3.1. QSAR analysis by PLS 
Projection methods are widely employed for establishing structure-activity 
relationships.  The best known methods are Principal Component Analysis (PCA) and 
Partial Least Squares Projection to Latent Structures (PLS). PCA transforms a large 
data set into a smaller set which contains a reduced number of variables derived from 
the linear combinations of the original variables. These new variables are called 
principal components and they summarize information residing in the original data in 
such a way that it is possible to reveal relationships between the compounds and the 
descriptors. PLS is a regression extension of PCA. It identifies the principal 
components that can concurrently explain the variance in the descriptor set as well as 
maximize the correlation to the dependent variable (biological activity).  It is useful in 
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cases where the descriptors are highly correlated to each other or where there are 
missing descriptor values.  Both these situations were encountered here. Many of the 
size and hydrophobic parameters were significantly correlated to each other based on 
their Spearman’s rho values (p ≤ 0.05) and HOMO4/LUMO4 energies were not 
collected for all compounds.   
Initially, all compounds (n =87) and descriptors (n =17) were analyzed by PLS 
using induction ratios (induction at a fixed concentration of 5 μM) as the dependent 
variable.  This approach failed to yield a significant model, possibly because the 
induction ratios were activities measured at a fixed concentration (5 μM) and may not 
accurately quantify activity.  The use of a concentration term as dependent variable is 
always the preferred practice in QSAR.  Hence, the next analysis was carried out with 
the CD values (expressed as pCD) which are concentration terms.  A shortcoming was 
that CD values were determined for only 31 compounds.  The remaining compounds 
were assigned CD of 50 μM since they had low induction ratios at 25 μM.  This 
approach also failed to yield a statistically valid model and the likely reason is the 
inclusion of arbitrary assigned CD values (50 μM) for a large number of the test 
compounds (n = 56, 64%). In view of these results, it was decided that only 
compounds with experimentally determined values (n = 31) would be used for 
analysis.  On the other hand, this would restrict the analysis to active compounds 
which may not be desirable.  Hence, two “inactive” compounds (5-1 and 8-2) were 
included and they were assigned CD values of 50 μM. Their inclusion also meant that 
every series would be represented in the QSAR analysis. 
When this new database of 33 compounds and 17 descriptors was analyzed by 
PLS, a significant one-component model was obtained.  It could explain 36 % (R2Y) 
and predict 26 % (Q2 ) of the variation in the data.  On inspection of the model 
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statistics, compounds in Series 6 (n=3) were found to have largest residual values 
(pCDobserved  – pCD predicted ).  These values were negative indicating that the predicted 
activities of the Series 6 compounds  should be greater than what was determined 
experimentally.  Series 6 comprised of the 4,6- dimethoxyisoaurones which, as 
discussed in Section 3.3.2. were weak NQO1 inducers. In view of their outlier status, 
the Series 6 compounds were removed and the data re-analyzed with fewer 
compounds (n =30).  A significantly improved PLS model was now obtained (one-
component, R2Y = 0.586, Q2 = 0.467).  The contribution of the various descriptors to 
activity is depicted in the coefficient plot (Figure 5-1).  In this plot, descriptors were 
depicted as columns of varying lengths and with positive (+) or negative (-) signs. The 
length of the column is directly related to its contribution to induction activity. A 
positive coefficient indicates a direct correlation to activity and a negative coefficient 
indicates an inverse relationship. Figure 5-1 shows that polar surface areas (TPSA, 
VDW-POL) and to a lesser extent the number of H bond donors (HD) and acceptors 
(HA) were inversely related to activity whereas large dimensions (area, volume), non-
polar surfaces (HAS-HYD, ASA) and lipophilicity (LogP) contributed directly to 
activity. A lower weight was accorded to electronic descriptors like HOMO, LUMO 
and dipole moment.  Thus, the PLS model identified potent inducers to be those with 
smaller total polar surface areas, larger VDW areas/volumes and larger hydrophobic 







Figure 5-1: Coefficient Plot generated by PLS on 30 compounds and 18 descriptors 
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To test the validity of the model, the 30 compounds were randomly divided 
into a training set (n =16) and a test set made up of the remaining 14 compounds. A 
model was generated with the training set using the same descriptors as before and it 
was used to predict the activity of the test set.  A reasonable error of prediction 













Figure 5-2: Plot of observed versus predicted pCD values for test set (n = 16, 17 
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5.3.2.  QSAR analysis by the genetic algorithm approach (GA) 
 GA is based on the concept of DNA evolution [131]. Individuals (models) are 
represented by strings of bits (combination of descriptors). An initial population of 
models with random bits is created. A “fitness” function evaluates the quality of 
each model and selects the best individual / model for “mating” and propagation of 
their “genetic material” (combination of descriptors) to the next generation by 
crossover or mutation. This process is repeated through several generations until the 
average fitness of the models / individuals in the population are optimized through 
the discovery of “good” combinations of genes (descriptors) and their propagation 
throughout the population. The advantage of GA over PLS is that it explores a 
larger space of possibilities and proposes multiple solutions, in contrast to the “one-
model at a time” procedure in PLS.  Moreover, the models are selected and 
validated statistically (by a “fitness function”) and there is minimum user 
intervention.  But the GA approach is often criticized as a “black-box” and the 
models proposed by GA may not be able to explain the observed SAR.  QSAR by 
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GA is usually attempted first and subsequently followed up with a conventional 
regression method.  However, the software used in this investigation ranks the 
output from GA and provides an equation for each model.    
 The GA approach was applied to the same database of 33 compounds and 17 
descriptors used for PLS.   Both “fixed length GA” and “variable length GA” were 
attempted. The difference between the two methods lies in the number of descriptors 
generated for the model.  In a variable length approach, there is no restriction to the 
number that could be identified and this can lead to over-fitted models.  In the case of 
fixed length GA, the user states the number of descriptors to be captured by the 
model. In this case, four descriptors were specified.  Figure 5-3 gives a snapshot of 
the top five models identified by the fixed length and variable length approaches. 
 
Figure 5.3: Best 5 models identified by (a) fixed length and (b) variable length GA 
approach on 33 compounds and 17 descriptors. RMSE : root mean square error; 
RMSE Test : root mean square error for test set (not applicable in this case);  RR : R2. 
multiple squared correlation coefficient; adjusted RR : Modified coefficient of 
determination; AIC : Akaike information criterion; LOF : Lack of Fit; F : Fischer 
statistic 
 
(a) Fixed length GA 
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(b) Variable length GA  
 
 
Fewer descriptors were identified in the “best” model generated by variable 
length GA (ASA-H : water accessible surface area and LUMO4) as compared to the 
fixed length approach (LUMO4, LogP, van der Waals surface area of H bond 
acceptors and van der Waals).  In accordance to the rule of parsimony (“Occam’s 
razor”) which is a basic tenet of QSAR, the model from the variable length approach 
was preferred because it gave a simpler model.   Statistically, this model which is 
represented again in Equation 1 has a smaller LOF and a larger F value, both of which 
are desirable features.   
 
Eqn 1:       pCD  = - 4.75 – 1.55 E LUMO  + 0.014 ASA_H 
RMSE = 0.552, R2 = 0.387, R2 (adjusted) = 0.346, AIC = 62.40, LOF = 0.394, F = 
9.45. 
ASA_H: Water accessible surface area 
 
The analysis was then carried out using the same training and test sets 
described for PLS, except that the Series 6 compounds were not omitted and one extra 
member (6-1) was included in the training set (n=17).  Equations were generated with 
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variable length GA and leave-one-out validation. Because of the nature of the method, 
slightly different equations were obtained for each run. These equations differed in 
the type of descriptors identified but consistently gave a high weight to the E LUMO 
term.  Equation 2 is an example generated with variable length GA and LOO.  
 
Eqn 2:       pCD  = - 5.50 – 1.94 E LUMO + 0.023 ASA – 0.59 MR 
RMSE = 0.527, RMSE (test set)= 0.567, R2 = 0.487, R2 (adjusted) = 0.377, AIC = 
37.99, LOF = 0.624, F = 4.42.    ASA : water accessible surface area; MR : molar 
refractivity 
  
 Unlike PLS, the analysis by GA identified E LUMO as a key contributor to 
activity (Figure 5-3, equations 1, 2).  An inverse relationship was predicted between 
activity (pCD) and E LUMO which meant that potent NQO1 inducers were compounds 
that had small LUMO energies.  E LUMO represents the energy required for a molecule 
in the dilute gas phase to accept an electron.  Compounds with lower E LUMO energies 
have greater affinities for electrons and are stronger oxidizing agents.  Therefore, GA 
analysis proposed that strong NQO1 inducers were those that had low lying E LUMO 
and were thus ready acceptors of electrons.   
To have a better understanding of the role of E LUMO, the distribution of 
LUMOs in two representative compounds were viewed (Figure 5-4).  The compounds 
were 1-5, a potent NQO1 inducer (CD 0.18 μM) and 8-2, a reduced analogue of 1-5 
and a weak inducer of NQO1 (CD > 25 μM).  As shown in Figure 5-4, the LUMOs in 
1-5 are spread over the benzofuranone template and ring B, with a concentration over 
the carbonyl and exocyclic double bonds.  In comparison, the distribution of LUMOs 
in 8-2 which has a reduced double bond is confined to the benzofuranone ring.  The E 
LUMO of 1-5 (-1.78 eV) and 8-2 (-1.00 eV) shows that 1-5 has greater electron affinity, 
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possibly a result of its intact double bond / Michael acceptor moiety.  Thus E LUMO 
may reflect the reactivity of the Michael acceptor as an electron acceptor, and this 
reactivity is related to the NQO1 induction potential of the aurone.  
 
Figure  5-4:  Distribution of LUMOs in 1-5 and 8-2 as displayed by SPARTAN. The 
red and blue meshes represent bonding and antibonding phases of LUMO.  
 
            
  1-5                                                                   8-2 
  
It was noted that 8-2 had the lowest LUMO energy among the 33 compounds 
and that the ELUMO values of the other compounds did not show marked variation in 
their values (range = 0.78 eV).  Hence, it is possible that the low ELUMO value of 8-2 
coupled with its negligible NQO1 induction activity influenced the outcome of the 
GA analysis. To test this hypothesis, the analysis was repeated without 8-2,  that is 
with 32 compounds and 17 descriptors. Indeed, it was found that the models 
generated by the variable length approach no longer included E LUMO as a descriptor 
(Figure 5-5).  Instead, only size parameters were identified.  As seen from the 1st 
equation in Figure 5-5. the direct correlation between water accessible surface area 
(which in spite of its nomenclature reflects the hydrophobic surface area of the 
molecule) with activity bears some similarity to the PLS model described in the 
preceding section.  On the other hand the inverse relationship between activity and 
van der Waals area has no precedent. 
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Figure 5-5: Best 5 models identified by variable length GA for 32 compounds 




5.4.  Discussion 
The analysis of SAR by PLS and GA showed that there were two important 
properties that influence the NQO1 induction activity of the target compounds, 
namely size descriptors, in particular those associated with non-polar surface areas, 
and E LUMO.   The PLS analysis highlighted the importance of various non-polar size 
parameters like van der Waals’ area and volume, hydrophobic van der Waals’ surface 
area, which agreed with the qualitative observations on SAR described in Section 3.4.  
These properties are largely influenced by the type of substituent on ring A.  Thus, the 
bulkier and more lipophilic dimethoxyaurones in Series 1 had more active inducers 
than the polar and sterically smaller hydroxylated aurones of Series 2-4.   In the same 
way, the absence of groups on ring A of the Series 5 compounds resulted in poor 
induction properties.  The emphasis on lipophilicity may reflect in part, the use of a 
cell-based assay and the ability of lipophilic compounds to cross cell membranes to 
exert their effect. 
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The GA approach identified E LUMO to be an important determinant of activity, 
with smaller contributions from size parameters similar to those identified by PLS.   
The significance of E LUMO to activity is traced to the exocyclic double bond as seen 
from the absence of this term when the data set was analyzed without 8-2. Hence, the 
E LUMO parameter must reflect some aspect of the exocyclic double bond and the 
Michael acceptor moiety of which it is a part.  There are two possibilities, namely (i) 
the reactivity of the Michael acceptor as an electron acceptor, and (ii) the role of the 
Michael acceptor moiety in influencing the conformation of the target compound. 
With regard to the 1st possibility, it should be noted that other QSAR studies 
on NQO1 induction activity recognized E HOMO and not E LUMO  as a key descriptor 
[132-134].   In these reports, compounds that were good donors of electrons (high E 
HOMO, good reducing agents) were associated with potent induction activity. The role 
of E HOMO  was explained by the involvement of active metabolites that mediated the 
actual biological response.  Lee-Hilz and co-workers postulated that flavonoids 
especially those with a catechol moiety were oxidized by various means (antioxidant 
action, enzymatic oxidation, auto-oxidation) to quinones or semiquinones which were 
the reactive species [134].  In a study of diphenols, a 2-step mechanism of NQO1 
induction was proposed involving an initial oxidation of the diphenol inducer to its 
quinone and the subsequent oxidation of reactive thiol groups in a protein involved in 
NQO1 induction by these quinones [133].  E HOMO of these compounds would then 
reflect the ease with which electron donation occurs to give these active species.  This 
hypothesis would not apply to the present series of compounds because except for 1-
8, the rest do not have the 1,4- or 1,2-diphenolic motif that is required for quinone 
formation. In fact, a relationship between activity of the present series of compounds 
and their HOMO energies would have been difficult to explain.    It has been argued 
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that when assessing the reduction potential of the couple A/A•-,  the E HOMO value of 
the anion of A ( that is , A•-)  is a better approximation of the electron affinity of A 
than the ELUMO  of the neutral A [133].  Unfortunately, the nature of the specie 
(equivalent to A•-)  resulting from the reduction of the aurone (equivalent to A) is not 
known.  Thus E HOMO of this putative species cannot be determined.  
Another relevant observation is that for compounds with intact double bonds,  
E LUMO fails to distinguish between active, moderately active or weak inducers.  This 
is well illustrated with the unsubstituted aurone 5-1 which is the other poor NQO1 
inducer (CD estimated at 50 μM) in the data base.  Its poor activity is better explained 
by its size (small area, volume, hydrophobic surface area due to absence of methoxy 
groups) than by its E LUMO (-2.17 eV) which is comparable to several active members. 
The other possibility is that E LUMO reflects the role of the double bond in 
influencing the conformation of the target compound.  This is primarily because the 
correlation between activity and  E LUMO depends primarily on whether exocyclic 
double bond is present or absent from the target compound.  Reduction of the 
exocyclic bond leads to a loss in planarity and greater conformational flexibility for 
ring B.  This feature may not have been adequately captured by the existing 
descriptors used in the QSAR analysis.  It is possible that E LUMO reflects to some 
degree the conformational change associated with the reduction of the double bond.  
The importance of conformational planarity was highlighted by the failure of the non-
planar flavanone taxifolin to activate ARE-mediated gene expression compared with 
other planar flavones (quercetin, fisetin among others)[74] .  The explanation was that 
interaction with Keap1 or other effector / receptor protein involves a stereospecific 
interaction which was diminished in a non-planar compound.  The structures of 
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taxifolin, fisetin and quercetin are given in Figure 5-6.  The non-planar nature of 
taxifolin  is traced to the absence of a double bond in its ring C.   
 





















In Chapter 4, it was proposed that aurones are mixed activators and induce 
NQO1 activity by activating two different routes (AhR/XRE and Keap1/Nrf2/ARE).   
The structural requirements for mixed activators have not been widely investigated.  
Logically, a mixed activator should have features that enable interactions with the 
AhR as well as bring about the disruption of the Keap1-Nrf2 complex.  Planarity and 
size are important components for interaction with the AhR [74, 135] and the aurones/ 
isoaurones show good compliance with respect to these properties. Michael acceptors 
are a prominent feature of Keap1 disruptors (monofunctional inducers) but many 
aurones in Series 1 are not sufficiently electrophilic to react with electron rich thiol 
reagents like N-acetylcysteine and glutathione although they have Michael acceptor 
moieties [136].  Flavonoids also do not demonstrate electrophilic activity [134] but 
they produce electrophilic metabolites that could react with glutathione or DNA [134, 
137] . This may be true for the aurones as well but would require confirmation.  
 Another option may be that the mode of action of mixed activators reflect the 
recently recognized coordinated regulation of AhR and Nrf2 gene batteries [51, 54, 
55].    It may be that aurones first interact with the AhR to bring about activation of 
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Nrf2 by different mechanisms.  Clearly, at this stage, there is still much to learn about 
the critical features that promote such interactions.  
 
5.5 Summary 
This chapter describes the use of QSAR to analyze the NQO1 induction 
activity of the present series of compounds.  Two different approaches were used, 
namely PLS and GA.  PLS identified size parameters, in particular those associated 
with non-polar surface areas, as an important determinant of induction activity.  It is 
proposed that the degree of substitution on ring A of the aurones and isoaurones 
reflect these size parameters.  GA identified E LUMO and size parameters as important 
contributors to activity, but with lesser input from the latter.  It is proposed that E 
LUMO is linked to some characteristic of the exocyclic double bond which may be the 
electrophilicity of the Michael acceptor moiety and /or the role of the exocyclic 













Chapter 6 Conclusions and Future Work 
 
The aim of this thesis was to test the hypothesis that aurones are potent 
inducers of chemopreventive Phase II enzymes.  The hypothesis is driven by several 
factors.  First, reports showed that two naturally occurring aurones (sulfuretin and 
6,4’-dihydroxy-3’-methoxyaurone) were inducers of the chemopreventive Phase II 
enzyme NQO1.  Aurones are a class of flavonoids, a family that has yielded several 
promising inducers of Phase II enzymes like quercetin and kaempferol.  Second, 
aurones have structural features that are associated with NQO1 induction activity. A 
Michael acceptor moiety is embedded in the aurone scaffold.  Moreover, a unique 
feature of the aurones not seen in other flavonoids is the exocyclic location of its 
olefinic double bond. An exocyclic double bond in other NQO1 inducers was 
associated with greater reactivity as electrophiles.  Yet, in spite of the structural 
potential of the aurones as NQO1 inducers, they have been the subject of limited 
investigations.  
The hypothesis was investigated by two approaches.  In the first approach, a 
series of 87 functionalized aurones and related analogs were synthesized to determine 
if structural modifications would result in more potent inducers.  The 2nd approach 
focuses on understanding the mode of action of aurones as NQO1 inducers, in 
particular to determine if aurones activated both AhR/XRE and Keap1/Nrf2/ARE to 
bring about NQO1 induction.  Agents that act by dual pathways (mixed activators) are 
potentially more promising chemopreventive agents than those that activate a single 
pathway.   
Functionalization of aurones was found to be a viable means of enhancing  
NQO1 induction activity.  In spite of the relatively simple modifications carried out in 
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this study, several potent inducers with CD values in the submicromolar range were 
identified.  An intact exocyclic double bond was found to be crucial for activity.  The 
most potent inducers were those with dimethoxy groups on ring A,  possibly related to 
the bulk and lipophilicity of these groups.  The optimal groups on Ring B were 
influenced to some degree by the type of substitution on Ring A but OCH3, OH and 
halogens (particularly at 2’ or 3’ or ring B) were clearly preferred to other groups like 
methyl, amino or replacing the phenyl ring B with pyridine or quinoline.  A switch in 
the positions of the exocyclic double bond and carbonyl group on ring C gave 
isomeric isoaurones which were less active, attributed in part to the reduced reactivity 
of the exocyclic double bond when adjacent to an ester carbonyl. 
In terms of the mechanism involved in the induction of NQO1, there was 
corroborative evidence to support the activation of both AhR/XRE and 
Keap1/Nrf2/ARE pathways by the aurones.  The involvement of the AhR/XRE 
pathway was seen from the failure of the target compounds to induce NQO1 activity 
in mutant Hepa1c1c7 cells that lacked functional Ah receptors (AhR).  Furthermore, 
almost all the target compounds induced CYP1A1 activity when monitored by the 
EROD assay in Hepa1c1c7 cells, but to a lesser degree than their induction of NQO1 
when tested at the same concentration. The involvement of the Nrf2/ARE pathway is 
seen from the ability of selected aurones that were potent NQO1 inducers to induce 
TrxR expression and increase GSH content in Hepa1c1c7 cells.  The role of Nrf2 in 
the coordinated induction of TR and (by implication) GCL which catalyzes the rate 
limiting synthesis of GSH, was ascertained by immunoblotting experiments that 
showed an increase in Nrf2 content in the presence of these aurones.   These results 
may support a mixed activator role for aurones which would give added significance 
to their potential as chemopreventive agents.  Alternatively, they may reflect the 
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multiple mechanisms linking AhR and Nrf2-induced gene batteries, the nature of 
which are less understood and would require further investigations. 
 QSAR analysis on a subset of the target compounds provided two important 
observations relating to NQO1 induction activity.  First, the emphasis on size, non-
polar surface areas and lipophilicity for good induction activity was noted.  
Qualitative observations on structure-activity trends provided the same insight.  
Second, the importance of the exocyclic double bond was reflected in the ELUMO term.  
ELUMO measures  the electron affinity or electrophilicity of the double bond.  It could 
also reflect the role of the double bond in influencing the conformation of the target 
compound.  Reduction of the exocyclic double bond resulted in a dramatic loss in 
induction activity, possibly due to the loss of low lying LUMO energies and thus the 
electrophilic character of the compound.  It may also stem from the loss in planarity 
and greater conformational flexibility of the resultant compound.  
The present work has raised several questions that can be pursued in future 
investigations.  An important outcome of this investigation is the recognition of the 
aurone scaffold as a source of potentially useful chemopreventive agents.  The 
structural modifications described here have been fairly limited and there is ample 
scope for the exploration of additional options.  For example, would tri-substitution of 
ring A improve potency in view of the emphasis on bulk and lipophilicity of ring A 
for good activity? How would activity be affected by replacing the phenyl ring B with 
isosteric heteroaromatic rings like pyrrole and thiophene?   Would replacing Cβ-H 
with Cβ-alkyl influence E/Z stereochemistry of the exocyclic double bond and if so, 
how would that affect activity ? Is the benzofuranone ring of the aurone just a scaffold 
for the attachment of pendant groups ? If so, how would the replacement of the ring 
oxygen or carbonyl oxygen affect activity ?   These proposed modifications are 
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summarized in Figure 6-1.  A desirable outcome of these modifications would be 
compounds with greater potency, selectivity and improved pharmacokinetic profiles.  
The latter is particularly relevant as most flavonoids (possibly including aurones) 
have notoriously poor bioavailability. The finding that some of the present aurones 
induced CYP1A1 (a phase 1 enzyme) requires further evaluation as this may have 
implications in metabolic issues (drug-drug interactions, metabolic activation of 
procarcinogens).  
 




X = CH2, NH
Y = S , N-OH, N-OR
Ar = Pyrrole, thiophene
R'




of ring A ? β
 
 
 Several aurones that are potent inducers of NQO1 in the murine hepatoma 
Hepa1c1c7 cells were identified in this report.  However, they have not been 
investigated for their abilitiy to confer protection against carcinogenic agents.  An 
appropriate model would be to assess their protective role against quinone toxicity in 
rat cardiomyocytes H9c2 [148].  If promising chemopreventive activity is observed, a 
follow- up on animal models for chemical carcinogenesis would be appropriate.  
One of the objectives of this thesis was to determine if aurones induced NQO1 
activity by functioning as mixed activators.  There is evidence that this may be so but 
further confirmation would be required.  One approach is to use reporter cell lines that 
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are stably transfected with a firefly luciferase reporter gene under expression 
regulation of an ARE or XRE-containing sequence from relevant genes [52].  In this 
way it would be possible to assess if the aurones act preferentially to induce one 
pathway more than the other.  If aurones are indeed mixed activators, there will be 
renewed interest in this scaffold primarily because of the limited knowledge 
pertaining to this mechanistic class of inducers and the many advantageous features 
associated with aurones.  These are their desirable drug-like profiles (in terms of size, 
lipophilicity, rotatable bonds and hydrogen bonding capabilities), their synthetic 
accessibility and their low cytotoxic potential as seen from their effects on murine and 
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Appendix 1: Characterization of Compounds in Series 1-8  
 
Series 1 (4,6-Dimethoxyaurones) 
2-Benzylidene-4, 6-dimethoxybenzofuran-3(2H)-one (1-1) 76 
40%; Yellow solid; mp 158-160 °C; 1H NMR (CDCl3, 300MHz): δ 3.92 (s, -OCH3), 
3.97 (s, -OCH3), 6.15 (d, J = 1.5 Hz, H5), 6.40 (d, J = 1.5 Hz, H7), 6.78 (s, olefinic H), 
7.37-7.46 (m, 3H), 7.84 (d, J = 6.9 Hz, 2H); 13C NMR (CDCl3, 75 MHz): δ 56.1 
(OCH3), 56.2 (OCH3), 89.2 (C7), 94.0 (C5), 105.2 (C9), 110.8 (CH=), 128.7, 129.3, 
131.1, 132.5, 147.8 (C2), 159.4 (C8), 169.0 (C4), 169.1 (C6), 180.7 (CO); MS (APCI) 
m/z [M+1]+ 283.3. Elemental analysis calculated for C17H14O4 : C, 72.33; H, 5.00. 
Found: C, 71.69; H, 5.56. 
 
2-(2'-Chlorobenzylidene)-4, 6-dimethoxybenzofuran-3(2H)-one (1-2) 
 90%; Yellow solid; mp 201-203 °C; 1H NMR (CDCl3, 300MHz): δ 3.89 (s, -OCH3), 
3.94 (s, -OCH3), 6.13 (d, J = 1.8 Hz, H5), 6.36 (d, J = 1.8 Hz, H7), 7.19 (s, olefinic H), 
7.25 (d, J =1.6 Hz,1H), 7.28 (d, J = 1.9 Hz, 1H), 7.31 (d,  J = 1.7 Hz, 1H), 7.41 (d, J = 
1.6 Hz, 1H); 13C NMR (CDCl3, 75 MHz): δ 56.1 (OCH3), 56.2 (OCH3), 89.3 (C7), 
94.2 (C5), 105.1 (C9), 105.8 (CH=), 126.9, 129.9, 130.0, 130.7, 131.8, 135.5, 148.7 
(C2), 159.6 (C8), 169.0 (C4), 169.1 (C6), 180.3 (CO); MS (APCI) m/z [M+1]+ 317.3. 







2-(3'-Chlorobenzylidene)-4, 6-dimethoxybenzofuran-3(2H)-one (1-3) 
60%; Yellow solid; mp 190-192 °C; 1H NMR (CDCl3, 300MHz): δ 3.94 (s, -OCH3), 
3.97 (s, -OCH3), 6.16 (d, J = 1.8 Hz, H5), 6.43 (d, J = 1.8 Hz, H7), 6.69 (s, olefinic H), 
7.34 (d, J = 5.7 Hz, 2H), 7.66-7.68 (m, 1H), 7.92 (s, 1H); 13C NMR (CDCl3, 75 MHz): 
δ 56.2 (OCH3), 56.2 (OCH3), 89.3 (C7), 94.2 (C5), 105.0 (C9), 108.9 (CH=), 129.1. 
129.2, 129.9, 130.4, 134.3, 134.6, 148.4 (C2), 159.5 (C8), 169.1 (C4), 169.1 (C6), 
180.4 (CO); MS (APCI) m/z [M+1]+ 317.3. Elemental analysis calculated for 
C17H13ClO4 : C, 64.46; H, 4.14. Found: C, 64.45; H, 4.09. 
 
2-(4'-Chlorobenzylidene)-4, 6-dimethoxybenzofuran-3(2H)-one (1-4) 76 
46%; Yellow solid; mp 179-180 °C; 1H NMR (CDCl3, 300MHz): δ 3.93 (s, -OCH3), 
3.97 (s, -OCH3), 6.15 (d, J = 2.1 Hz, H5), 6.40 (d, J = 1.8 Hz, H7), 6.72 (s, olefinic H), 
7.40 (d, J = 8.4 Hz, 2H), 7.80 (d, J = 8.7 Hz, 2H); 13C NMR (DMSO-d6, 75 MHz): δ 
56.2 (OCH3), 56.6 (OCH3), 90.0 (C7), 94.6 (C5), 105.2 (C9), 108.1 (CH=), 129.0, 
131.1, 132.4, 133.9, 147.5 (C2), 158.9 (C8), 168.2 (C4), 169.0 (C6), 178.8 (CO); MS 
(APCI) m/z [M+1]+ 317.3. Elemental analysis calculated for C17H13ClO4 : C, 64.46; H, 
4.14. Found: C, 64.45; H, 4.34. 
 
4, 6-Dimethoxy-2-(2'-hydroxybenzylidene)-benzofuran-3(2H)-one (1-5) 100 
98%; Orange crystal; mp 266-267 °C; 1H NMR (DMSO-d6, 300 MHz): δ 3.89 (s, -
OCH3), 3.92 (s, -OCH3), 6.35 (d, J = 1.5 Hz, H5), 6.71 (d, J = 1.5 Hz, H7), 6.90-6.95 
(m, 2H), 7.01 (s, olefinic H), 7.25 (t, J = 7.8 Hz, 1H), 8.07 (d, J = 7.5 Hz, 1H), 10.3 
(br s, -OH); 13C NMR (DMSO-d6, 75 MHz): δ 56.1 (OCH3), 56.4 (OCH3), 89.8 (C7), 
94.3 (C5), 103.7 (C9), 104.1 (CH=), 115.7, 118.8, 119.4, 130.6, 131.1, 146.7 (C2), 
157.0, 158.8 (C8), 168.0 (C4), 168.7 (C6), 178.9 (CO); MS (APCI) m/z [M+1]+ 298.8. 
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Elemental analysis calculated for C17H14O5 : C, 68.45; H, 4.73. Found: C, 68.05 ; H, 
4.68. 
 
4, 6-Dimethoxy-2-(3'-hydroxybenzylidene)-benzofuran-3(2H)-one (1-6) 97 
54%; Yellow solid; mp 284-286 °C; 1H NMR (DMSO-d6, 300 MHz): δ 3.89 (s, -
OCH3), 3.91 (s, -OCH3), 6.35 (d, J = 1.5 Hz, H5), 6.61 (d, J = 1.5 Hz, H7), 6.68 (s, 
olefinic H), 6.83 (d, J = 6 Hz,1H), 7.27 (s, 1H), 7.36 (d, 2H, J = 3.5 Hz ), 9.66 (br s, -
OH); 13C NMR (DMSO-d6, 75 MHz): δ 56.8 (OCH3), 57.1 (OCH3), 90.7 (C7), 95.2 
(C5), 105.8 (C9), 112.2 (CH=), 118.2, 118.6, 123.9, 131.0, 134.8, 149.2 (C2), 159.1 
(C8), 161.1, 170.4 (C4), 171.5 (C6), 182.1 (CO); MS (APCI) m/z [M+1]+ 298.8. 
Elemental analysis calculated for C17H14O5 : C, 68.45; H, 4.73. Found: C, 68.03 ; H, 
4.78. 
 
4, 6-Dimethoxy-2-(4'-hydroxybenzylidene)-benzofuran-3(2H)-one (1-7) 97 
43%; Yellow solid; mp 283-284 °C; 1H NMR (DMSO-d6, 300 MHz): δ  3.88 (s, -
OCH3), 3.91 (s, -OCH3), 6.35 (d, J = 1.5 Hz, H5), 6.65 (d, J = 1.5 Hz, H7), 6.69 (s, 
olefinic H), 6.88 (d, J = 8.7 Hz, 2H), 7.81 (d, J = 9 Hz, 2H); 13C NMR (DMSO-d6, 75 
MHz): δ 56.0 (OCH3), 56.4 (OCH3), 89.7 (C7), 94.2 (C5), 104.2 (C9), 110.4 (CH=), 
115.9, 123.0, 133.0, 145.6 (C2), 158.7, 159.0 (C8), 167.9 (C4), 168.5 (C6), 178.8 
(CO); MS (APCI) m/z [M+1]+ 299.2. Elemental analysis calculated for C17H14O5 : C, 
68.45; H, 4.73. Found: C, 67.18; H, 4.92. 
 
2-(2', 3'-Dihydroxybenzylidene)-4, 6-dimethoxybenzofuran-3(2H)-one (1-8) 
15 %; Dark orange solid; mp 284-286°C ; 1H NMR (DMSO-d6, 300 MHz): δ  3.89 (s, 
-OCH3), 3.91 (s, -OCH3), 6.34 (d, J = 1.5 Hz, H5), 6.71 (d, J = 5.7 Hz, H7), 6.83 (d, J 
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= 6.9 Hz, 1H), 7.03 (s, 1H), 6.75 (d, J= 7.9Hz, 1H), 7.55 (d, J= 9 Hz, 1H), 9.19 (s, -
OH), 9.64 (s, -OH); 13C NMR (DMSO-d6, 75 MHz): δ 56.1 (OCH3), 56.4 (OCH3), 
89.8 (C7), 94.3 (C5), 103.7 (C9), 104.1 (CH=), 116.5, 118.1, 121.3, 131.0, 146.7 
(C2), 157.0, 158.8 (C8), 160.1, 168.0 (C4), 168.7 (C6), 180.1 (CO); HRMS (TOF-ES) 
calcd for C17H15O6+  ([M+1]+): 315.0869, found: 315.0863. Elemental analysis 
calculated for C17H14O6 : C, 64.97; H, 4.49. Found: C, 63.35; H, 4.68. 
 
2-(2', 4'-Dihydroxybenzylidene)-4, 6-dimethoxybenzofuran-3(2H)-one (1-9) 
20 %; Orange solid; mp 273-275°C ; 1H NMR (DMSO-d6, 300 MHz): δ  3.89 (s, -
OCH3), 3.91 (s, -OCH3), 6.31 (d, J = 1.5 Hz, H5), 6.36 (s, 1H), 6.39 (d, J = 2.6 Hz, 
1H), 6.66 (s, H7), 6.96 (s, 1H), 7.93 (d, J= 8.6 Hz, 1H), 9.96 (s, -OH), 10.23 (s, -OH); 
13C NMR (DMSO-d6, 75 MHz): δ 56.1 (OCH3), 56.4 (OCH3), 89.8 (C7), 94.3 (C5), 
103.7 (C9), 104.1 (CH=), 116.3, 118.4, 119.1, 131.4, 146.7 (C2), 157.1, 158.8 (C8), 
159.8, 168.0 (C4), 168.7 (C6), 180.1 (CO); MS (APCI) m/z [M+1]+ 315.3. Elemental 
analysis calculated for C17H14O6.2 ¼ H2O: C, 57.50; H, 5.21. Found: C, 57.89; H, 
4.90. 
 
4, 6-Dimethoxy-2-(2'-methoxybenzylidene)-benzofuran-3(2H)-one (1-10) 101 
94%; Yellow powder; mp 215-217 °C; 1H NMR (CDCl3, 300 MHz): δ 3.90 (s, -
OCH3), 3.91 (s, -OCH3), 3.96 (s, -OCH3), 6.14 (d, J = 1.5 Hz, H5), 6.39 (d, J = 1.8 Hz, 
H7), 6.93 (d, J = 8.4 Hz, 1H), 7.33 (s, olefinic H), 7.06 (t, J = 8.1 Hz, 1H), 7.36 (t, J = 
8.4 Hz, 1H), 8.24 (dd, J1 = 1.2 Hz, J2 = 7.8 Hz, 1H); 13C NMR (CDCl3, 75 MHz): δ 
55.5 (OCH3), 56.0 (OCH3), 56.2 (OCH3), 89.2 (C7), 93.9 (C5), 105.0 (C9), 105.4 
(CH=), 110.7, 120.6, 121.6, 130.8, 131.6, 147.9 (C2), 158.5, 159.4 (C8), 168.7 (C4), 
168.9 (C6), 180.7 (CO); HRMS (TOF-ES) calcd for C18H17O5+  ([M+1]+): 313.1076, 
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found: 313.1084. Elemental analysis calculated for C18H16O5: C, 69.22; H, 5.16. 
Found: C,70.21; H, 5.27. 
 
4, 6-Dimethoxy-2-(3'-methoxybenzylidene)-benzofuran-3(2H)-one (1-11): 
20%; Yellow powder; mp 190-191 °C; 1H NMR (CDCl3, 300 MHz): δ 3.87 (s, -
OCH3), 3.92 (s, -OCH3), 3.96 (s, -OCH3), 6.15 (d, J =1.8 Hz, H5), 6.39 (d, J = 1.5 Hz, 
H7), 6.75 (s, olefinic H), 6.95 (dd, J1 = 1.5 Hz, J2 = 7.8 Hz, 1H), 7.37 (t, J = 8.1 Hz, 
1H), 7.46 (t, J = 2.1 Hz, 2H); 13C NMR (CDCl3, 75 MHz): δ 55.3 (OCH3), 56.1 
(OCH3), 56.2 (OCH3), 89.2 (C7), 94.1 (C5), 105.2 (C9), 110.6 (CH=), 115.1, 116.2, 
123.8, 129.7, 133.8, 147.9 (C2), 159.4, 159.7 (C8), 169.0 (C4, C6), 180.6 (CO); MS 
(APCI) m/z [M+1]+ 313.4. Elemental analysis calculated for C18H16O5: C, 69.22; H, 
5.16. Found: C, 68.75; H, 5.10. 
 
4, 6-Dimethoxy-2-(4'-methoxybenzylidene)-benzofuran-3(2H)-one (1-12) 63, 97 
74%; Yellow crystal; mp 170-171 °C; 1H NMR (CDCl3, 300 MHz): δ 3.86 (s, -
OCH3), 3.92 (s, -OCH3), 3.96 (s, -OCH3), 6.14 (d, J = 1.5 Hz, H5), 6.39 (d, J = 1.5 Hz, 
H7), 6.76 (s, olefinic H), 6.98 (d, J = 8.7 Hz, 2H), 7.85 (d, J = 8.7 Hz, 2H); 13C NMR 
(CDCl3, 75 MHz): δ 55.2 (OCH3), 56.0 (OCH3), 56.1 (OCH3), 89.1 (C7), 93.8 (C5), 
105.3 (C9), 110.9 (CH=), 114.2, 125.2, 132.7, 146.7 (C2), 159.2 (C8), 160.5, 168.6 
(C4), 168.7 (C6), 180.5 (CO); MS (APCI) m/z [M+1]+ 313.3. Elemental analysis 
calculated for C18H16O5: C, 69.22; H, 5.16. Found: C, 69.33; H, 5.18. 
4, 6-Dimethoxy-2-(2'-fluorobenzylidene)-benzofuran-3(2H)-one (1-13) 
58 %; Yellow crystal; mp 187-189 °C; 1H NMR (CDCl3, 300 MHz): δ 3.93 (s, -
OCH3), 3.97 (s, -OCH3), 6.16 (d, J = 1.8 Hz, H5), 6.40 (d, J= 1.8 Hz, H7), 7.07 (s, 
olefinic H), 7.08 (d, J = 11 Hz, 1H), 7.15 (d, J = 10 Hz, 1H), 7.35 (t, J = 5.4 Hz, 1H), 
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8.27 (t, J = 7.5 Hz, 1H); 13C NMR (CDCl3, 75 MHz): δ 56.0 (OCH3), 56.4 (OCH3), 
89.7 (C7), 94.3 (C5), 103.7 (C9), 104.1 (CH=), 115.3, 123.1, 124.1, 128.0, 129.5, 
146.7 (C2), 158.8 (C8), 162.0, 168.2 (C4), 168.8 (C6), 180.1 (CO); MS (APCI) m/z 
[M+1]+ 301.3. Elemental analysis calculated for C17H13FO4: C, 68.00; H, 4.36. Found: 
C, 68.10; H, 4.12. 
 
4, 6-Dimethoxy-2-(3'-fluorobenzylidene)-benzofuran-3(2H)-one (1-14) 
37 %; Yellow solid; mp 178-179 °C; 1H NMR (CDCl3, 300MHz): δ 3.93 (s, -OCH3), 
3.97 (s, -OCH3), 6.16 (d, J =1.8 Hz, H5), 6.42 (d, J = 1.5 Hz, H7), 6.73 (s, olefinic H), 
7.10 (t, J = 8.4 Hz, 1H), 7.42 (dd, J1= 8.1 Hz, J2 = 14 Hz, 1H), 7.55 (d, J = 7.5 Hz, 
1H), 7.70 (d, J = 10 Hz, 1H); 13C NMR (CDCl3, 75 MHz): δ 56.1 (OCH3), 56.4 
(OCH3), 89.8 (C7), 94.3 (C5), 103.7 (C9), 104.1 (CH=), 114.0, 115.1, 124.3, 130.0, 
135.8, 146.7 (C2), 158.8 (C8), 162.1, 168.0 (C4), 168.7 (C6), 180.1 (CO); MS (APCI) 
m/z [M+1]+ 301.3. Elemental analysis calculated for C17H13FO4: C, 68.00; H, 4.36. 
Found: C, 67.72; H, 4.97. 
 
4, 6-Dimethoxy-2-(4'-fluorobenzylidene)-benzofuran-3(2H)-one (1-15) 76 
80 %; Yellow solid; mp 185-186 °C; 1H NMR (CDCl3, 300MHz): δ 3.93 (s, -OCH3), 
3.97 (s, -OCH3), 6.15 (d, J = 1.5 Hz, H5), 6.40 (d, J = 1.5 Hz, H7), 6.74 (s, olefinic H), 
7.15 (t, J = 8.7 Hz, 2H), 7.89 (dd, J1= 5.4 Hz, J2 = 8.7 Hz, 2H); 13C NMR (CDCl3, 75 
MHz): δ 56.1 (OCH3), 56.3 (OCH3), 89.8 (C7), 94.4 (C5), 104.3(C9), 106.1 (CH=), 
115.2, 126.9, 130.0, 146.7 (C2), 158.8 (C8), 161.6, 168.0 (C4), 168.7 (C6), 180.1 
(CO); MS (APCI) m/z [M+1]+ 301.3. Elemental analysis calculated for C17H13FO4: C, 
68.00; H, 4.36. Found: C, 68.02; H, 4.50. 
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2-(4'-Cyanobenzylidene)-4, 6-dimethoxybenzofuran-3(2H)-one (1-16) 76 
67%; Yellow powder; mp 242-244 °C; 1H NMR (CDCl3, 300 MHz): δ 3.94 (s, -
OCH3), 3.98 (s, -OCH3), 6.17 (J = 1.8 Hz, H5), 6.42 (d, J = 1.8 Hz, H7), 6.76 (s, 
olefinic H), 7.69 (d, J = 8.4 Hz, 2H), 7.98 (d, J = 9 Hz, 2H); 13C NMR (CDCl3, 75 
MHz): δ 56.2 (OCH3), 56.3 (OCH3), 89.5 (C7), 94.4 (C5), 104.7 (C9), 107 (CH=), 
112.0, 118.7 (C≡N), 131.1, 132.3, 137.1, 149.3 (C2), 159.6 (C8), 169.1 (C4), 169.5 
(C6), 180.1 (CO); HRMS (TOF-ES) calcd for C18H14NO4+  ([M+1]+): 308.0923, 
found: 308.0935; Elemental analysis calculated for C18H13NO4: C, 73.35; H, 4.26. 
Found: C, 68.81; H, 4.18. 
 
4, 6-Dimethoxy-2-(4'-trifluoromethylbenzylidene)-benzofuran-3(2H)-one (1-17) 
46 %; Light yellow solid; mp 186-187 °C; 1H NMR (CDCl3, 300 MHz): δ 3.94 (s, -
OCH3), 3.97 (s, -OCH3), 6.17 (d, J = 1.8 Hz, H5), 6.41 (d, J = 1.8 Hz, H7), 6.71 (s, 
olefinic H), 7.71 (d, J = 8.4 Hz, 2H), 7.95 (d, J = 8.1 Hz, 2H); 13C NMR (CDCl3, 75 
MHz): δ 56.0 (OCH3), 56.5 (OCH3), 89.8 (C7), 94.1 (C5), 103.7 (C9), 105.0 (CH=), 
124.6, 125.0, 129.0, 131.1, 135.3, 146.7 (C2), 158.8 (C8), 168.2 (C4), 168.8 (C6), 
180.1 (CO); MS (APCI) m/z [M+1]+ 351.1. Elemental analysis calculated for 
C18H13F3O4: C, 61.72; H, 3.74. Found: C, 61.66; H, 3.72.  
 
4, 6-Dimethoxy-2-(4'-nitrobenzylidene)-benzofuran-3(2H)-one (1-18) 
38 %; Orange solid; mp 283-284 °C; 1H NMR (CDCl3, 300 MHz): δ 3.95 (s, -OCH3), 
3.98 (s, -OCH3), 6.19 (d, J = 1.5 Hz, H5), 6.44 (d, J = 1.8 Hz, H7), 6.76 (s, olefinic H), 
8.01 (d, J = 9 Hz, 2H), 8.29 (d, J = 8.7 Hz, 2H); 13C NMR (DMSO-d6, 75 MHz): δ 
56.1 (OCH3), 56.4 (OCH3), 89.8 (C7), 94.3 (C5), 103.7 (C9), 104.1 (CH=), 123.9, 
129.0, 138.3, 146.7 (C2), 147.1, 158.8 (C8), 168.0 (C4), 168.7 (C6), 180.1 (CO); MS 
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(APCI) m/z [M+1]+ 328.3. Elemental analysis calculated for C17H13NO6: C, 62.39; H, 
4.00. Found: C, 59.38; H, 4.33.  
 
4, 6-Dimethoxy-2-(2'-methylbenzylidene)-benzofuran-3(2H)-one (1-19) 
37%; Yellow powder; mp 194-195 °C; 1H NMR (CDCl3, 300 MHz): δ 2.50 (s, -CH3), 
3.91 (s, -OCH3), 3.96 (s, -OCH3), 6.15 (J = 1.8 Hz, H5), 6.38 (d, J = 1.8 Hz, H7), 7.00 
(s, olefinic H), 7.30-7.36 (m, 3H), 8.17 (dd, J1 = 2.1 Hz, J2 = 8.4 Hz, 1H); 13C NMR 
(CDCl3, 75 MHz): δ 20.2 (CH3), 56.0 (OCH3), 56.1 (OCH3), 89.2 (C7), 94.0 (C5), 
105.2 (C9), 107.6 (CH=), 126.1, 129.2, 130.5, 131.0, 138.7, 148.0 (C2), 159.4 (C8), 
168.9 (C4, C6), 180.6 (CO); MS (APCI) m/z [M+1]+ 297.5. Elemental analysis 
calculated for C18H16O4: C, 72.96; H, 5.44. Found: C, 72.48; H, 5.25.  
 
4, 6-Dimethoxy-2-(4'-methylbenzylidene)-benzofuran-3(2H)-one (1-20) 
65%; Yellow powder; mp 186-188 °C; 1H NMR (CDCl3, 300MHz): δ 2.40 (s, -CH3), 
3.92 (s, -OCH3), 3.96 (s, -OCH3), 6.14 (d, J = 1.5 Hz, H5), 6.40 (d, J = 1.5 Hz, H7), 
6.77 (s, olefinic H), 7.26 (d, J = 8.1 Hz, 2H), 7.78 (d, J = 7.8 Hz, 2H); 13C NMR 
(CDCl3, 75 MHz): δ 21.4 (CH3), 55.9 (OCH3), 56.0 (OCH3), 89.1 (C7), 93.8 (C5), 
105.2 (C9), 110.9 (CH=), 129.4, 129.6, 131.0, 139.6, 147.3 (C2), 159.2 (C8), 168.7 
(C4, C6), 180.6 (CO); MS (APCI) m/z [M+1]+ 297.4. Elemental analysis calculated 
for C18H16O4: C, 72.96; H, 5.44. Found: C, 72.09; H, 5.41.  
 
4, 6-Dimethoxy-2-(4'-dimethylaminobenzylidene)-benzofuran-3(2H)-one (1-21) 76 
21 %; Orange solid; mp 182-183 °C; 1H NMR (CDCl3, 300 MHz): δ 3.03 (s, 6H), 3.88 
(s, -OCH3), 3.92 (s, -OCH3), 6.10 (d, J = 1.8 Hz, H5), 6.36 (d, J = 1.8 Hz, H7), 6.72 (d, 
J = 8.4 Hz, 2H), 6.75 (s, olefinic H), 7.78 (d, J = 9 Hz, 2H); 13C NMR (CDCl3, 75 
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MHz): δ 40.4, 56.1 (OCH3), 56.4 (OCH3), 89.8 (C7), 94.3 (C5), 103.7 (C9), 104.1 
(CH=), 111.6, 121.7, 130.0, 146.7 (C2), 151.1, 159.1 (C8), 168.0 (C4), 168.7 (C6), 
180.1 (CO); HRMS (TOF-ES) calcd for C19H20NO4+  ([M+1]+): 326.1392, found: 
326.1380. Elemental analysis calculated for C19H19NO4: C, 70.14; H, 5.89. Found: C, 




20 %; Orange solid; mp 156-158 °C; 1H NMR (CDCl3, 300 MHz): δ 2.68-2.80 (m, 
4H), 3.11 (s, 3H), 3.60-3.74 (m, 4H), 3.92 (s, -OCH3), 3.96 (s, -OCH3), 6.14 (d, J = 
1.5 Hz, H5), 6.39 (d, J = 1.5 Hz, H7), 6.74 (s, olefinic H), 6.95 (d, J = 8.7 Hz, 2H), 
7.82 (d, J = 8.7 Hz, 2H); 13C NMR (CDCl3, 75 MHz): δ 43.3, 49.5, 54.7, 56.1 
(OCH3), 56.4 (OCH3), 89.8 (C7), 94.3 (C5), 103.7 (C9), 104.1 (CH=), 111.6, 122.0, 
130.0, 146.7 (C2), 152.0, 158.8 (C8), 168.0 (C4), 168.7 (C6), 180.1 (CO); MS (APCI) 
m/z [M+1]+ 381.7. Elemental analysis calculated for C22H24N2O4.HCl.1 ¼ H2O: C, 
60.08; H, 5.43. Found: C, 59.66; H, 6.60.  
 
4, 6-Dimethoxy-2-(pyridin-2'-ylmethylene)-benzofuran-3(2H)-one (1-23) 
20%; Yellow solid; mp 186-189°C; 1H NMR (CDCl3, 300 MHz): δ 3.91 (s, -OCH3), 
3.95 (s, -OCH3), 6.14 (d, J = 1.5 Hz, H5), 6.42 (d, J = 1.8 Hz, H7), 6.90 (s, olefinic H), 
7.15-7.32 (m, 1H), 7.75 (t, J = 7.9 Hz, 1H), 8.02 (d, J = 7.9 Hz, 1H), 8.70 (d, J = 1.8 
Hz, 1H); 13C NMR (CDCl3, 75 MHz): δ 56.1 (OCH3), 56.4 (OCH3), 89.8 (C7), 94.3 
(C5), 103.7 (C9), 104.1 (CH=), 122.7, 124.2, 135.1, 146.7 (C2), 149.1, 154.8, 158.8 
(C8), 168.0 (C4), 168.7 (C6), 180.1 (CO); MS (APCI) ) m/z [M+1]+ 284.6. Elemental 
analysis calculated for C16H13NO4: C, 67.84; H, 4.63. Found: C, 67.94; H, 5.12 
 147
.  
4, 6-Dimethoxy-2-(pyridin-3'-ylmethylene)-benzofuran-3(2H)-one (1-24) 
27%; Yellow solid; mp 184-187°C; 1H NMR (CDCl3, 300 MHz): δ 3.94 (s, -OCH3), 
3.97 (s, -OCH3), 6.16 (d, J = 1.5 Hz, H5), 6.40 (d, J = 1.5 Hz, H7), 6.73 (s, olefinic H), 
7.33 (t, J = 1.6 Hz, 1H), 8.21 (d, J = 8.3 Hz, 1H), 8.58 (d, J = 1.3 Hz, 1H), 9.02 (s, 
1H); 13C NMR (CDCl3, 75 MHz): δ  56.1 (OCH3), 56.4 (OCH3), 89.8 (C7), 94.3 (C5), 
103.7 (C9), 104.1 (CH=), 125.1, 132.4, 132.5, 146.7 (C2), 148.0, 150.1, 158.8 (C8), 
168.0 (C4), 168.7 (C6), 180.1 (CO); MS (APCI) m/z [M+1]+ 284.4. Elemental 
analysis calculated for C16H13NO4: C, 67.84; H, 4.63. Found: C, 67.28; H, 4.79 
 
4, 6-Dimethoxy-2-(pyridin-4'-ylmethylene)-benzofuran-3(2H)-one (1-25) 
30 %; Yellow solid; mp 254-257°C ; 1H NMR (CDCl3, 300 MHz): δ 3.94 (s, -OCH3), 
3.97 (s, -OCH3), 6.17 (d, J = 1.5 Hz, H5), 6.41 ((d, J = 1.5 Hz, H7), 6.65 (s, olefinic 
H), 7.76 (d, J = 8.6 Hz, 2H), 8.68 (d, J = 8.7 Hz, 2H);  13C NMR (CDCl3, 75 MHz): δ  
56.1 (OCH3), 56.4 (OCH3), 89.8 (C7), 94.3 (C5), 103.7 (C9), 104.1 (CH=), 123.1, 
146.3, 146.7 (C2), 150.2, 158.8 (C8), 168.0 (C4), 168.7 (C6), 180.1 (CO); HRMS 
(TOF-ES) calcd for C16H14NO4+  ([M+1]+): 284.0923, found: 284.0977; Elemental 
analysis calculated for C16H13NO4: C, 67.84; H, 4.63. Found: C, 66.20; H, 5.01 
 
4, 6-Dimethoxy-2-(quinolin-3'-ylmethylene)-benzofuran-3(2H)-one (1-26) 
51 %; Pale orange solid; mp 219-220 °C; 1H NMR (CDCl3, 300 MHz): δ 3.96 (s, -
OCH3), 3.98 (s, -OCH3), 6.18 (d, J = 1.5 Hz, H5), 6.47 (d, J = 1.8 Hz, H7), 6.91 (s, 
olefinic H), 7.60 (t, J = 7.9 Hz, 1H), 7.80 (t, J = 8.3 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 
8.14 (d, J = 8.4 Hz, 1H), 8.66 (d, J = 1.5 Hz, 1H), 9.35 (d, J = 2.1 Hz, 1H); 13C NMR 
(CDCl3, 75 MHz): δ 56.2 (OCH3), 56.3 (OCH3), 89.4 (C7), 94.2 (C5), 105.0 (C9), 
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106.9 (C=), 126.1, 127.2, 127.8, 129.3, 130.5, 137.5, 147.5 (C2), 149.1, 152.0, 159.6 
(C8), 169.3, 180.1 (CO); MS (APCI) m/z [M+1]+  334.7. Elemental analysis calculated 
for C20H15NO4: C, 72.12; H, 4.90. Found: C, 72.06; H, 4.54 
 
Series 2 (4,6-Dihydroxyaurones) 
2-Benzylidene-4, 6-dihydroxybenzofuran-3(2H)-one (2-1) 98 
15%; Yellow solid; mp 249-250 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.09 (d, J = 
1.5 Hz, H5), 6.24 (d, J = 1.5 Hz, H7), 6.61 (s, olefinic H), 7.40-7.50 (m, 3H), 7.90 (d, J 
= 7.5 Hz, 2H); 13C NMR (DMSO-d6, 75 MHz): δ 91.8 (C7), 98.9 (C5), 103.3 (C9), 
112.6 (C=), 128.6, 129.3, 131.1, 132.6, 148.8 (C2), 158.9 (C8), 168.6 (C4), 168.9 
(C6), 180.6 (CO); MS (APCI) m/z [M+1]+ 255.0. Elemental analysis calculated for 
C15H10O4: C, 70.8; H, 3.93. Found: C, 71.28; H, 4.25 
 
2-(2'-Chlorobenzylidene)-4, 6-dihydroxybenzofuran-3(2H)-one (2-2) 
44%; Yellow solid; mp 294-295°C; 1H NMR (300MHz, DMSO-d6) δ 6.09 (d, J = 1.5 
Hz, H5), 6.22 (d, J = 1.5 Hz, H7), 6.80 (s, olefinic H), 7.39-7.51 (m, 2H), 7.59 (d, 1H, 
J = 8.1 Hz),  8.22 (d, 1H, J = 7.8 Hz);  13C NMR (DMSO-d6, 75 MHz): δ 91.8 (C7), 
99.0 (C5), 103.2 (C9), 106.8 (C=), 126.9, 129.9, 130.0, 130.7, 132.0, 135.5, 149.4 
(C2), 159.6 (C8), 168.6 (C4, C6), 180.2 (CO); MS (APCI) m/z [M+1]+ 289.3. 
Elemental analysis calculated for C15H9ClO4. ¾ H2O: C, 59.57; H, 3.47. Found: C, 
59.39; H, 3.63 
 
2-(3'-Chlorobenzylidene)-4, 6-dihydroxybenzofuran-3(2H)-one (2-3) 
23%; Yellow solid; mp 248-249 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.07 (d, J = 
1.5 Hz, H5), 6.22 (d, J = 1.5 Hz, H7), 6.61 (s, olefinic H), 7.46-7.53 (m, 2H), 7.86-7.92 
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(m, 2H); 13C NMR (DMSO-d6, 75 MHz): δ 91.8 (C7), 98.7 (C5), 101.5 (C9), 111.5 
(C=), 129.1, 129.1, 130.0, 130.2, 133.8, 134.6, 149.2 (C2), 160.1 (C8), 169.8 (C4, 
C6), 180.1 (CO); MS (APCI) m/z [M+1]+ 289.0. Elemental analysis calculated for 
C15H9ClO4. 1/5 H2O: C, 61.58; H, 3.22. Found: C, 61.74; H, 3.76 
 
2-(4'-Chlorobenzylidene)-4, 6-dihydroxybenzofuran-3(2H)-one (2-4) 
16%; Yellow solid; mp 253-255 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.07 (d, J = 
1.5 Hz, H5), 6.20 (d, J = 1.5 Hz, H7), 6.62 (s, olefinic H), 7.53 (d, J = 8.7 Hz, 2H), 
7.90 (d, J = 8.7 Hz, 2H);  13C NMR (DMSO-d6, 75 MHz): δ 91.8 (C7), 99.0 (C5), 
103.2 (C9), 107.8 (C=), 130.7, 131.5, 131.9, 135.4, 149.4 (C2), 159.6 (C8), 168.6 
(C4, C6), 180.2 (CO); MS (APCI) m/z [M+1]+ 289.1. Elemental analysis calculated 
for C15H9ClO4. H2O: C, 58.69; H, 3.59. Found: C, 58.66; H, 4.07 
 
4, 6-Dihydroxy-2-(2'-hydroxybenzylidene)-benzofuran-3(2H)-one (2-5) 64 
31%; Orange solid; mp 266-268 °C;1H NMR (DMSO-d6, 300 MHz):  δ 6.05 (d, J = 
1.5 Hz, H5), 6.20 (d, J = 1.5 Hz, H7), 6.89-6.93 (m, 2H), 6.92 (s, olefinic H), 7.19-7.24 
(m, 1H), 8.02 (d, J = 6.8 Hz, 1H), 10.25 (br s, -OH); 13C NMR (DMSO-d6, 75 MHz): 
δ 91.8 (C7), 98.9 (C5), 103.3 (C9), 112.6 (C=), 115.7, 118.8, 119.4, 130.6, 131.1, 
148.8 (C2), 157.0, 158.9 (C8), 168.6 (C4), 168.9 (C6), 180.6 (CO); MS (APCI) m/z 
[M+1]+ 271.4. Elemental analysis calculated for C15H10O5. ¼ H2O: C, 65.52; H, 3.82. 
Found: C, 65.19; H, 4.45 
 
4, 6-Dihydroxy-2-(3'-hydroxybenzylidene)-benzofuran-3(2H)-one (2-6) 
43%; Yellow solid; mp 254-255 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.07 (d, J = 
1.5 Hz, H5), 6.20 (d, J = 1.5 Hz, H7), 6.49 (s, olefinic H), 6.80 (d, J = 7.1 Hz, 1H), 
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7.25-7.33 (m, 3H), 9.64 (br s, -OH); 13C NMR (DMSO-d6, 75 MHz): δ 91.8 (C7), 
98.9 (C5), 103.3 (C9), 112.6 (C=), 118.2, 118.6, 123.9, 131.0, 134.8, 148.8 (C2), 
158.9, 161.1, 168.6 (C4), 168.9 (C6), 180.6 (CO); MS (APCI) m/z [M+1]+ 271.3. 
Elemental analysis calculated for C15H10O5: C, 66.61; H, 3.70. Found: C, 66.25; H, 
3.71 
 
4, 6-Dihydroxy-2-(4'-hydroxybenzylidene)-benzofuran-3(2H)-one (2-7) 97 
62%; Yellow solid; mp 271-273 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.03 (d, J = 
1.5 Hz, H5), 6.18 (d, J = 1.5 Hz, H7), 6.52 (s, olefinic H), 6.85 (d, J = 8.7, 2H), 7.74 
(d, J = 8.7, 2H); 13C NMR (DMSO-d6, 75 MHz): δ 92.0 (C7), 98.5 (C5), 103.2 (C9), 
112.0 (C=), 115.8, 123.0, 133.0, 149.2 (C2), 158.7, 160.1 (C8), 169.8 (C4, C6), 180.1 
(CO); MS (APCI) m/z [M+1]+ 271.3. Elemental analysis calculated for C15H10O5. ½ 
H2O: C, 64.46; H, 3.94. Found: C, 64.18; H, 4.45 
 
4, 6-Dihydroxy-2-(2'-methoxybenzylidene)-benzofuran-3(2H)-one (2-8) 102 
35%; Yellow solid; mp 250-251 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 3.89 (s, -
OCH3), 6.06 (d, J = 1.5 Hz, H5), 6.20 (d, J = 1.5 Hz, H7), 6.90 (s, olefinic H), 7.07-
7.12 (m, 2H), 7.37-7.42 (t, J = 7.5 Hz, 1H), 8.09 (d, J = 7.5 Hz, 1H); 13C NMR 
(DMSO-d6, 75 MHz): δ 56.9 (OCH3), 91.8 (C7), 98.9 (C5), 103.3 (C9), 110.1, 112.6 
(C=), 121.4, 122.1, 131.8, 132.5, 148.8 (C2), 158.3, 158.9 (C8), 168.6 (C4), 168.9 
(C6), 180.6 (CO); MS (APCI) m/z [M+1]+ 285.3. Elemental analysis calculated for 





4, 6-Dihydroxy-2-(3'-methoxybenzylidene)-benzofuran-3(2H)-one (2-9) 
68%; Yellow solid; mp 249-250 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 3.80 (s, -
OCH3), 6.04 (d, J = 1.5 Hz, H5), 6.19 (d, J = 1.5 Hz, H7), 6.56 (s, olefinic H), 6.98 (d, 
J = 8.3, 1H), 7.38-7.49 (m, 3H); 13C NMR (DMSO-d6, 75 MHz): δ 55.6 (OCH3), 91.8 
(C7), 98.9 (C5), 103.3 (C9), 112.6 (C=), 115.1, 116.2, 123.8, 129.7, 133.8, 148.8 
(C2), 159.0, 159.1 (C8), 168.5 (C4), 168.9 (C6), 180.6 (CO); MS (APCI) m/z [M+1]+ 
285.4. Elemental analysis calculated for C16H12O5. ¼  H2O: C, 66.49; H, 4.33. Found: 
C, 66.63; H, 4.96 
 
4, 6-Dihydroxy-2-(4'-methoxybenzylidene)-benzofuran-3(2H)-one (2-10) 64 
31%; Yellow solid; mp 261-263 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 3.81 (s, -
OCH3), 6.05 (d, J = 1.5 Hz, H5), 6.20 (d, J = 1.5 Hz, H7), 7.05 (d, J = 9 Hz, 2H), 7.85 
(d, J = 8.6, 2H); 13C NMR (DMSO-d6, 75 MHz): δ 55.6 (OCH3), 91.8 (C7), 98.7 (C5), 
101.5 (C9), 111.5 (C=), 114.2, 125.2, 132.7, 149.2 (C2), 160.1 (C8), 169.0, 169.8 
(C4, C6), 180.1 (CO); MS (APCI) m/z [M+1]+ 285.4. Elemental analysis calculated 
for C16H12O5: C, 67.54; H, 4.22. Found: C, 67.12; H, 4.30 
 
2-(4'-Cyanobenzylidene)-4, 6-dihydroxybenzofuran-3(2H)-one (2-11) 
20%; Yellow solid; mp 276-278 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.10 (d, J = 
1.5 Hz, H5), 6.24 (d, J = 1.5 Hz, H7), 6.69 (s, olefinic H), 7.92 (d, J = 8.4 Hz, 2H), 
8.06 (d, J = 7.8 Hz, 2H); 13C NMR (DMSO-d6, 75 MHz): δ 91.8 (C7), 98.9 (C5), 
103.3 (C9), 112.6 (C=), 112.1, 118.8 (C≡N), 131.4, 132.1, 137.1, 148.8 (C2), 158.9 
(C8), 168.6 (C4), 168.9 (C6), 180.6 (CO); MS (APCI) m/z [M+1]+ 280.3. Elemental 
analysis calculated for C16H9NO4: C, 68.76; H, 3.22. Found: C, 68.62; H, 3.13 
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4, 6-Dihydroxy-2-(4'-methylbenzylidene)-benzofuran-3(2H)-one (2-12) 
65%; Yellow solid; mp 255-256 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 2.34 (s, -
CH3), 6.07 (d, J = 1.5 Hz, H5), 6.23 (d, J = 1.5 Hz, H7), 6.57 (s, olefinic H), 7.28 (d, J 
= 7.9 Hz, 2H), 7.77 (d, J = 8.3 Hz, 2H); 13C NMR (DMSO-d6, 75 MHz): δ 21.6 
(CH3), 91.8 (C7), 98.7 (C5), 101.5 (C9), 111.5 (C=), 130.7, 131.2, 132.2, 141.2, 149.2 
(C2), 160.1 (C8), 169.8 (C4, C6), 180.1 (CO); MS (APCI) m/z [M+1]+ 269.4. 
Elemental analysis calculated for C16H12O4: C, 71.57; H, 4.47. Found: C, 71.66; H, 
4.72 
 
4, 6-Dihydroxy-2-(2'-fluorobenzylidene)-benzofuran-3(2H)-one (2-13) 
28 %; Yellow solid; mp 260-270 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.07 (d, J = 
1.5 Hz, H5), 6.21 (d, J = 1.5 Hz, H7), 6.61 (s, olefinic H), 7.29-7.37 (m, 2H), 7.44 (t, J 
= 6 Hz, 1H), 8.16 (t, J = 7.2 Hz, 1H); 13C NMR (DMSO-d6, 75 MHz): δ 91.5 (C7), 
99.1 (C5), 103.3 (C9), 105.8 (C=), 115.1, 123.4, 124.2, 127.8, 129.5, 149.4 (C2), 
159.6 (C8), 162.0, 168.6 (C4, C6), 180.1 (CO); MS (APCI) m/z [M+1]+ 273.4. 
Elemental analysis calculated for C15H9FO4: C, 66.18; H, 3.33. Found: C, 66.61; H, 
3.81. 
 
4, 6-Dihydroxy-2-(3'-methoxy, 4'-hydroxybenzylidene)-benzofuran-3(2H)-one (2-
14)64 
15%; Orange solid, mp 261-262 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 3.92 (OCH3), 
6.09 (d, J = 1.5 Hz, H5), 6.27 (d, J = 1.5 Hz, H7), 6.68 (s, olefinic H), 7.21 (t, J = 2.3 
Hz, 2H); 7.37 (t, J = 8.1 Hz, 1H); 13C NMR (DMSO-d6, 75 MHz): δ 56.0, 91.8 (C7), 
99.0 (C5), 103.2 (C9), 107.8 (C=), 112.1, 117.8, 123.1, 125.3, 149.4 (C2), 158.0, 
159.1, 159.6 (C8), 168.6 (C4, C6), 180.2 (CO); MS (APCI) m/z [M+1]+ 301.3. 
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Elemental analysis calculated for C16H12O6: C, 64.00; H, 4.03. Found: C, 64.16; H, 
5.40. 
 
4, 6-Dihydroxy-2-(3', 4', 5'-trimethoxybenzylidene)-benzofuran-3(2H)-one (2-15) 
32%; Orange solid; mp 222-224 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 3.50 (OCH3), 
3.91 (OCH3), 3.94 (OCH3), 6.09 (d, J = 1.5 Hz, H5), 6.27 (d, J = 1.5 Hz, H7), 6.69 (s, 
olefinic H), 7.13 (s, 2H); 13C NMR (DMSO-d6, 75 MHz): δ 56.1, (OCH3), 57.0 
(OCH3), 91.8 (C7), 98.9 (C5), 103.3 (C9), 112.6 (C=), 110.1, 123.8, 148.8 (C2), 
156.1, 158.5, 158.9 (C8), 168.6 (C4), 168.9 (C6), 180.6 (CO); MS (APCI) m/z [M+1]+ 
345.4. Elemental analysis calculated for C18H16O7: C, 62.79; H, 4.68. Found: C, 
62.27; H, 4.57. 
 
Series 3 (5-hydroxyaurones) 
2-Benzylidene-5-hydroxybenzofuran-3(2H)-one (3-1) 99 
25 %; Yellow solid; mp 225-226 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.88 (s, 
olefinic H), 7.03 (d, J = 1.9 Hz, H4), 7.23 (dd, J1 = 2.1 Hz, J2 = 11 Hz, H6), 7.41 (J = 
8.7 Hz, H7), 7.45-7.51 (m, 3H), 7.98 (d, J = 7.5 Hz, 2H); 13C NMR (DMSO-d6, 75 
MHz): δ 108.1 (C9), 112.7 (CH=), 115.0, 122.1, 125.9, 128.6, 129.3, 131.1, 132.6, 
146.7 (C2), 154.2 (C5), 159.8 (C8), 184.4 (CO); MS (APCI) m/z [M+1]+ 239.3. 




55 %; Yellow solid; mp 190-191 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 7.04 (s, 
olefinic H), 7.05 (d, J = 2.7 Hz, H4), 7.25 (dd, J1 = 2.6 Hz, J2 = 11 Hz, H6), 7.42 (J = 9 
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Hz, H7), 7.48-7.53 (m, 2 H), 7.62 (d, J = 7.1 Hz, 1H), 8.31 (d, J = 7.9 Hz, 1H); 13C 
NMR (DMSO-d6, 75 MHz): δ 108.1 (C9), 112.7 (CH=), 115.0, 122.1, 125.9, 126.9, 
129.9, 130.0, 130.7, 132.0, 135.5, 146.7 (C2), 154.2 (C5), 159.8 (C8), 184.4 (CO); 
MS (APCI) m/z [M+1]+ 273.3. Elemental analysis calculated for C15H9ClO3: C, 
66.01; H, 3.30. Found: C, 65.70; H, 3.53 
 
2-(3'-Chlorobenzylidene)-5-hydroxybenzofuran-3(2H)-one (3-3) 
22 %; Yellow solid; mp 199-201 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.86 (s, 
olefinic H), 7.03 (d, J = 2.3 Hz, H4), 7.23 (dd, J1 = 2.6 Hz, J2 = 11 Hz, H6), 7.41 (d, J 
= 8.7 Hz, H7), 7.49-7.54 (m, 2H), 7.91-7.99 (m, 2H); 13C NMR (DMSO-d6, 75 MHz): 
δ 109.0 (C9), 112.1 (C=), 115.2, 121.8, 127.7, 130.1, 130.9, 131.3, 131.9, 134.7, 
134.9, 148.6 (C2), 154.5 (C5), 160.8 (C8), 185.9 (CO); MS (APCI) m/z [M+1]+ 273.4. 




58 %; Yellow solid; mp 236-237 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.85 (s, 
olefinic H), 7.01 (d, J = 2.6 Hz, H4), 7.21 (dd, J1 = 2.6 Hz, J2 = 11 Hz, H6), 7.36 (d, J 
= 8.6 Hz, H7), 7.53 (d, J = 8.3 Hz, 2H), 7.95 (d, J = 8.3 Hz, 2H); 13C NMR (DMSO-
d6, 75 MHz): δ 108.1 (C9), 112.7 (CH=), 115.0, 122.1, 125.9, 129.0, 131.1, 132.4, 
133.9, 146.7 (C2), 154.2 (C5), 159.8 (C8), 184.4 (CO); MS (APCI) m/z [M+1]+ 273.4. 






47 %; Yellow solid; mp 238-240 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.93-6.96 
(m, 2H), 7.03 (d, J = 2.3 Hz, H4), 7.19 (s, olefinic H), 7.25 (dd, J1 = 2.4 Hz, J2 = 9 Hz, 
H6), 7.28 (d, J = 7.5 Hz, 1H), 7.38 (d, J = 8.6 Hz, H7), 8.12 (d, J = 7.9 Hz, 1H); 13C 
NMR (DMSO-d6, 75 MHz): δ 108.1 (C9), 112.7 (CH=), 115.0, 115.7, 118.8, 119.4, 
122.1, 125.9, , 130.6, 131.1, 146.7 (C2), 154.2 (C5), 157.0, 159.8 (C8), 184.4 (CO); 
MS (APCI) m/z [M+1]+ 255.4. Elemental analysis calculated for C15H10O4: C, 70.87; 
H, 3.94. Found: C, 70.96; H, 4.23 
 
2-(3'-Hydroxybenzylidene)-5-hydroxybenzofuran-3(2H)-one (3-6) 
60 %; Yellow solid; mp 233-235 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.76 (s, 
olefinic H), 6.86 (d, J = 7.9 Hz, 1H), 7.03 (d, J = 1.9 Hz, H4), 7.22 (dd, J1 = 2.6 Hz, J2 
= 11 Hz, H6), 7.25 (t, J = 7.9 Hz, 1H), 7.35 (m, H7 + 2H), 9.74 (br s, -OH), 9.86 (br s, 
-OH); 13C NMR (DMSO-d6, 75 MHz): δ 108.1 (C9), 112.7 (CH=), 115.0, 118.2, 
118.6, 122.1, 123.9, 125.9, 131.0, 134.8, 146.7 (C2), 154.2 (C5), 159.8 (C8), 161.1, 
184.4 (CO); MS (APCI) m/z [M+1]+ 255.3. Elemental analysis calculated for 
C15H10O4: C, 70.87; H, 3.94. Found: C, 70.69; H, 4.22 
 
2-(4'-Hydroxybenzylidene)-5-hydroxybenzofuran-3(2H)-one (3-7) 99 
60 %; Yellow solid; mp 280-281 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.82 (s, 
olefinic H), 6.89 (d, J = 8.6 Hz, 2H), 7.01 (d, J = 2.2 Hz, H4), 7.20 (dd, J1 = 2.6 Hz, J2 
= 11 Hz, H6), 7.39 (d, J = 8.6 Hz, H7), 7.84 (d, J = 8.3 Hz, 2H), 9.80 (br s, -OH), 10.2 
(br s, -OH); 13C NMR (DMSO-d6, 75 MHz): δ 108.1 (C9), 112.7 (CH=), 115.0, 115.9, 
122.1, 123.0, 133.0, 125.9, 146.7 (C2), 154.2 (C5), 158.7, 159.8 (C8), 184.4 (CO); 
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MS (APCI) m/z [M+1]+ 255.4. Elemental analysis calculated for C15H10O4.1/3 H2O: 
C, 69.17; H, 4.10. Found: C, 69.11; H, 4.43 
 
5-Hydroxy-2-(2'-methoxybenzylidene)-benzofuran-3(2H)-one (3-8) 
50 %; Yellow solid; mp 243-244 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 3.90 (s, -
OCH3), 7.03 (d, J = 2.6 Hz, H4), 7.07-7.12 (m, 2H), 7.14 (s, olefinic H), 7.21 (dd, J1 = 
2.6 Hz, J2 = 11.6 Hz, H6), 7.38 (d, J = 9 Hz, H7), 7.42-7.47 (m, 1H), 8.18 (d, J = 6.4 
Hz, 1H); 13C NMR (DMSO-d6, 75 MHz): δ 55.5 (OCH3), 108.1 (C9), 110.7, 112.7 
(CH=), 115.0, 120.6, 121.6, 122.1, 125.9, 130.8, 131.6, 146.7 (C2), 154.2 (C5), 158.5, 
159.8 (C8), 184.4 (CO); MS (APCI) m/z [M+1]+ 269.2. Elemental analysis calculated 
for C16H12O4: C, 71.64; H, 4.51. Found: C, 71.72; H, 5.05 
 
5-Hydroxy-2-(3'-methoxybenzylidene)-benzofuran-3(2H)-one (3-9) 
22 %; Yellow solid; mp 214-215 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 3.82 (s, -
OCH3), 6.86 (s, olefinic H), 7.03 (d, J = 2.6 Hz, H4), 7.06 (d, J = 2.4, 1H), 7.23 (dd, J1 
= 2.6 Hz, J2 = 11 Hz, H6), 7.41-7.45 (m, H7 + 1H), 7.54-7.59 (m, 2H); 13C NMR 
(DMSO-d6, 75 MHz): δ 55.6 (OCH3), 108.1 (C9), 112.7 (CH=), 115.0, 115.1, 116.2, 
122.1, 123.8, 125.9, 129.7, 133.8, 146.7 (C2), 154.2 (C5), 159.0, 159.8 (C8), 184.4 
(CO); MS (APCI) m/z [M+1]+ 269.3. Elemental analysis calculated for C16H12O4: C, 
71.64; H, 4.51. Found: C, 72.12; H, 5.18 
 
5-Hydroxy-2-(4'-methoxybenzylidene)-benzofuran-3(2H)-one (3-10) 
28 %; Yellow solid; mp 273-274 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 3.83 (s, -
OCH3), 6.87 (s, olefinic H), 7.02 (d, J = 2.4 Hz, H4), 7.10 (d, J = 8.7 Hz, 2H), 7.21 
(dd, J1 = 2.6 Hz, J2 = 11.3 Hz, H6), 7.41 (d, J = 9 Hz, H7), 7.98 (d, J = 8.7 Hz, 2H); 
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13C NMR (DMSO-d6, 75 MHz): δ 55.5 (OCH3), 108.1 (C9), 112.7 (CH=), 114.1, 
115.0, 122.1, 125.2, 125.9, 133.7, 146.7 (C2), 154.2 (C5), 159.8 (C8), 161.4, 184.4 
(CO); MS (APCI) m/z [M+1]+ 269.4. Elemental analysis calculated for C16H12O4. 1/6 
H2O: C, 70.78; H, 4.55. Found: C, 70.88; H, 5.00 
 
2-(4'-Cyanobenzylidene)-5-hydroxybenzofuran-3(2H)-one (3-11) 
50 %; Yellow solid; mp 270-272 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.93 (s, 
olefinic H), 7.04 (d, J = 2.3 Hz, H4), 7.24 (dd, J1 = 2.6 Hz, J2 = 11.3 Hz, H6), 7.41 (d, 
J = 8.7 Hz, H7), 7.94 (d, J = 8.3 Hz, 2H), 8.12 (d, J = 8.3 Hz, 2H); 13C NMR (DMSO-
d6, 75 MHz): δ 108.1 (C9), 112.7 (CH=), 112.0, 115.0, 118.7 (C≡N), 122.1, 125.9, 
131.2, 132.1, 137.1, 146.7 (C2), 154.2 (C5), 159.8 (C8), 184.4 (CO); MS (APCI) m/z 
[M+1]+ 264.3. Elemental analysis calculated for C16H9NO3: C, 72.93; H, 3.42. Found: 
C, 72.94; H, 4.07 
  
5-Hydroxy-2-(4'-methylbenzylidene)-benzofuran-3(2H)-one (3-12) 
65 %; Yellow solid; mp 219-220 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 2.35 (s, -
CH3), 6.85 (s, olefinic H), 7.02 (d, J = 2.6 Hz, H4), 7.22 (dd, J1 = 2.6 Hz, J2 = 11.3 
Hz, H6), 7.31 (d, J = 7.9 Hz, 2H), 7.39 (d, J = 8.6 Hz, H7), 7.86 (d, J = 7.9 Hz, 2H); 
13C NMR (DMSO-d6, 75 MHz): δ 21.2 (CH3), 108.1 (C9), 112.7 (CH=), 115.0, 122.1, 
125.9, 129.4, 129.6, 131.0, 139.6, 146.7 (C2), 154.2 (C5), 159.8 (C8), 184.4 (CO); 
MS (APCI) m/z [M+1]+ 253.3. Elemental analysis calculated for C16H12O3: C, 76.11; 





Series 4 (6-Hydroxyaurones) 
2-Benzylidene-6-hydroxybenzofuran-3(2H)-one (4-1) 64, 77, 103 
38 %; Yellow solid; mp 232-233 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.73 (dd, J1 
=1.8 Hz, J2 = 10 Hz, H5), 6.79 (s, olefinic H), 6.81 (d, J = 1.8 Hz, H7), 7.44-7.53 (m, 
3H), 7.64 (d, J = 8.4 Hz, H4), 7.96 (d, J = 7.2 Hz, 2H); 13C NMR (DMSO-d6, 75 
MHz): δ 99.7 (C7), 113.5 (C=), 114.1 (C5), 114.9 (C9), 124.9 (C4), 128.6, 129.3, 
131.1, 132.6, 147.6 (C2), 167.9 (C6), 169.5 (C8), 183.8 (CO); MS (APCI) m/z [M+1]+ 
238.8. Elemental analysis calculated for C15H10O3. H2O: C, 70.25; H, 4.68. Found: C, 
70.75; H, 4.74 
 
2-(2'-Chlorobenzylidene)-6-hydroxybenzofuran-3(2H)-one (4-2)  
33 %; Yellow solid; mp 258-259 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.74 (dd, J1 
= 1.9 Hz, J2 = 10 Hz, H5), 6.81 (d, J = 1.5 Hz, H7), 6.97 (s, olefinic H), 7.44-7.50 (m, 
1H), 7.54 (d, J = 6.8 Hz, 1H), 7.62 (d, J = 7.5 Hz, 1H), 7.67 (d, J = 8.3 Hz, H4), 8.29 
(d, J = 7.5 Hz, 1H); 13C NMR (DMSO-d6, 75 MHz): δ 99.7 (C7), 113.5 (C=), 114.1 
(C5), 114.9 (C9), 124.9 (C4), 126.9, 129.9, 130.0, 130.7, 132.0, 135.5, 147.6 (C2), 
167.9 (C6), 169.5 (C8), 183.8 (CO); MS (APCI) m/z [M+1]+ 272.7. Elemental 
analysis calculated for C15H9ClO3: C, 66.01; H, 3.30. Found: C, 66.36; H, 3.52 
 
2-(3'-Chlorobenzylidene)-6-hydroxybenzofuran-3(2H)-one (4-3) 
65 %; Yellow solid; mp 238-240 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.73 (dd, J1 
= 1.9 Hz, J2 = 10 Hz, H5), 6.80 (s, olefinic H), 6.82 (t, J = 2.1 Hz, H7), 7.50-7.55 (m, 
2H), 7.64 (d, J = 8.4 Hz, H4), 7.93-7.97 (m, 2H); 13C NMR (DMSO-d6, 75 MHz): δ 
99.7 (C7), 113.5 (C=), 114.1 (C5), 114.9 (C9), 124.9 (C4), 129.1, 129.2, 129.9, 130.4, 
133.7, 134.6, 147.6 (C2), 167.9 (C6), 169.5 (C8), 184.1 (CO); MS (APCI) m/z [M+1]+ 
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272.9. Elemental analysis calculated for C15H9ClO3. 1 ¾ H2O: C, 59.18; H, 4.11. 
Found: C, 59.51; H, 3.59 
 
2-(4'-Chlorobenzylidene)-6-hydroxybenzofuran-3(2H)-one (4-4) 
67 %; Yellow solid; mp 260-261 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.73 (dd, J1 
= 1.8 Hz, J2 = 10 Hz, H5), 6.80 (d, J = 1.8 Hz, H7), 6.82 (s, olefinic H), 7.57 (d, J = 
8.4 Hz, 2H), 7.64 (d, J = 8.4 Hz, H4), 7.97 (d, J = 8.4 Hz, 2H); 13C NMR (DMSO-d6, 
75 MHz): δ  99.7 (C7), 113.5 (C=), 114.1 (C5), 114.9 (C9), 124.9 (C4), 129.0, 131.1, 
132.4, 133.9, 147.6 (C2), 167.9 (C6), 169.5 (C8), 183.9 (CO); MS (APCI) m/z [M+1]+ 
272.9. Elemental analysis calculated for C15H9ClO3. H2O: C, 61.92; H, 3.78. Found: 
C, 61.63; H, 3.64 
 
2-(2'-Hydroxybenzylidene)-6-hydroxybenzofuran-3(2H)-one (4-5) 101 
43 %; Yellow solid; mp 248-250 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.71 (dd, J1 
= 1.5 Hz, J2 = 10 Hz, H5), 6.80 (d, J = 1.9 Hz, H7), 6.93-6,96 (m, 2H), 7.10 (s, olefinic 
H), 7.24 (m, 1H), 7.62 (d, J = 8.3 Hz, H4), 8.09 (d, J = 7.5, 1H); 13C NMR (DMSO-d6, 
75 MHz): δ  99.8 (C7), 114.0 (C=), 114.3 (C5), 114.9 (C9), 115.7, 118.8, 119.4, 125.1 
(C4), 147.6 (C2), 130.6, 131.1, 157.0, 167.9 (C6), 169.5 (C8), 184.0 (CO); MS 
(APCI) m/z [M+1]+ 255.0. Elemental analysis calculated for C15H10O4. ¾ H2O: C, 
67.23; H, 4.29. Found: C, 67.26; H, 4.54 
 
2-(3'-Hydroxybenzylidene)-6-hydroxybenzofuran-3(2H)-one (4-6) 103 
30 %; Yellow solid; mp 237-238 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.69 (s, 
olefinic H), 6.72 (dd, J1 = 1.8 Hz, J2 = 10 Hz, H5), 6.78 (d, J = 1.5 Hz, H7), 6.85 (d, J 
= 7.8 Hz, 1H), 7.26 (t, J = 7.8 Hz, 1H), 7.35-7.39 (m, 2H), 7.63 (d, J = 8.4 Hz, H4); 
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13C NMR (DMSO-d6, 75 MHz): δ 99.6 (C7), 113.5 (C=), 114.1 (C5), 114.9 (C9), 
118.2, 118.6, 123.9, 125.2 (C4), 131.0, 134.8, 147.7 (C2), 161.1, 167.9 (C6), 169.5 
(C8), 183.8 (CO); MS (APCI) m/z [M+1]+ 255.2. Elemental analysis calculated for 
C15H10O4. 1 ¼ H2O: C, 65.04; H, 4.44. Found: C, 65.03; H, 4.52 
 
2-(4'-Hydroxybenzylidene)-6-hydroxybenzofuran-3(2H)-one (4-7) 64, 97 
53 %; Orange solid; mp 254-255 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.69 (dd, J1 
= 1.8 Hz, J2 = 10 Hz, H5), 6.72 (s, overlap, olefinic H), 6.77 (d, J = 1.8 Hz, H7), 6.88 
(d, J = 8.7 Hz, 2H), 7.60 (d, J = 8.4 Hz, H4), 7.81 (d, J = 8.7 Hz, 2H); 13C NMR 
(DMSO-d6, 75 MHz): δ 99.7 (C7), 113.5 (C=), 114.1 (C5), 114.9 (C9), 117.2, 124.9 
(C4), 126.9, 134.7, 147.6 (C2), 160.7, 167.9 (C6), 169.5 (C8), 183.8 (CO); MS 
(APCI) m/z [M+1]+ 255.4. Elemental analysis calculated for C15H10O4: C, 70.87; H, 
3.94. Found: C, 70.48; H, 4.41 
 
6-Hydroxy-2-(2'-methoxybenzylidene)-benzofuran-3(2H)-one (4-8) 
62 %; Yellow solid; mp 280-281 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 3.91 (s, -
OCH3), 6.72 (dd, J1 = 1.5 Hz, J2 = 10 Hz, H5), 6.80 (d, J = 1.5 Hz, H7), 7.10 (s, 
olefinic H), 7.11-7.14 (m, 2H), 7.42-7.47 (m, 1H), 7.63 (d, J = 8.3 Hz, H4), 8.16 (d, J 
= 7.9 Hz, 2H); 13C NMR (DMSO-d6, 75 MHz): δ 55.5 (OCH3), 99.7 (C7), 113.5 (C=), 
114.1 (C5), 114.9 (C9), 110.7, 120.6, 121.6, 124.9 (C4), 130.8, 131.6, 147.6 (C2), 
158.5, 167.9 (C6), 169.5 (C8), 183.8 (CO); MS (APCI) m/z [M+1]+ 269.1. Elemental 






50 %; Yellow solid; mp 231-232 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 3.82 (s, -
OCH3), 6.72 (dd, J1 = 1.8 Hz, J2 = 10 Hz, H5), 6.77 (s, olefinic H), 6.81 (d, J = 1.5 Hz, 
H7), 7.01-7.04 (m, 1H), 7.39 (t, J = 8.1 Hz, 1H), 7.50-7.57 (m, 2H), 7.63 (d, J = 8.3 
Hz, H4); 13C NMR (DMSO-d6, 75 MHz): δ 55.6 (OCH3), 99.7 (C7), 113.5 (C=), 114.1 
(C5), 114.9 (C9), 115.1, 116.2, 123.8, 124.9 (C4), 129.7, 133.8, 147.6 (C2), 159.0, 
167.9 (C6), 169.5 (C8), 183.8 (CO); MS (APCI) m/z [M+1]+ 269.1. Elemental 
analysis calculated for C16H12O4. 2 ¼ H2O: C, 62.18; H, 5.34. Found: C, 62.25; H, 
4.29 
 
6-Hydroxy-2-(4'-methoxybenzylidene)-benzofuran-3(2H)-one (4-10) 97, 104 
24 %; Yellow solid; mp 257-258 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 3.82 (s, -
OCH3), 6.70 (dd, J1 = 1.8 Hz, J2 = 10 Hz, H5), 6.76 (olefinic H), 6.78 (d, J = 1.5 Hz, 
H7), 7.06 (d, J = 8.7 Hz, 2H), 7.60 (d, J = 8.3 Hz, H4), 7.91 (d, J = 8.7 Hz, 2H); 13C 
NMR (DMSO-d6, 75 MHz): δ 55.6 (OCH3), 99.7 (C7), 113.5 (C=), 114.1 (C5), 114.9 
(C9), 114.2, 124.9 (C4), 125.2, 132.7, 147.6 (C2), 167.9 (C6), 169.0169.5 (C8), 183.8 
(CO); MS (APCI) m/z [M+1]+ 269.2. Elemental analysis calculated for C16H12O4. 1 ½ 
H2O: C, 65.03; H, 5.08. Found: C, 64.81; H, 4.53 
 
2-(4'-Cyanobenzylidene)-6-hydroxybenzofuran-3(2H)-one (4-11) 
76 %; Yellow solid; mp 230-232 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.74 (dd, J1 
= 1.8 Hz, J2 = 10 Hz, H5), 6.82 (d, J = 1.5 Hz, H7), 6.86 (s, overlap, olefinic H), 7.65 
(d, J = 8.3 Hz, H4), 7.94 (d, J = 8.4 Hz, 2H), 8.10 (d, J = 8.4 Hz, 2H); 13C NMR 
(DMSO-d6, 75 MHz): δ 99.7 (C7), 112.0, 113.5 (C=), 114.1 (C5), 114.9 (C9), 118.7 
(C≡N), 124.9 (C4), 131.2, 132.1, 137.1, 147.6 (C2), 167.9 (C6), 169.5 (C8), 183.8 
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(CO); MS (APCI) m/z [M+1]+ 264.3. Elemental analysis calculated for C16H9NO3. 1 
1/3 H2O: C, 66.84; H, 4.06. Found: C, 66.61; H, 4.01 
 
6-Hydroxy-2-(4'-methylbenzylidene)-benzofuran-3(2H)-one (4-12) 
60 %; Yellow solid; mp 243-244 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 2.36 (s, -
CH3), 6.71 (dd, J1 = 1.8 Hz, J2 = 10 Hz, H5), 6.76 (olefinic H), 6.80 (d, J = 1.5 Hz, 
H7), 7.31 (d, J = 8.1 Hz, 2H), 7.62 (d, J = 8.4 Hz, H4), 7.84 (d, J = 8.1 Hz, 2H); 13C 
NMR (DMSO-d6, 75 MHz): δ 21.2 (CH3), 99.7 (C7), 113.5 (C=), 114.1 (C5), 114.9 
(C9), 129.4, 129.6, 124.9 (C4), 131.0, 139.6, 147.6 (C2), 167.9 (C6), 169.5 (C8), 
183.8 (CO); MS (APCI) m/z [M+1]+ 253.3. Elemental analysis calculated for 
C16H12O3. 1 ½ H2O: C, 68.75; H, 5.37. Found: C, 68.63; H, 5.05 
 
Series 5 (Unsubstituted Ring A aurones) 
2-(2'-Hydroxybenzylidene)-benzofuran-3(2H)-one (5-1) 79 
65 %; Orange solid, mp 231-233 °C; 1H NMR (DMSO-d6, 300 MHz):  δ 6.94-6.99 
(m, 3H), 7.24 (s, olefinic H), 7.27-7.35 (m, 3H), 7.56 (d, J = 8.7 Hz, 1H), 7.78-7.82 
(m, 2H), 8.16 (d, J = 9 Hz, 1H); 13C NMR (Acetone-d6 + DMSO-d6, 75 MHz): δ 
107.6 (C9), 113.9 (C=), 116.7, 120.1, 120.5, 122.5 (C7), 124.5, 124.9 (C4, C5), 132.4, 
132.5, 137.9 (C6), 147.2 (C2), 158.8, 166.7 (C8), 184.5 (CO) ; MS (APCI) m/z 
[M+1]+ 239.0. Elemental analysis calculated for C15H10O3: C, 75.62; H, 4.23. Found: 
C, 75.54; H, 4.20 
 
2-(2'-Chlorobenzylidene)-benzofuran-3(2H)-one (5-2) 
31 %; Light yellow solid, mp 140-141 °C; 1H NMR (CDCl3, 300 MHz): 7.32-7.41 (m, 
4H), 7.37 (s, overlap, olefinic H), 7.56 (d, J = 7.2 Hz, 1H), 7.67 (t, J = 6 Hz, 1H), 7.83 
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(d, J = 7.2 Hz, 1H), 8.38 (d, J = 7.8 Hz, 1H); 13C NMR (CDCl3, 75 MHz): δ 107.8 
(C9), 112.5 (C=), 122.4 (C7), 124.3, 125.0 (C4, C5), 126.9, 129.9, 130.0, 130.7, 
132.0, 135.5, 138.0 (C6), 147.1 (C2), 166.7 (C8), 184.5 (CO); MS (APCI) m/z [M+1]+ 
257.5. Elemental analysis calculated for C15H9ClO2: C, 70.19; H, 3.53. Found: C, 
70.17; H, 3.64 
 
Series 6 (4, 6-Dimethoxy Isoaurones) 
3-Benzylidene-4, 6-dimethoxybenzofuran-2(3H)-one (6-1) 84 
47 %; Yellow solid, mp 177-178 °C; E-isomer: 1H NMR (CDCl3, 300 MHz): δ 3.85 
(s, -OCH3), 3.97 (s, -OCH3), 6.27 (d, J = 1.5 Hz, H5), 6.33 (d, J = 1.5 Hz, H7), 7.36-
7.45 (m, 3H), 7.99 (s, olefinic H), 7.65 (d, J = 9 Hz, 2 H), 13C NMR (CDCl3, 75 
MHz): δ 54.5, 55.8, 89.6, 94.1, 104.2, 120.0, 126.7, 128.2, 130.6, 135.8, 136.6, 156.2, 
156.7, 163.2, 169.8; Z-isomer: 1H NMR (CDCl3, 300 MHz): δ 3.89 (s, OCH3) 3.90 (s, 
OCH3), 6.25 (d, J = 2.1 Hz, H4), 6.31 (d, J =2.1 Hz, H6), 7.45 (s, olefinic H), 7.32-
7.35 (m, 3H), 8.02 (d, J= 6.5 Hz, 2H); HRMS (TOF-ES) calcd for C17H15O4+ 
([M+1]+): 283.0970, found: 283.0987; Elemental analysis calculated for C17H14O4: C, 
72.33; H, 5.00. Found: C, 70.23; H, 5.21 
 
4, 6-Dimethoxy-3-(2'-hydroxybenzylidene)-benzofuran-2(3H)-one (6-2) 
12 %; Yellow solid, mp 210-212 °C; E-isomer: 1H NMR (CDCl3, 300 MHz): δ 3.85 
(s, -OCH3), 3.96 (s, -OCH3), 6.15 (d, J = 1.5 Hz, H5), 6.20 (d, J = 1.5 Hz, H7), 7.13 (t, 
J = 7.5 Hz, 1H), 7.33 (d, J = 7.8 Hz, 1H), 7.43 (d, J = 7.5 Hz, 1H), 7.64 (d, J = 7.8 Hz, 
1H), 7.90 (s, olefinic H), 13C NMR (CDCl3, 75 MHz): δ 54.5, 55.7, 89.4, 94.0, 104.2, 
117.6, 120.1, 122.9, 123.9, 126.7, 131.1, 139.5, 156.1, 156.4, 158.5, 163.2, 169.8 ; Z-
isomer: 1H NMR (CDCl3, 300 MHz): δ  3.89 (s, OCH3) 3.90 (s, OCH3), 6.25 (d, J = 
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2.1 Hz, H4), 6.31 (d, J =2.1 Hz, H6), 7.31 (s, olefinic H), 7.22 t, J = 7.5 Hz, 1H), 7.48 
(d, J =6.9 Hz, 1H), 7.60 (d, J =7.3 Hz, 1H), 8.26 (d, J= 7.5 Hz, 1H); MS (APCI) m/z 
[M+1]+ 298.9. HPLC: Mobile system 1 (Methanol: water = 25: 75), 5.6 min, 97%; 
Mobile system 2 (acetonitrile: water = 20: 80), 2.9 min, 98 %. 
 
4, 6-Dimethoxy-3-(2'-methoxybenzylidene)-benzofuran-2(3H)-one (6-3) 
25 %; Yellow solid, mp 171-173 °C; E-isomer: 1H NMR (CDCl3, 300 MHz): δ 3.47 
(s, -OCH3), 3.85 (s, 6H, -OCH3), 6.16 (d, J = 1.5 Hz, H5), 6.38 (d, J = 1.5 Hz, H7), 
6.88 (d, J = 8.7 Hz, 1H), 6.93 (d, J = 7.5 Hz, 1H), 7.15 (d, J = 7.5 Hz, 1H), 7.36 (t, J = 
7.5 Hz, 1H), 7.90 (s, olefinic H), 13C NMR (CDCl3, 75 MHz): δ 54.5, 55.8, 56.1, 89.6, 
94.1, 104.2, 118.0, 120.0, 122.9, 123.9, 126.7, 131.8, 140.9,156.2, 156.7, 160.9, 
163.2, 169.8 ; Z-isomer: 1H NMR (CDCl3, 300 MHz): δ  3.89 (s, OCH3) 3.91 (s, × 2 
OCH3), 6.25 (d, J = 2.1 Hz, H4), 6.31 (d, J =2.1 Hz, H6), 7.00 (t, J = 7.5 Hz, 1H), 7.33 
(s, olefinic H), 7.45 (d, J =7.3 Hz, 1H), 7.52 (d, J =6.9 Hz, 1H), 8.10 (d, J = 7.8 Hz, 
1H); MS (APCI) m/z [M+1]+ 312.9. Elemental analysis calculated for C18H16O5: C, 
69.22; H, 5.16. Found: C, 69.13; H, 5.68 
3-(2'-Chlorobenzylidene)-4, 6-dimethoxybenzofuran-2(3H)-one (6-4) 
48 %; Yellow solid, mp 183-185 °C; E-isomer: 1H NMR (CDCl3, 300 MHz): δ 3.85 
(s, -OCH3), 3.95 (s, -OCH3), 6.13 (d, J = 1.5 Hz, H5), 6.38 (d, J = 1.5 Hz, H7), 7.22-
7.25 (m, 2H), 7.42 (d, J = 7.5 Hz, 2H), 7.76 (olefinic H); 13C NMR (CDCl3, 75 MHz): 
δ 54.5, 55.8, 89.6, 94.1, 104.2, 120.3, 126.7, 127.5, 127.9, 130.3, 130.8, 132.1, 133.4, 
156.2, 156.7, 163.2, 169.7 ; Z-isomer: 1H NMR (CDCl3, 300 MHz): δ 3.89 (s, OCH3) 
3.91 (s, OCH3), 6.25 (d, J = 2.1 Hz, H4), 6.31 (d, J =2.1 Hz, H6), 7.40-7.44 (m, 2H), 
7.35 (s, olefinic H), 7.61 (d, J = 3 Hz, 1H), 7.73 (d, J= 7.8 Hz, 1H); MS (APCI) m/z 
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[M+1]+ 317.2. . Elemental analysis calculated for C17H13ClO4: C, 64.46; H, 4.14. 
Found: C, 64.49; H, 4.22 
 
3-(4'-Chlorobenzylidene)-4, 6-dimethoxybenzofuran-2(3H)-one (6-5) 
31 %; Yellow solid, mp 173-175 °C; E-isomer: 1H NMR (CDCl3, 300 MHz): δ 3.86 
(s, -OCH3), 3.96 (s, -OCH3), 6.18 (d, J = 1.5 Hz, H5), 6.39 (d, J = 1.5 Hz, H7), 7.37 (d,  
J = 8.7, 2H), 7.40 (d,  J = 8.7, 2H), 7.90 (s, olefinic H); 13C NMR (CDCl3, 75 MHz): δ 
54.5, 55.8, 89.6, 94.1, 104.2, 120.0, 126.7, 129.1, 130.8, 132.5, 136.0, 156.2, 156.7, 
163.2, 169.8; Z-isomer: 1H NMR (CDCl3, 300 MHz): δ  3.89 (s, OCH3) 3.90 (s, 
OCH3), 6.21 (d, J = 2.1 Hz, H4), 6.29 (d, J =2.1 Hz, H6), 7.60 (d, J =8.4 Hz, 2H), 7.67 
(s, olefinic H), 7.96 (d, J =8.7 Hz, 2H); MS (APCI) m/z [M+1]+ 317.1. Elemental 
analysis calculated for C17H13ClO4: C, 64.46; H, 4.14. Found: C, 64.48; H, 4.10 
 
Series 7 (5-Hydroxy Isoaurones) 
3-Benzylidene-5-hydroxybenzofuran-2(3H)-one (7-1) 
25 %; Yellow solid, mp 198-200 °C; E-isomer: 1H NMR (DMSO-d6, 300 MHz):  δ 
6.82 (dd, J1 = 2.2 Hz, J2 = 8.7 Hz, H6), 7.11 (d, J = 8.7 Hz, H7), 7.15 (d, J = 2.4 Hz, 
H4), 7.51 (d, J = 6.3 Hz, 1H), 7.57 (d, J = 6.7 Hz, 2H), 7.76 (d, J = 9 Hz, 2H), 7.83 
(olefinic H) 9.50 (br s, OH); 13C NMR (DMSO-d6, 75 MHz): δ 109.1, 112.0, 118.3, 
121.0, 118.3, 121.9, 122.5, 129.2, 129.7, 131.0, 133.7, 141.0, 147.2, 153.7, 169.1; Z-
isomer: 1H NMR (DMSO-d6, 300 MHz):  δ 6.78 (dd, J1= 2.4 Hz, J2 = 10 Hz, H6), 
7.02 (d, J = 8.7 Hz, H7), 7.23 (d, J = 2.3 Hz, H4), 7.49-7.51 (m, 3H), 7.56 (s, olefinic 
H), 7.98 (d, J = 7.2 Hz, 2 H);MS (APCI) m/z [M+1]+ 239.3. Elemental analysis 




65 %; Yellow solid, mp 254-255 °C; E-isomer: 1H NMR (DMSO-d6, 300 MHz):  δ 
6.78 (dd, J1 = 2.4 Hz, J2 = 11 Hz, H6), 6.94-6.97 (m, 3H), 7.18 (d, J = 2.4 Hz, H7), 
7.34 (t, J = 2.4 Hz, H4), 7.69 (d, J = 7.5 Hz, 1H), 7.97 (s, olefinic H); 13C NMR 
(DMSO-d6, 75 MHz): δ 111.1 , 112.6, 117.6, 118.8, 120.8, 122.9, 123.3, 124.4, 131.1, 
134.2, 139.1, 149.5, 155.3, 158.6, 171.9; Z-isomer: 1H NMR (DMSO-d6, 300 MHz):  
δ 6.67 (d, J1= 2.4 Hz, J2 = 10 Hz, H6), 7.03 (d, J = 8.7 Hz, H7), 7.19 (d, J = 2.4 Hz, 
H4), 7.29 (d, J= 6.8 Hz, 1H), 7.35 (olefinic H), 7.55 (d, J = 7.4 Hz, 1H), 7.63 (d, J 
=6.9 Hz, 1H), 8.20 (d, J =7.4 Hz, 1H); MS (APCI) m/z [M+1]+ 255.3. Elemental 
analysis calculated for C15H10O4: C, 70.87; H, 3.94. Found: C, 70.85; H, 4.01 
 
3-(3'-Hydroxybenzylidene)-5-hydroxybenzofuran-2(3H)-one (7-3) 
20 %; Orange solid, mp 235-236 °C; E-isomer: 1H NMR (DMSO-d6, 300 MHz):  δ 
6.70 (dd, J1 = 2.1 Hz, J2 = 11 Hz, H6), 6.80-6.83 (m, H4 + H7), 6.97 (d, J =7.5 Hz , 
1H), 7.12 (t, J =1.2 Hz, 1H), 7.17 (d, J = 7.8 Hz, 1H), 7.27 (d, J = 2.7 Hz, 1H), 7.61 
(olefinic H); 13C NMR (DMSO-d6, 75 MHz): δ 109.4, 112.2, 118.1, 119.0, 121.5, 
123.1, 124.3, 125.1, 132.0, 136.4, 140.0, 147.4, 159.1, 153.9, 170.1; Z-isomer: 1H 
NMR (DMSO-d6, 300 MHz):  δ 6.67 (d, J1= 2.4 Hz, J2 = 10 Hz, H6), 7.03 (d, J = 8.7 
Hz, H7), 7.19 (d, J = 2.4 Hz, H4), 7.23 (d, J =7.5 Hz, 1H), 7.36 (s, olefinic H), 7.48 (d, 
J =6.7 Hz, 1H), 8.30 (d, J = 7.5 Hz, 2H); MS (APCI) m/z [M+1]+ 255.2. Elemental 
analysis calculated for C15H10O4: C, 70.87; H, 3.94. Found: C, 70.26; H, 3.96 
 
3-(4'-Hydroxybenzylidene)-5-hydroxybenzofuran-2(3H)-one (7-4) 81, 92 
18 %; Orange solid, mp 241-243 °C; E-isomer: 1H NMR (DMSO-d6, 300 MHz):  δ 
6.82 (dd, J1 = 2.1 Hz, J2 = 13 Hz, H6), 6.93 (d, J =2.3 Hz, H4), 7.41 (d, J =2.1 Hz, H7), 
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7.61 (d, J =8.7 Hz, 2H), 7.75 (s, olefinic H), 8.21 (d, J = 8.4 Hz, 2H); 13C NMR 
(DMSO-d6, 75 MHz): δ 109.4, 112.2, 115.7, 119.0, 121.5, 124.1, 124.5, 124.8, 131.6, 
136.4, 147.4, 153.9, 159.9, 169.0 ; Z-isomer: 1H NMR (DMSO-d6, 300 MHz):  δ 6.78 
(d, J1= 2.4 Hz, J2 = 10 Hz, H6), 7.03 (d, J = 8.7 Hz, H7), 7.19 (d, J = 2.4 Hz, H4), 6.98 
(d, J =7.9 Hz, 2H), 7.46 (s, olefinic H), 8.60 (d, J =8.1 Hz, 2H); MS (APCI) m/z 
[M+1]+ 255.2. Elemental analysis calculated for C15H10O4. 1 ¼ H2O: C, 65.04; H, 
4.44. Found: C, 64.97; H, 4.01 
 
5-Hydroxy-3-(2'-methoxybenzylidene)-benzofuran-2(3H)-one (7-5) 
32 %; Yellow solid, mp 211-212 °C; E-isomer: 1H NMR (DMSO-d6, 300 MHz): δ 
3.87 (s, OCH3),  6.79 (dd, J1 = 2.4 Hz, J2 = 8.7 Hz, H6), 7.01 (d, J =2.2 Hz, H4), 7.08 
(d, J = 9 Hz, H7), 7.13 (d, J = 7.5 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H), 7.56 (t, J =7.5 Hz, 
1H), 7.72 (d, J =7.5 Hz, 1H), 7.80 (s, olefinic H); 13C NMR (DMSO-d6, 75 MHz): δ 
56.0, 109.2, 111.8, 112.1, 118.0, 118.6, 120.7, 122.0, 122.1, 129.7, 133.3, 136.6, 
147.0, 153.7, 158.0, 169.1; Z-isomer: 1H NMR (DMSO-d6, 300 MHz): δ 3.88 (s, 
OCH3), 6.74 (dd, J1= 2.4 Hz, J2 = 10 Hz, H6), 7.04 (d, J = 8.7 Hz, H7), 7.21 (d, J = 2.4 
Hz, H4), 7.10 (s, olefinic H), 7.37 (d, J= 6.8 Hz, 1H), 7.57 (t, J =7.5 Hz, 2H), 8.10 (d, 
J= 7.5 Hz, 1H); MS (APCI) m/z [M+1]+ 269.3. Elemental analysis calculated for 
C16H12O4: C, 71.64; H, 4.51. Found: C, 71.32; H, 4.54 
 
5-Hydroxy-3-(4'-methoxybenzylidene)-benzofuran-2(3H)-one (7-6) 
32 %; Orange solid, mp 201-203 °C; E-isomer: 1H NMR (DMSO-d6, 300 MHz):  δ 
3.87 (s, OCH3), 6.80 (dd, J1 =2.1 Hz, J2 = 8.7 Hz, H6), 6.97-7.04 (m, H4 + H7), 7.10 
(d, J = 8.7 Hz, 2H), 7.74 (d, J = 8.6 Hz, 2H), 7.75 (s, olefinic H); 13C NMR (DMSO-
d6, 75 MHz): δ 56.0, 109.4, 112.2, 119.0, 121.5, 124.5, 131.7, 136.4, 139.7, 141.3, 
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147.4, 153.9, 161.5, 168.5; Z-isomer: 1H NMR (DMSO-d6, 300 MHz):  δ 3.89 (s, 
OCH3), 6.75 (dd, J1= 2.4 Hz, J2 = 10 Hz, H6), 6.92 (d, J = 8.7 Hz, H7), 7.05 (d, J = 8.1 
Hz, 2H), 7.31 (d, J = 2.4 Hz, H4), 7.69 (s, olefinic H), 8.32 (d, J =8.1 Hz, 2H); MS 
(APCI) m/z [M+1]+ 269.3.  Elemental analysis calculated for C16H12O4: C, 71.64; H, 
4.51. Found: C, 70.78; H, 4.64 
 
3-(2'-Chlorobenzylidene)-5-hydroxybenzofuran-2(3H)-one (7-7) 
15 %; Yellow solid, mp 231-232 °C; E-isomer: 1H NMR (DMSO-d6, 300 MHz):  δ 
6.75 (d, J = 2.1 Hz, H4), 6.83 (dd, J1 = 2.6 Hz, J2 = 9 Hz, H6), 7.12 (d, J =8.7 Hz, H7), 
7.52-7.62 (m, 2H), 7.69 (d, J = 7.5 Hz, 1H), 7.76 (s, olefinic H), 7.83 (d, J = 6.8 Hz, 
1H); 13C NMR (DMSO-d6, 75 MHz): δ 109.4, 112.2, 119.0, 121.5, 124.8, 127.5, 
127.9, 130.3, 130.8, 132.1, 133.4, 136.4, 147.4, 153.9, 168.5; Z-isomer: 1H NMR 
(DMSO-d6, 300 MHz):  δ 6.77 (dd, J1= 2.4 Hz, J2 = 10 Hz, H6), 7.03 (d, J = 8.7 Hz, 
H7), 7.21 (d, J = 2.4 Hz, H4), 7.40-7.44 (m, 2H), 7.61 (d, J = 3 Hz, 1H), 7.58 (s, 
olefinic H), 8.02 (d, J= 7.8 Hz, 1H); MS (APCI) m/z [M+1]+ 273.3. Elemental 
analysis calculated for C15H9ClO3: C, 66.01; H, 3.30. Found: C, 66.03; H, 3.49 
 
3-(4'-Chlorobenzylidene)-5-hydroxybenzofuran-2(3H)-one (7-8) 92 
22 %; Orange solid, mp 202-204 °C; E-isomer: 1H NMR (DMSO-d6, 300 MHz):  δ 
6.82 (dd, J1 = 2.3 Hz, J2 = 8.7 Hz, H6), 7.08 (d, J = 2.3 Hz, H4), 7.11 (d, J = 8.7 Hz, 
H7), 7.64 (d, J = 8.3 Hz, 2H), 7.79 (d, J = 8.1 Hz, 2H), 7.80 (s, overlap, olefinic H ), 
9.46 (br H, OH); 13C NMR (DMSO-d6, 75 MHz): δ 109.4, 112.2, 119.0, 121.5, 124.5, 
129.1, 130.8, 132.5, 136.0, 136.4, 147.4, 153.9, 168.5; Z-isomer: 1H NMR (DMSO-
d6, 300 MHz):  δ 6.77 (dd, J1= 2.4 Hz, J2 = 10 Hz, H6), 7.03 (d, J = 8.7 Hz, H7), 7.19 
(d, J = 2.4 Hz, H4), 7.20 (s, olefinic H), 7.60 (d, J =8.4 Hz, 2H), 8.22 (d, J =8.4 Hz, 
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2H); MS (APCI) m/z [M+1]+ 273.2. Elemental analysis calculated for C15H9ClO3: C, 
66.01; H, 3.30. Found: C, 66.26; H, 3.46 
 
3-(2'-Fluorobenzylidene)-5-hydroxybenzofuran-2(3H)-one (7-9) 
20 %; Yellow solid, mp 211-212 °C; E-isomer: 1H NMR (DMSO-d6, 300 MHz): δ 
6.83 (dd, J1 = 2.4 Hz, J2 = 8.7 Hz, H6), 6.97-7.03 (m, H4 + H7),  7.20 (d, J = 9 Hz, 1 
H), 7.47 (m, 2H), 7.71 (t, J = 7.2 Hz, 1H), 7.87 (olefinic H); 13C NMR (DMSO-d6, 75 
MHz): δ 109.4, 112.2, 115.3, 119.0, 121.5, 123.1, 124.1, 124.4, 128.0, 129.5, 136.4, 
147.4, 153.9, 162.0, 168.5; Z-isomer: 1H NMR (DMSO-d6, 300 MHz): δ 6.83 (dd, 
J1= 2.4 Hz, J2 = 10 Hz, H6), 6.98 (d, J = 8.7 Hz, H7), 7.06 (d, J = 8 Hz, H4), 7.14 (d, J 
= 2.4 Hz, 1H), 7.47-7.50 (m, 2H), 7.79 (s, olefinic H), 8.58 (d, J = 10 Hz, 1H); MS 
(APCI) m/z [M+1]+ 257.3. Elemental analysis calculated for C15H9FO3: C, 70.31; H, 
3.54. Found: C, 70.03; H, 3.74 
 
3-(3'-Fluorobenzylidene)-5-hydroxybenzofuran-2(3H)-one (7-10) 
31 %; Yellow solid, mp 206-208 °C; E-isomer: 1H NMR (DMSO-d6, 300 MHz): δ 
6.85 (dd, J1 = 2.4 Hz, J2 = 8.7 Hz, H6), 7.01 (d, J = 8.7, H7), 7.15 (d, J = 2.2 Hz, H4), 
7.19 (d, J = 6.7, 1H), 7.43 (d, J = 6.7, 1H), 7.47 (d, J = 7.8 Hz, 2H), 7.79 (olefinic H); 
13C NMR (DMSO-d6, 75 MHz): δ 109.4, 112.2, 114.0, 115.1, 119.0, 121.5, 124.5, 
124.8, 130.0, 135.8, 136.4, 147.4, 153.9, 162.1, 168.5; Z-isomer: 1H NMR (DMSO-
d6, 300 MHz): δ 6.78 (dd, J1 = 2.4 Hz, J2 = 11 Hz, H6), 6.94 (d, J = 8.7 Hz, H7), 7.11 
(d, J = 9 Hz, H4), 7.39-7.43 (m, 2H), 7.44 (s, olefinic H), 7.78 (t, J = 8.1 Hz, 1H), 8.03 
(d, J = 10.2 Hz, 1H); MS (APCI) m/z [M+1]+ 257.3. Elemental analysis calculated for 
C15H9FO3: C, 70.31; H, 3.54. Found: C, 69.90; H, 3.68 
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3-(4'-Fluorobenzylidene)-5-hydroxybenzofuran-2(3H)-one (7-11) 92 
55 %; Yellow solid, mp 215-216 °C; E-isomer: 1H NMR (DMSO-d6, 300 MHz): δ 
6.83 (dd, J1 = 2.4 Hz, J2 = 8.7 Hz, H6), 7.02 (d, J = 8.7 Hz, H7), 7.15 (d, J = 2.2 Hz, 
H4), 7.68 (dd, J = 8.6 Hz, 2H), 8.13 (dd, J = 8.7 Hz, 2H), 7.81 (olefinic H); 13C NMR 
(DMSO-d6, 75 MHz): δ 109.1, 112.0, 116.1, 119.0, 121.3, 124.4, 130.2, 131.5, 136.4, 
147.4, 153.9, 163.6, 169.0; Z-isomer: 1H NMR (DMSO-d6, 300 MHz): δ 6.80 (dd, 
J1= 2.4 Hz, J2 = 10 Hz, H6), 6.98 (d, J = 8.7 Hz, H7), 7.01 (d, J = 8 Hz, H4), 7.50 (s, 
olefinic H), 7.16 (d, J = 8.5 Hz, 2H), 8.23 (J =8.5 Hz, 2H); MS (APCI) m/z [M+1]+ 
257.2. Elemental analysis calculated for C15H9FO3: C, 70.31; H, 3.54. Found: C, 
70.35; H, 3.67 
 
Series 8 (Dehydro compounds) 
2-Benzyl-4, 6-dimethoxybenzofuran-3(2H)-one (8-1) 
50 %; White solid, mp 114-115 °C; 1H NMR (CDCl3, 300 MHz):  δ 2.94 (dd, J1 = 9 
Hz, J2 = 24 Hz, benzylic H), 3.36 (dd, J1 = 3 Hz, J2 = 18 Hz, benzylic H), 3.84 (s, -
OCH3), 3.90 (s, -OCH3), 4.76 (dd, J1 = 3 Hz, J2 = 12 Hz, H2), 5.97 (d, J = 1.5 Hz, H5), 
6.12 (d, J = 1.5 Hz, H7), 7.22-7.31 (m, 5H); 13C NMR (CDCl3, 75 MHz): δ 36.3 
(CH2), 56.1 (OCH3), 56.7 (OCH3), 85.9 (C2), 90.1, 94.8 (C5, C7), 103.2 (C8), 128.6, 
129.3, 131.1, 132.6, 157.8 (C9), 167.7, 175.0 (C4, C6), 195.1 (CO); MS (APCI) m/z 
[M+1]+ 285.2. Elemental analysis calculated for C17H16O4: C, 71.82; H, 5.67. Found: 






4, 6-Dimethoxy-2-(2'-hydroxybenzyl)-benzofuran-3(2H)-one (8-2) 
35 %; White solid, mp 187-189 °C; 1H NMR (CDCl3, 300 MHz):  δ 3.11 (dd, J1 = 6.8 
Hz, J2 = 22 Hz, benzylic H), 3.35 (dd, J1 = 4 Hz, J2 = 19 Hz, benzylic H), 3.86 (s, -
OCH3), 3.89 (s, -OCH3), 4.87 (dd, J1 = 4 Hz, J2 = 11 Hz, H2), 5.98 (d, J = 1.5 Hz, H5), 
6.15 (d, J = 1.5 Hz, H7), 6.83-6.90 (m, 2H), 7.11-7.18 (m, 2H); 13C NMR (CDCl3, 75 
MHz): δ 36.1 (CH2), 56.2 (OCH3), 56.8 (OCH3), 86.0 (C2), 90.1, 94.9 (C5, C7), 103.3 
(C8), 115.6, 118.9, 119.2, 130.5, 131.1, 157.1, 157.9 (C9), 168.1, 174.5, 195.1; MS 
(APCI) m/z [M+1]+ 301.4. Elemental analysis calculated for C17H16O5: C, 67.99; H, 


















Appendix 2: NQO1 induction of active aurones and isoaurones in Hepa1c1c7 and 
Bprc1 cell lines (CD Hepa given in parentheses). 
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Appendix 3: QSAR analysis of Aurones and Isoaurones 
Table (a) Descriptors for 87 compounds calculated by MOE and SPARTAN. 


























Table (a)  Descriptors for 87 compounds calculated by MOE and SPARTAN. 
 
Compound pCD a 
Induction 
Ratiob MW Log P Rot B DM MR APOL HA HD TPSA ASA VSA-HD
1-1 6.51 7.70 282.295 3.768 3 3.478 7.907 42.463 3.000 0.000 44.760 530.109 0.000
1-2 6.4 5.59 316.74 4.358 3 4.017 8.407 43.976 3.000 0.000 44.760 556.726 0.000
1-3 6.21 3.98 316.74 4.397 3 4.439 8.403 43.976 3.000 0.000 44.760 556.653 0.000
1-4 4.3 2.13 316.74 4.36 3 4.133 8.403 43.976 3.000 0.000 44.760 559.312 0.000
1-5 6.74 5.28 298.294 3.458 3 2.720 8.033 43.265 4.000 1.000 64.990 536.484 0.000
1-6 5.01 1.20 298.294 3.497 3 3.852 8.029 43.265 4.000 1.000 64.990 540.544 0.000
1-7 4.3 1.18 298.294 3.46 3 4.271 8.029 43.265 4.000 1.000 64.990 540.861 0.000
1-8 5.47 2.53 314.293 3.148 3 3.252 8.155 44.067 5.000 2.000 85.220 548.245 0.000
1-9 4.3 1.10 314.293 3.187 3 4.735 8.151 44.067 5.000 2.000 85.220 548.121 0.000
1-10 6.51 2.21 312.321 3.722 4 2.453 8.542 46.359 4.000 0.000 53.990 568.585 0.000
1-11 4.3 0.91 312.321 3.761 4 3.467 8.538 46.359 4.000 0.000 53.990 571.199 0.000
1-12 4.3 1.06 312.321 3.724 4 4.107 8.538 46.359 4.000 0.000 53.990 572.230 0.000
1-13 6.8 1.91 300.285 3.919 3 4.430 7.976 42.353 3.000 0.000 44.760 535.212 0.000
1-14 6.82 4.47 300.285 3.958 3 5.110 7.972 42.353 3.000 0.000 44.760 538.669 0.000
1-15 6.17 2.16 300.285 3.921 3 4.608 7.972 42.353 3.000 0.000 44.760 539.182 0.000
1-16 4.3 1.36 307.305 3.428 4 6.546 8.536 44.656 4.000 0.000 68.550 572.920 0.000
1-17 4.3 1.08 350.292 4.70276 4 6.218 8.480 45.227 3.000 0.000 44.760 579.219 0.000
1-18 4.3 1.61 327.292 3.703 4 8.461 8.442 44.500 3.000 0.000 90.580 566.974 0.000
1-19 4.3 1.79 296.322 4.064 3 3.384 8.360 45.557 3.000 0.000 44.760 559.688 0.000
1-20 4.3 1.34 296.322 4.066 3 3.348 8.356 45.557 3.000 0.000 44.760 557.660 0.000
1-21 4.3 1.16 325.364 3.683 4 2.559 9.162 50.417 3.000 0.000 48.000 611.351 0.000
1-22 4.3 1.25 367.425 2.94 4 31.572 10.279 57.704 3.000 0.000 64.610 654.366 5.683
1-23 5.42 2.26 283.283 2.497 3 4.610 7.780 41.136 4.000 0.000 57.650 523.020 0.000
1-24 4.3 1.80 283.283 2.535 3 5.411 7.780 41.136 4.000 0.000 57.650 524.997 0.000
1-25 5.07 1.82 283.283 2.536 3 5.157 7.780 41.136 4.000 0.000 57.650 520.460 0.000
1-26 4.3 1.79 333.343 4.006 3 5.318 9.389 49.510 4.000 0.000 57.650 592.111 0.000
1-27 4.3 0.93 194.186 1.219 2 3.504 4.995 27.476 4.000 0.000 44.760 386.485 0.000
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2-1 4.3 1.39 254.241 3.24 1 3.083 6.886 36.276 3.000 2.000 66.760 466.313 0.000
2-2 5.77 2.64 288.686 3.83 1 3.654 7.377 37.789 3.000 2.000 66.760 486.160 0.000
2-3 4.3 1.45 288.686 3.869 1 3.999 7.374 37.789 3.000 2.000 66.760 486.942 0.000
2-4 4.3 1.59 288.686 3.832 1 3.657 7.374 37.789 3.000 2.000 66.760 486.385 0.000
2-5 5.52 2.92 270.24 2.93 1 2.459 7.007 37.078 4.000 3.000 86.990 474.923 0.000
2-6 4.3 1.60 270.24 2.969 1 3.525 7.004 37.078 4.000 3.000 86.990 476.842 0.000
2-7 4.61 1.24 270.24 2.932 1 3.892 7.004 37.078 4.000 3.000 86.990 478.193 0.000
2-8 4.3 1.48 284.267 3.194 2 2.262 7.521 40.172 4.000 2.000 75.990 508.573 0.000
2-9 5.36 2.15 284.267 3.233 2 3.192 7.518 40.172 4.000 2.000 75.990 505.994 0.000
2-10 4.3 1.15 284.267 3.196 2 3.751 7.518 40.172 4.000 2.000 75.990 506.234 0.000
2-11 4.3 1.14 279.251 2.9 2 5.970 7.505 38.469 4.000 2.000 90.550 485.601 0.000
2-12 4.3 1.38 268.268 3.538 1 2.886 7.339 39.370 3.000 2.000 66.760 497.085 0.000
2-13 5.26 2.20 272.231 3.391 1 4.121 6.946 36.166 3.000 2.000 66.760 465.554 0.000
2-14 4.78 1.53 300.266 2.923 2 3.730 7.638 40.974 5.000 3.000 96.220 519.954 0.000
2-15 4.3 1.47 344.319 2.68148 4 5.031 8.783 47.963 6.000 2.000 94.450 585.177 0.000
2-16 4.3 0.93 166.132 0.691 0 3.131 3.967 21.289 4.000 2.000 66.760 323.691 0.000
              
3-1 5.41 2.28 238.242 3.513 1 3.104 6.759 35.474 2.000 1.000 46.530 448.023 0.000
3-2 4.3 1.33 272.687 4.103 1 3.764 7.251 36.987 2.000 1.000 46.530 474.442 0.000
3-3 6.02 4.68 272.687 4.142 1 3.529 7.247 36.987 2.000 1.000 46.530 480.438 0.000
3-4 4.3 1.32 272.687 4.105 1 2.844 7.247 36.987 2.000 1.000 46.530 478.666 0.000
3-5 5.62 2.65 254.241 3.203 1 3.557 6.886 36.276 3.000 2.000 66.760 458.374 0.000
3-6 4.3 1.29 254.241 3.242 1 4.035 6.882 36.276 3.000 2.000 66.760 456.692 0.000
3-7 4.3 1.22 254.241 3.205 1 3.915 6.882 36.276 3.000 2.000 66.760 458.960 0.000
3-8 6.33 3.10 268.268 3.467 2 3.281 7.398 39.370 3.000 1.000 55.760 494.968 0.000
3-9 4.3 1.19 268.268 3.506 2 3.914 7.394 39.370 3.000 1.000 55.760 498.101 0.000
3-10 4.3 1.00 268.268 3.469 2 3.971 7.394 39.370 3.000 1.000 55.760 496.297 0.000
3-11 4.3 1.30 263.252 3.173 2 3.914 7.378 37.667 3.000 1.000 70.320 486.493 0.000






4-1 4.3 1.14 238.242 3.513 1 1.889 6.759 35.474 2.000 1.000 46.530 451.945 0.000
4-2 4.3 1.02 272.687 4.103 1 2.541 7.251 36.987 2.000 1.000 46.530 476.311 0.000
4-3 5.55 2.85 272.687 4.142 1 2.760 7.247 36.987 2.000 1.000 46.530 478.951 0.000
4-4 5.11 1.51 272.687 4.105 1 2.353 7.247 36.987 2.000 1.000 46.530 479.674 0.000
4-5 5.03 1.45 254.241 3.203 1 1.696 6.886 36.276 3.000 2.000 66.760 463.625 0.000
4-6 4.95 1.64 254.241 3.242 1 2.560 6.882 36.276 3.000 2.000 66.760 464.264 0.000
4-7 4.3 1.01 254.241 3.205 1 2.759 6.882 36.276 3.000 2.000 66.760 466.659 0.000
4-8 4.3 0.50 268.268 3.467 2 1.396 7.398 39.370 3.000 1.000 55.760 494.725 0.000
4-9 4.3 1.22 268.268 3.506 2 2.282 7.394 39.370 3.000 1.000 55.760 494.370 0.000
4-10 4.3 1.19 268.268 3.469 2 2.689 7.394 39.370 3.000 1.000 55.760 494.006 0.000
4-11 4.3 1.15 263.252 3.173 2 4.785 7.378 37.667 3.000 1.000 70.320 488.238 0.000
4-12 4.3 1.59 252.269 3.811 1 1.859 7.210 38.568 2.000 1.000 46.530 485.322 0.000
              
5-1 4.3 1.41 238.242 3.474 1 2.461 6.763 35.474 2.000 1.000 46.530 458.038 0.000
5-2 4.3 0.92 256.688 4.374 1 2.963 7.121 36.185 1.000 0.000 26.300 461.244 0.000
              
6-1 4.6 1.43 282.295 3.865 3 6.147 7.907 42.463 3.000 0.000 44.760 499.702 0.000
6-2 4.3 1.49 298.294 3.555 3 6.997 8.033 43.265 4.000 1.000 64.990 506.072 0.000
6-3 4.94 1.79 312.321 3.819 4 6.846 8.542 46.359 4.000 0.000 53.990 536.913 0.000
6-4 5.19 2.12 316.74 4.455 3 6.475 8.407 43.976 3.000 0.000 44.760 508.235 0.000
6-5 4.3 1.42 316.74 4.457 3 5.413 8.403 43.976 3.000 0.000 44.760 520.861 0.000
              
7-1 4.3 1.15 238.242 3.61 1 3.960 6.759 35.474 2.000 1.000 46.530 442.877 0.000
7-2 5.55 2.43 254.241 3.3 1 4.893 6.886 36.276 3.000 2.000 66.760 448.950 0.000
7-3 4.3 1.64 254.241 3.339 1 4.730 6.882 36.276 3.000 2.000 66.760 451.387 0.000
7-4 4.3 1.30 254.241 3.302 1 4.268 6.882 36.276 3.000 2.000 66.760 450.547 0.000
7-5 4.3 1.01 268.268 3.564 2 4.730 7.398 39.370 3.000 1.000 55.760 477.910 0.000
7-6 4.3 1.35 268.268 3.566 2 4.377 7.394 39.370 3.000 1.000 55.760 486.078 0.000
7-7 4.3 1.02 272.687 4.2 1 4.407 7.251 36.987 2.000 1.000 46.530 460.602 0.000





7-9 4.3 1.05 256.232 3.761 1 4.941 6.820 35.364 2.000 1.000 46.530 443.915 0.000
7-10 4.3 1.14 256.232 3.8 1 3.756 6.816 35.364 2.000 1.000 46.530 446.395 0.000
7-11 4.3 1.20 256.232 3.763 1 2.720 6.816 35.364 2.000 1.000 46.530 448.816 0.000
8-1 R 4.3 1.50 284.311 3.216 4 3.385 7.960 43.797 4.000 0.000 44.760 539.839 0.000
8-2 R 4.3 1.50 300.31 2.906 4 2.248 8.087 44.599 5.000 1.000 64.990 546.379 0.000
 
Table (a) (continued): 
Compound VSA-HA VDW-Area VDW-Vol HAS-HYD VSA-Pol HOMO 4 c LUMO 4 c 
1-1 18.574 275.538 379.355 236.036 18.574 -5.68151 -1.8878 
1-2 18.574 293.119 395.311 254.329 18.574 -5.82683 -2.04675 
1-3 18.574 293.119 395.311 254.329 18.574 -5.89339 -2.08347 
1-4 18.574 293.119 395.311 254.329 18.574  
1-5 18.574 285.568 387.877 228.686 32.141 -5.46122 -1.77929 
1-6 18.574 285.568 387.877 228.686 32.141 -5.64998 -1.87561 
1-7 18.574 285.568 387.877 228.686 32.141  
1-8 18.574 295.598 396.399 221.336 45.708 -5.4257 -1.74567 
1-9 18.574 295.598 396.399 221.336 45.708  
1-10 21.078 307.774 414.446 264.344 21.078 -5.40034 -1.75406 
1-11 21.078 307.774 414.446 264.344 21.078  
1-12 21.078 307.774 414.446 264.344 21.078  
1-13 18.574 279.947 382.497 241.157 18.574 -5.75227 -1.96964 
1-14 18.574 279.947 382.497 241.157 18.574 -5.82865 -2.025 
1-15 18.574 279.947 382.497 241.157 18.574 -5.70349 -1.93361 
1-16 36.317 299.268 404.785 222.436 36.317  
1-17 18.574 305.997 413.211 267.207 18.574  
1-18 18.574 303.676 403.257 230.955 18.574  
1-19 18.574 292.770 403.784 251.844 18.574  
1-20 18.574 292.770 403.784 251.844 18.574  
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1-21 18.574 337.787 446.116 294.726 18.574  
1-22 18.574 369.848 501.250 308.125 24.257  
1-23 24.257 273.682 370.279 229.210 24.257 -5.89111 -2.03714 
1-24 24.257 273.682 370.279 229.210 24.257  
1-25 24.257 273.682 370.279 229.210 24.257 -6.08813 -2.22791 
1-26 24.257 311.140 442.297 265.244 24.257  
1-27 21.078 189.231 245.854 152.576 21.078  
   
2-1 13.567 231.126 326.218 164.719 40.701  
2-2 13.567 248.708 342.174 183.012 40.701 -5.93703 -2.13491 
2-3 13.567 248.708 342.174 183.012 40.701  
2-4 13.567 248.708 342.174 183.012 40.701  
2-5 13.567 241.156 334.740 157.369 54.268 -5.55557 -1.85963 
2-6 13.567 241.156 334.740 157.369 54.268  
2-7 13.567 241.156 334.740 157.369 54.268 -5.49319 -1.84344 
2-8 16.071 263.362 361.309 193.028 43.205  
2-9 16.071 263.362 361.309 193.028 43.205 -5.72065 -1.92035 
2-10 16.071 263.362 361.309 193.028 43.205  
2-11 31.309 254.856 351.648 151.119 58.443  
2-12 13.567 248.358 350.647 180.528 40.701  
2-13 13.567 235.535 329.360 169.840 40.701 -5.86146 -2.0571 
2-14 16.071 273.392 369.831 185.678 56.771 -5.29802 -1.81621 
2-15 21.078 327.834 431.490 249.644 48.212  
2-16 16.071 144.819 192.717 81.260 43.205  
   
3-1 13.567 221.096 317.696 172.069 27.134 -5.76127 -2.29888 
3-2 13.567 238.678 333.652 190.362 27.134  
3-3 13.567 238.678 333.652 190.362 27.134 -5.94582 -2.49299 
3-4 13.567 238.678 333.652 190.362 27.134  
3-5 13.567 231.126 326.218 164.719 40.701 -5.57719 -2.17398 
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3-6 13.567 231.126 326.218 164.719 40.701  
3-7 13.567 231.126 326.218 164.719 40.701  
3-8 16.071 253.332 352.787 200.378 29.638 -5.52477 -2.14623 
3-9 16.071 253.332 352.787 200.378 29.638  
3-10 16.071 253.332 352.787 200.378 29.638  
3-11 31.309 244.826 343.126 158.469 44.876  
3-12 13.567 238.328 342.125 187.878 27.134  
   
4-1 13.567 221.096 317.696 172.069 27.134  
4-2 13.567 238.678 333.652 190.362 27.134  
4-3 13.567 238.678 333.652 190.362 27.134 -6.13936 -2.3379 
4-4 13.567 238.678 333.652 190.362 27.134 -6.02938 -2.30884 
4-5 13.567 231.126 326.218 164.719 40.701 -5.67298 -2.02272 
4-6 13.567 231.126 326.218 164.719 40.701 -5.86786 -2.12859 
4-7 13.567 231.126 326.218 164.719 40.701  
4-8 16.071 253.332 352.787 200.378 29.638  
4-9 16.071 253.332 352.787 200.378 29.638  
4-10 16.071 253.332 352.787 200.378 29.638  
4-11 31.309 244.826 343.126 158.469 44.876  
4-12 13.567 238.328 342.125 187.878 27.134  
   
5-1 13.567 221.096 317.696 172.069 27.134 -5.72260 -2.17649 
5-2 13.567 228.648 325.130 197.712 13.567  
   
6-1 18.574 275.538 379.355 229.786 18.574 -5.50931 -1.87418 
6-2 18.574 285.568 387.877 222.436 32.141  
6-3 21.078 307.774 414.446 258.094 21.078 -5.3096 -1.71543 
6-4 18.574 293.119 395.311 248.079 18.574 -5.65007 -1.99657 
6-5 18.574 293.119 395.311 248.079 18.574  
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7-1 13.567 221.096 317.696 165.819 27.134  
7-2 13.567 231.126 326.218 158.469 40.701 -5.6463 -2.11761 
7-3 13.567 231.126 326.218 158.469 40.701  
7-4 13.567 231.126 326.218 158.469 40.701  
7-5 16.071 253.332 352.787 194.128 29.638  
7-6 16.071 253.332 352.787 194.128 29.638  
7-7 13.567 238.678 333.652 184.112 27.134  
7-8 13.567 238.678 333.652 184.112 27.134 -5.90279 -2.43575 
7-9 13.567 225.505 320.838 170.940 27.134  
7-10 13.567 225.505 320.838 170.940 27.134  
7-11 13.567 225.505 320.838 170.940 27.134  
8-1 R 21.078 276.961 385.257 236.036 21.078  
8-2 R 21.078 286.991 393.779 228.686 34.645 -5.82719 -1.00732 
a. pCD = -Log (CD) where CD is the concentration to increase NQO1 activity by twofold.  
b. NQO1 fold induction at 5 µM. 
c. Calculated using SPARTAN for 33 compounds with CD values. 
 
 
Table (b) Spearman’s rho values for the 18 descriptors used in QSAR analysis 
 MW Log_P Rot_B DM APOL MR HA HD 
Correlation Coefficient 1.000 .262(*) .802(**) .409(**) .885(**) .925(**) .461(**) -.450(**)




N 87 87 87 87 87 87 87 87
Correlation Coefficient .262(*) 1.000 .013 .051 .129 .187 -.610(**) -.481(**)




N 87 87 87 87 87 87 87 87
Correlation Coefficient .802(**) .013 1.000 .408(**) .917(**) .922(**) .563(**) -.653(**)




N 87 87 87 87 87 87 87 87
 185 
Correlation Coefficient .409(**) .051 .408(**) 1.000 .338(**) .394(**) .225(*) -.291(**)




N 87 87 87 87 87 87 87 87
Correlation Coefficient .885(**) .129 .917(**) .338(**) 1.000 .980(**) .544(**) -.521(**)




N 87 87 87 87 87 87 87 87
Correlation Coefficient .925(**) .187 .922(**) .394(**) .980(**) 1.000 .503(**) -.564(**)




N 87 87 87 87 87 87 87 87
Correlation Coefficient .461(**) -.610(**) .563(**) .225(*) .544(**) .503(**) 1.000 .099




N 87 87 87 87 87 87 87 87
Correlation Coefficient -.450(**) -.481(**) -.653(**) -.291(**) -.521(**) -.564(**) .099 1.000




N 87 87 87 87 87 87 87 87
Correlation Coefficient .632(**) -.185 .884(**) .448(**) .761(**) .779(**) .649(**) -.568(**)




N 87 87 87 87 87 87 87 87
Correlation Coefficient .185 -.137 .169 .185 .185 .185 -.023 -.134




N 87 87 87 87 87 87 87 87
Correlation Coefficient .815(**) .399(**) .854(**) .279(**) .880(**) .895(**) .236(*) -.755(**)




N 87 87 87 87 87 87 87 87
Correlation Coefficient -.330(**) -.662(**) -.429(**) -.163 -.340(**) -.375(**) .338(**) .917(**)




N 87 87 87 87 87 87 87 87
 186 
Correlation Coefficient .893(**) .120 .904(**) .293(**) .975(**) .966(**) .521(**) -.527(**)




N 87 87 87 87 87 87 87 87
Correlation Coefficient -.066 -.728(**) -.139 .032 -.062 -.092 .533(**) .734(**)
Sig. (2-tailed) .547 .000 .198 .771 .569 .395 .000 .000





Correlation Coefficient .930(**) .129 .920(**) .396(**) .986(**) .991(**) .562(**) -.504(**)




N 87 87 87 87 87 87 87 87
Correlation Coefficient .903(**) .129 .923(**) .373(**) .995(**) .988(**) .549(**) -.521(**)




N 87 87 87 87 87 87 87 87
Correlation Coefficient .115 -.306 .294 .051 .338 .238 .536(**) .182




N 33 33 33 33 33 33 33 33
Correlation Coefficient .514(**) -.382(*) .638(**) .050 .682(**) .558(**) .810(**) .029




N 33 33 33 33 33 33 33 33
*  Correlation is significant at the 0.05 level (2-tailed).  
 **  Correlation is significant at the 0.01 level (2-tailed). 
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